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Summary 
Anfinsen’s seminal work has shown that the information required for a protein to fold into its 
specific three-dimensional structure is encoded into its amino acid sequence. The protein 
structure was believed to determine its activity, meaning that a protein needs to fold in order to 
function. More recently, intrinsically disordered proteins (IDPs) have been shown to represent 
a significant portion of the proteome. Despite the lack of a predefined structure, they still play 
important roles in cellular function, challenging the structure-function paradigm. Proteins are 
largely studied in isolated conditions, but in a cellular environment they are part of a vastly 
more complex system. The work presented here aims to shed light on how context can influence 
folding and binding mechanisms.  
First, we used SasG – a bacterial protein that defies the disorder prediction with its unique 
sequence composition and unusual structure – as a template to investigate co-translational 
folding, and how the presence of the ribosome can affect its folding mechanism. SasG in vitro 
translation was investigated utilising force profile experiments. We showed that both the G52 
and E-G52 constructs can fold very early, when still inside the vestibule of the ribosome. 
Moreover, our results suggest that non-native interactions can also provide sufficient force to 
release the stall sequence. 
Next we employed protein members of the BCL-2 family – involved in controlling the cell 
death mechanism – to understand what encodes a coupled folding and binding reaction. 
Although displaying a variety of conformations, some IDPs can fold upon binding to a partner 
protein. Promiscuous binding is a great advantage of disordered molecules, as multiple IDPs 
are able to bind and fold to the same partner protein. This raises the question of what 
orchestrates a coupled folding and binding reaction: the IDP or the partner protein? Using phi-
value analysis we studied four IDP-partner protein complexes, composed of alternative pairs of 
BCL-2 family members. In the bimolecular context, the disordered protein dictates the 
transition state interactions. Therefore, analogous to Anfinsen’s postulate, the folding pathway 
is encoded by the protein that folds, even when binding to another macromolecule is required.  
Finally, studies of the BCL-2 member BID on its full-length context showed that it cannot 
interact with its partner A1 unless it is cleaved and unfolded (tBID). These results provide 
insights on the role of tBID as a player during programmed cell death and hence why the 
pathway of cleaving BID with caspase is energetically favourable.  
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1 
1 Introduction 
 
1.1  From DNA to protein 
The discovery of the DNA double helix structure in 1953 (Watson & Crick, 1953) is 
considered a milestone in the history of science as it opened new perspectives in the way 
biology is perceived. The subsequent interest in how genes control the cellular chemical 
processes gained vast attention in the scientific community and gave rise to very powerful 
techniques (e.g. recombinant DNA tools, gene sequencing and engineering). Moreover, 
major advances such as mapping the human genome (Venter et al., 2001; Lander et al., 
2001) and the promise of gene therapy, all have their origins in the unveiling of the DNA 
structure.  
The two DNA strands are known as polynucleotides, since the monomeric units are called 
nucleotides. DNA nucleotides are comprised of a phosphate, a pentose sugar (deoxyribose) 
and four nitrogenous bases (adenosine, A; cytosine, C; guanine, G and thymine, T; 
Figure 1.1).  
   
Figure 1.1:Schematic of DNA nucleotides.  
Each group of three nucleotides, named codons, contain the coding information for an amino 
acid (e.g. GGG = glycine). The great potential of DNA is to encode genes from codons. 
Genes are a sequence of codons that encode multiple amino acids. These covalently linked 
amino acid polymers, classically known as proteins, are key players in cellular function.   
H	
Phosphate	
Pentose	sugar	
(Deoxyribose)	
Nitrogenous	base	
(C,	G,	A,	T)	
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1.2 Protein building blocks 
Considering that in a codon the 4 different DNA nucleotide bases should be arranged in a 
group of 3 to encode an amino acid, one could expect that 64 different amino acids could 
be produced (43). However, only 20 naturally occurring amino acids exist, with different 
codons being able to encode the same amino acid. This biological strategy reduces the 
chances of a single nucleotide mutation resulting in a different amino acid and potentially 
altering the protein sequence, structure and function. Amino acids are classically divided 
into four different groups, based on their chemical properties: charged, aromatic, non-polar 
and polar (Figure 1.2). 
 
Figure 1.2: Naturally occurring amino acids represented by their structures, full names, three letters 
and single letter codes. pKa values at pH 7 are reported for charged residues. Structures were 
constructed using ChemDraw 18.2.   
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Amino acids are the protein building blocks, as they form a linear polymer, known as a 
polypeptide chain, where the monomeric units are linked through the peptide bonds (ω). 
The peptide bond is planar and can be in two conformations: trans (ω =180˚) or cis (ω =0˚) 
(Figure 1.3). Due to steric clashes of the polypeptide side chain, the vast majority of peptide 
bonds are found in trans conformation (Stewart et. al., 1990). Polypeptide backbones 
provide two extra rotational bonds, known as psi (ψ) and phi (ϕ) torsion angles (Figure 1.3). 
 
Figure 1.3: Peptide bond conformations. Tripeptide structures showing the first peptide bond (ω) 
in (A) trans and (B) cis conformations. Psi (ψ) and (ϕ) angles are also represented. R indicates the 
amino acid side chains. Structures were constructed using ChemDraw 18.2.  
 
1.3 From a polypeptide chain to a folded protein 
In vivo, proteins are normally found in solution. Interactions between the amino acids and 
the solvent can influence the psi and phi angles of a polypeptide chain. However, intra-
molecular interactions can also occur and allow the extended chain of residues to fold into 
a more compact, well-packed three-dimensional structure (Figure 1.4). When the folded 
state is lower in energy compared to the denatured state, folding becomes a spontaneous 
event. Despite the specificity of the inter-residue interactions, folded proteins are only 
marginally stable, with the Gibbs free energy for folding (ΔGfolding) of about -2 to -10 
kcal.mol- 1 (Savage et al. 1993; Taverna and Goldstein 2002). A single hydrogen bond, for 
instance, is estimated to contribute with 1-5 kcal.mol-1 (Fersht et al. 1985), suggesting that 
all interactions can significantly affect protein stability.  
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Figure 1.4: A polypeptide chain can fold to form a more compact 3-dimensional structure. (A) an 
extended, 1-dimentional structure of a polypeptide chain. (B) interactions of residues in the 
polypeptide chain can drive the folding of the molecule, forming a more compact, structured 
conformation. For simplicity, only the backbone structure is represented, with carbons (gray), 
nitrogen (blue) and oxygen (red) atoms illustrated. Structures were constructed using PyMOL 
(version 1.5.0.4, Schrödinger) and the PDB code 1A2P. 
 
1.3.1  Hydrogen bonds 
A hydrogen bond is essentially an electrostatic attraction between a hydrogen covalently 
bound to a highly electronegative atom – the donor (e.g. oxygen, nitrogen, fluorine) and 
another electronegative atom containing an unshared pair of electrons – the acceptor. In a 
polypeptide chain, hydrogen bonds can be formed between the amide (donor) and the 
carbonyl groups (acceptor) present in the amino acids backbones. Although the formation 
of intra-molecular hydrogen bonds seems to be sufficient and very favourable, the solvent 
also needs to be considered (Dill 1990; Hunter 2004). Water can act as a hydrogen bond 
donor or acceptor. Since hydrogen bonds can be formed between residue and solvent, 
intramolecular hydrogen bonds do not confer a significant contribution to protein stability. 
Nevertheless, specific structures can be constructed with the hydrogen bonds between the 
amino acids, which makes this type of interaction very important to the ability of proteins 
to adopt a folded conformation. 
 
A	
B	
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1.3.2 Van der Waals  
Van der Waals is a distance-dependant interaction based on attraction and repulsion forces. 
It differs from covalent and ionic interactions, where attractions result in the formation of a 
chemical electronic bond. In comparison, van der Waals force is weaker and is strongly 
influenced by the distance between the interacting molecules (Roth et al, 1996). Atoms of 
any kind have fluctuating electron distribution relative to their nuclei, resulting in transient 
dipoles. When two atoms are close in proximity, the dipole of one can induce a dipole on 
the other, leading to an attraction force. However, the decrease of the distance between the 
two atoms can cause the two electron orbits to overlay, causing a repulsion effect. The 
optimal distance between the two atoms required for an effective van der Waals interaction 
is dependent on the nature of the atom. When a protein folds into its three-dimensional 
conformation, the atoms are packed in a distance that favours dipole interaction, van der 
Waals force play significant role in protein structure formation and stability (Pace, 2014).  
 
1.3.3 Effect of electrostatics 
Considering the 20 naturally occurring amino acids, at different pH environment, a subset 
of them can be ionised, resulting in either loss or acceptance of a proton (Figure 1.2). 
Electrostatic interactions can be formed by the attraction and repulsion of charges. Although 
hydrogen bonds and van der Waals force are also considered to be electrostatic in nature, 
charge-charge interactions can be effective at much longer distances (e.g. 5-10 Å) (Zhou 
and Pang 2018). Therefore, opposite charged interactions can be expected to substantially 
drive protein folding. However, the aqueous nature of the solvent needs to be considered: 
dipoles present in water molecules allow not only the hydrogen bond formation but also 
charge-charge interactions to occur between the water and the charged residues. 
Consequently, when polypeptide chains fold, most polar side chains seek the exterior, where 
they can be solvated by water molecules in the solvent (Perutz 1978). Nonetheless, charged 
interactions can contribute to the formation of the correct structure upon folding. An 
unpaired charged residue is likely to be located in the solvent accessible surface of the 
protein, where it can interact with water. For that reason, electrostatics interactions can also 
play a role in promoting protein solubility.   
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1.3.4 Hydrophobic effect 
The hydrophobic effect is the propensity of non-polar substances to attract each other in an 
aqueous environment, in order to exclude the water molecules (Chandler 2005). 
Considering the protein building blocks, non-polar amino acids would repel water 
molecules, forming a hydrophobic core. Note that the attractive forces between non-polar 
residues are not driven by the amino acids per se, but originate from the water molecules. 
There are two hypothesis that try to explain this effect: 1) Water molecules have a decrease 
in entropy in the presence of hydrophobic molecules. The water molecules undergo a special 
rearrangement around the hydrophobic residues in order to maximise their ability to form 
hydrogen bonds (Ball 2011; Camilloni et al. 2016). 2) Hydrophobic residues create an 
enthalpic penalty by disrupting the water hydrogen bond network (Lum, 1999). Either way, 
a solvent exposed hydrophobic group in a protein structure would imply an energetic 
disadvantage. Therefore, the hydrophobic packing of a polypeptide chain is associated with 
a substantial gain in free energy. For that reason, the hydrophobic effect is considered the 
driving force of protein folding (Dill, 1990; Pace 2014). 
 
1.3.5 Disulphide bonds 
Typically called S-S bonds, disulphide bonds are covalent interactions between two thiol 
groups that are located in close proximity in space. The thiol group present in the cysteine 
residue can form S-S bonds when two of these residues are in an oxidising environment and 
close to each other. Hence, it is more likely to form these interactions in a folded state, 
where the residues are in a much closer proximity, compared to the unfolded state. 
Although, the formation of a disulphide bond after the protein is folded can provide an 
enthalpic gain and contribute to the stability of the folded state, this is not always true 
(Creighton 1988). Formation of disulphide bonds can increase the strain of the native state 
structure (Clarke, 1995a; Clarke, 1995b) as well as stabilising the unfolded state by the 
presence of the intramolecular interactions (Clarke et al. 2000). Although some of the 
proteins studied in this thesis contain cysteine residues, none of them have native disulphide 
bonds present in their folded structure. 
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1.4 Protein structure 
Proteins can adopt different conformational structures, with the simplest being the uni-
dimensional covalent linkage of the amino acids forming a polypeptide chain, known as 
primary structure. In order to adopt more complex structures, amino acids psi and phi angles 
can experience torsions that allow a structure rearrangement. Although the possibilities 
might be vast, many of the psi (ψ) and phi (ϕ) angle combinations, and the associated 
structure conformations, are not favourable due to steric clashes (Ramachandran, 1963). 
The Ramachandran plot (Figure 1.5) describes the torsional psi and phi angles of the amino 
acids in a peptide.  
 
Figure 1.5: General Ramachandran plot. psi (ψ) and phi (ϕ) angle combinations of a typical amino 
acid residue is restricted to the outlined regions. Amino acids (black points) usually fall within 
favored regions (interior lines). The regions favor distinct secondary structures: α-helices (α), left-
handed α-helices (αL) and β-sheets (β). Figure was adapted from Lovell et al., 2003 and shows the 
favourable psi and phi angle combinations for all amino acids, except glycine and proline.  
As previously discussed, all amino acid residues with the exception of prolines, are capable 
of forming hydrogen bonds with each other through both amide and carbonyl groups. 
Considering the unfavourable psi and phi angle torsions, intramolecular hydrogen bonds 
can occur in two manners: 1) the carbonyl group of one residue (i) can interact with the 
amide group of another residue located 3 to 4 residues ahead (i+4) (Figure 1.6, A). These 
interactions originate a helical structure, most commonly found with turns every 3.6 
residues, known as α-helices. 2) Interactions can also occur between the carbonyl and amide 
groups of amino acids that are much further apart (e.g. when a turn is introduced in a 
polypeptide chain). These can originate much more extended structures, known as β-sheets 
αL
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(Figure 1.6, B). The torsion angles in α-helices and β-sheets confers a much more ordered 
assembly in comparison with the flexible primary structure of a polypeptide chain, and 
together they represent the secondary structures of proteins.  
   
Figure 1.6: Intramolecular hydrogen bonding generates protein secondary structures. (A) In an α-
helix, the carbonyl of one residue can hydrogen bond with the amide group of another residue when 
they are 4 residues apart. (B) In a β-sheet, residues located at much further distances can come 
closer when a turn is made in the primary structure allowing the residues to hydrogen bond. Some 
hydrogen bonds are represented by dashed lines. For simplicity, only the backbone structure is 
represented, with carbons (gray), nitrogen (blue) and oxygen (red) atoms illustrated. Structures 
were constructed using PyMOL (version 1.5.0.4, Schrödinger). 
Elements of secondary structure can then interact and build the most complex level of 
unimolecular protein structure: the tertiary (Figure 1.7). These interactions are driven by the 
amino acid side chains and the forces previously discussed in section 1.3. 
 
Figure 1.7: Different representations of a protein tertiary structure. (A) Barnase represented by the 
secondary structure elements that come together to form the protein structure. (B) The tight packing 
of the protein residues can be easily visualised when we represent all atoms. (C) Cartoon 
representation only shows the secondary structure elements. The three structures were constructed 
using PyMOL (version 1.5.0.4, Schrödinger) and the PDB code: 1A2P.  
A	
B	
A B C
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1.5 Why study protein folding 
Proteins differ from one another in their sequence of amino acids and most fold to form 
highly specific, three-dimensional structures. In vivo proteins are not isolated, and many 
other factors will influence folding, such as metal ions, salts, ligands, temperature, post-
translational modifications and chaperones.  
The protein folding field started to gain importance and began to develop in the late 50’s, 
after the first protein structure was determined (Kendrew et al., 1958). Since then, there has 
been a continuous and increasing interest in understanding how protein structures are 
formed and the mechanisms by which they fold. 
Further investigation and experiments showed that all the information required for a protein 
to fold into its native conformation is carried in the amino acid sequence (Anfinsen et al., 
1961). However, the mechanisms for folding and the relationship of folding mechanisms 
from primary sequence to tertiary structure are still not completely understood.  
The protein folding timescale can vary from hours to milliseconds, but what drives this 
difference in time is not well defined. In 1968, Levinthal demonstrated, using simple 
calculations, that because of the large number of degrees of freedom in the psi/phi angles in 
a polypeptide chain, a random search of all possible pathways for folding would be on a 
geological timescale. Hence, it would not be possible for a protein to fold into its native 
conformation in a short timescale if it had to sequentially sample all the possible 
conformations. He proposed the idea of the folding being driven by a rapid formation of a 
local nucleus that determines the following folding of the polypeptide chain (Levinthal 
1968, 1969). This conclusion supported the idea of folding pathways, which are pre-
determined routes that allow the protein to fold from its denatured to its native state in a 
biologically relevant timescale.  
There are a number of principles that drive the protein folding field. The reason why a 
protein folds is due to the native state being lower in energy than its denatured state. 
However, proteins are very easily destabilized, and even small changes in amino acid 
sequence can be enough to make the native state higher in energy compared to the 
denatured, thus preventing the protein from folding (Fersht, 1999). 
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Protein folding studies are still a significant challenge in science. Tackling the most 
fundamental questions on how a protein folds, is stabilized, interacts with ligands and 
functions, have a profound impact on how we may perceive metabolic regulation, cellular 
function and possibly better understand underlying processes in disease states. Ultimately, 
such studies could open possibilities for new treatments in order to ameliorate a patient’s 
quality of life (Hammarström et al. 2003). 
 
1.5.1 Models of protein folding 
Over the past decades, different models have been described in order to explain how proteins 
fold. The first models, also known as the “classical view” of protein folding, were based on 
the idea of folding pathways. The framework model (Ptitsyn 1973), for instance, suggests 
that the folding starts with the formation of secondary structure elements that then interact 
to form subsequent intermediates. The final structure is accomplished with the packing of 
the side chains. Another model, typically referred to as the nucleation condensation, states 
that the folding limiting step is the formation of a nucleus, followed by the rapid propagation 
of the protein structure (Fersht 1997). The nucleus is an expanded version of the protein 
native structure, which is further stabilised by long range interactions within the protein 
sequence. Thus, the formation of the nucleus is coupled with the condensation of the whole 
structure (Itzhaki, 1995). 
Subsequent studies have proposed what is commonly referred to as the “new view” of 
protein folding model: the energy landscape theory applied to protein folding (Bryngelson 
et al., 1995; Onuchic et al., 1997). The landscape describes the dependence of free energy 
on all protein conformations. High and low energy conformations are represented by a hill 
and a valley, respectively. Hence, the energy surface is typically referred to as the energy 
funnel. The energy landscape theory suggests that a protein does not follow a single folding 
pathway but different routes down the folding funnel are possible. The downhill nature of 
folding allows it to proceed one residue at a time, randomly. Populated intermediates are 
interpreted as regions of kinetic traps in the landscape.  
A lot has been discussed in the protein folding community regarding folding mechanisms, 
with the majority of the work based on globular proteins. In this thesis we want to investigate 
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non-traditional protein structures: SasG, a bacterial protein with an usual sequence 
composition and structure, as well as, a subset of proteins that are disordered in isolation 
and only fold upon binding to a partner protein. 
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1.6 Staphylococcus aureus surface protein G (SasG) 
 
1.6.1 Biological background 
Bacterial cells enclosed in a polymeric matrix can adhere to a living or inert surface to form 
functional communities known as bacterial biofilms (Costerton, Stewart, and Greenberg 
1999). The formation of a biofilm involves an initial attachment of these communities onto 
a surface and a subsequent maturation phase that is physiologically specific to each 
organism. The maturation step consists of an intracellular aggregation and the formation of 
a 3-dimensional structure, characteristic of a mature biofilm. Once the maturation step is 
complete, a final detachment phase disperses the bacterial cells to new infection sites in the 
human body (Otto 2008). Biofilms are very difficult to eradicate as they are resistant to the 
host immune system and to antimicrobial agents (Dunne 2002; Lewis 2001; Steward and 
Costdrton 2001). 
The most frequent bacteria found on human skin and mucous surfaces are Staphylococci, 
which are a common cause of infections caused by biofilms. S. aureus and S. epidermis can 
form biofilms on implanted medical devices causing infections that often require device 
removal (Harris and Richards 2006). Staphylococcus aureus surface protein G (SasG) 
promotes cell-to-cell accumulation during biofilm formation (Geoghegan et al., 2010). 
SasG is a protein from the MSCRAMMs (microbial surface components recognizing 
adhesive matrix molecules) group that contains an LPXTG motif essential for covalent 
linkage to the cell peptidoglycan (Corrigan et al. 2007). SasG has an A domain at its N-
terminus, which is responsible for promoting adhesion to epithelial cells (Roche, Meehan, 
and Foster 2003) followed by a B region, that promotes accumulation during biofilm 
formation (Geoghegan et al., 2010). 
The SasG B region is composed of nine repeats of two domains (Figure 1.4, A): the G5 
domain which is approximately 80 residues (PFAM accession number PF07501; Bateman 
et al., 2004; Bateman, Holden and Yeats, 2005) and the E domain which is approximately 
50 residues (D. T. Gruszka et al. 2012). The G5 domain was named after its five conserved 
glycine residues, also present in the E domain. The sequence identity between G5 domains 
(except for the first and last G5s) and between E domains is >97% (D. T. Gruszka et al. 
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2012). On the PONDR-FIT (Xue et al. 2010) and other disorder predictor analysis, G5 and 
E domains are expected to be disordered as they have an intrinsically disordered protein 
(IDP) sequence composition (Figure 1.8). 
 
Figure 1.8: SasG G5 and E domains disorder prediction. (A) Schematic representation of the 
domains arrangement within SasG. (B) G5 and E domains PONDR-FIT analysis show that both 
domains are predicted to be disordered. The sequence composition of G5 and E have also been 
shown.  
 
1.6.2 Biophysical background 
During my MPhil, I investigated the role of the glycine residues in the SasG protein. The 
project involved stability and kinetics studies, which provided evidence of the importance 
of the interface between the E and the G52 domains and solid information for the 
characterization of the folding pathway of G52 and E-G52 constructs. All the following data 
and analysis were previously presented and discussed in my MPhil thesis. 
 
a 
G5^1 PKTITELEKKVEEIPFKKERKFNPDLAPGTEKVTREGQKGEKTITTPTLKNPLTGVIISKGEPKEEITKDPINELTEYGP!
G5^2 VKGDSIVEK~~EEIPFEKERKFNPDLAPGTEKVTREGQKGEKTITTPTLKNPLTGEIISKGESKEEITKDPINELTEYGP!
G5^3 VKGDSIVEK~~EEIPFEKERKFNPDLAPGTEKVTREGQKGEKTITTPTLKNPLTGVIISKGEPKEEITKDPINELTEYGP!
G5^4 VKGDSIVEK~~EEIPFKKERKFNPDLAPGTEKVTREGQKGEKTITTPTLKNPLTGEIISKGESKEEITKDPINELTEYGP!
G5^5 VKGDSIVEK~~EEIPFEKERKFNPDLAPGTEKVTREGQKGEKTITTPTLKNPLTGEIISKGESKEEITKDPINELTEYGP!
G5^6 VKGDSIVEK~~EEIPFKKERKFNPDLAPGTEKVTREGQKGEKTITTPTLKNPLTGEIISKGESKEEITKDPINELTEYGP!
G5^7 VKGDSIVEK~~EEIPFEKERKFNPDLAPGTEKVTREGQKGEKTITTPTLKNPLTGEIISKGESKEEITKDPINELTEYGP!
G5^8 VKGDSIVEK~~EEIPFEKERKFNPDLAPGTEKVTREGQKGEKTITTPTLKNPLTGEIISKGESKEEITKDPVNELTEFGG!
G5^9 KTGTPETKT~~VEIPFETKREFNPKLQPGEERVKQEGQPGSKTITTPITVNPLTGEKVGEGQPTEEITKQPVDKIVEFGG!
E^1 ETIAPGHRDEFDPKLPTGEKEEVPGKPGIKNPETGDVVRPPVDSVTKYGP!
E^2 ETITPGHRDEFDPKLPTGEKEEVPGKPGIKNPETGDVVRPPVDSVTKYGP!
E^3 ETITPGHRDEFDPKLPTGEKEEVPGKPGIKNPETGDVVRPPVDSVTKYGP!
E^4 ETITPGHRDEFDPKLPTGEKEEVPGKPGIKNPETGDVVRPPVDSVTKYGP!
E^5 ETITPGHRDEFDPKLPTGEKEEVPGKPGIKNPETGDVVRPPVDSVTKYGP!
E^6 ETITPGHRDEFDPKLPTGEKEEVPGKPGIKNPETGDVVRPPVDSVTKYGP!
E^7 ETITPGHRDEFDPKLPTGEKEEVPGKPGIKNPETGDVVRPPVDSVTKYGP!
E^8 EKIPQGHKDIFDPNLPTDQTEKVPGKPGIKNPDTGKVIEEPVDDVIKHGP!
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The role of the E-G52 interface in stability 
 
Equilibrium studies of the G52 domain in isolation showed that mutations of the most 
conserved glycines G584A and G587A, located in the triple helical region, were so 
significantly destabilizing to the domain structure, that the G52 domain was mostly unfolded 
in 0 M urea (G587A~70% unfolded and G584A~100% unfolded). In the E-G52 construct, 
the same mutations are also significantly destabilizing but both E and G52 are folded in that 
context (Figure 1.9). 
The data show that the addition of the intrinsically disordered E domain to an unfolded G52 
rescues the stability of the system. This result shows the significant free energy contribution 
that comes from the inter-domain interface. As has been shown previously, the E-G52 
interface is more stable than the domains themselves (estimated to be > 6 kcal.mol-1; 
(Gruszka et al., 2015). 
 
Figure 1.9: Equilibrium curves comparison of the mutants G584A and G587A in G52 in isolation 
and E-G52 construct. (A) G52 domain crystal structure with mutants highlighted and equilibrium 
fraction folded data for G52-WT (black), and its mutants G584A (grey) and G587A (blue). (B) E- G52 
domain crystal structure with mutants highlighted and equilibrium fraction folded data for E-G52-
WT (red), and its mutants G584A (grey) and G587A (blue). 
Folding mechanism of SasG 
 
In the context of the G52 in isolation, all the mutations in the C-terminal region of the domain 
show a Φ-value of about 1, whereas mutations in its N-terminal region result in a Φ-value 
of approximately 0 (Figure 1.10). The data clearly suggest that in the transition state (TS) 
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the G52 domain has structure in its C-terminal region that is almost completely native-like. 
This is where the domain starts to fold.  
In the E-G52 construct, mutations in the N-terminal region of G52 and all mutants located 
in the E domain show a Φ-value of 0 suggesting that this whole region of the protein is 
unstructured in the TS. Dr. Gruszka’s Φ-value analysis for Pro-to-Ala and Tyr-to-Trp 
mutations are in agreement with all the glycine to alanine data. Pro-to-Ala mutations located 
in the E domain and in the N-terminal region of G52 domain also have a Φ-value of 0 
whereas in the C-terminal end of the G52, Φ-values of 1 are also observed (Figure 1.10). 
The Φ-value analysis show that the folding of G52 domain starts via its C-terminal end, 
which is also the rate-limiting step for the folding of the entire E-G52 construct.  
 
 
Figure 1.10:  Mapping the structure of the WT folding pathway for G52 and E-G52 constructs 
(Proline data and global fitting provided by Dr. Dominika Gruszka). (A) Chevron plots for G52-WT 
(black) and its mutants (colour-coded). Left panel shows mutants that unfold faster than G52-WT 
and fold at approximately the same rate (Φ=0). Right panel shows mutants that fold slower than 
G52-WT but unfold at the same rate (Φ=1). (B) Structure of the G52 TS mapped into the domain 
crystal structure. (C) Chevron plots for E-G52-WT (black) and its mutants (colour-coded). Left panel 
shows mutants that unfold faster than E-G52-WT and fold at approximately the same rate (Φ=0). 
Right panel shows mutants that fold slower than E-G52-WT but unfold at the same rate (Φ=1). (D) 
Structure of the E-G52 TS mapped into the construct crystal structure. (Figure taken from Gruszka 
et al., 2016).  
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Alternative folding pathway of E-G52 
 
In the context of the E-G52, Gly-to-Ala mutations located in the C-terminal region (G576A 
and G626A) and in the triple helical region (G584A and G587A) of the G52 domain, show 
a change in the dependence of the rate constant for folding on denaturant 
concentration (mkf). The data suggest an alternative pathway for folding once the C-terminal 
region of G52 is destabilized. Dr. Gruszka observed the same change in the folding m-value 
for the mutant E-G52-Y625W (also in the C-terminal region of the G52).  
As the change in the folding m-value is only detected in the E-G52 construct and it is 
observed for the proteins with the triple helical region or C-terminal end destabilized, we 
hypothesised that the alternative pathway for folding could start via the inter-domain 
interface.  
A pseudo-WT analysis, in the context of E-G52-Y626, two mutations (P540A and P599A) 
revealed results that contributed to the characterization of the alternative pathway for 
folding. 
1) The E domain is partially folded in the transition state of the alternative pathway: 
The mutant P540A resulted in an intermediate phi (0.3< Φ <0.7) in the context of the 
E-G52-Y625W, implying that the triple helical region of the E domain is partially structured 
in the TS (Figure 1.11). 
2) If the interface between the two domains is destabilized, then the E-G52 reverts 
to the original folding pathway: the chevron plot of the mutant E-G52-Y625W-P599A has 
the same mkf as E-G52-P599A and E-G52-WT, indicating the wild-type-like folding 
pathway. This supports the hypothesis that in the alternative folding pathway the interface 
between the two domains is folded (Figure 1.11).  
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Figure 1.11: Kinetic data of the Pro-to-Ala mutants in the context of E-G52-Y625W pseudo-WT. (A) 
Proline and tyrosine residues in E-G52 structure. (B) Chevron plots for E-G52-WT (blue), E-G52-
Y625W (green), E-G52-P540A (black) and E-G52-Y625W-P540A (cyan). (C) Chevron plots for E-
G52-WT (blue), E-G52-Y625W (green) E-G52-P599A (black) and E-G52-Y625W-P599A (orange). 
  
-3
-2
-1
0
1
2
3
4
0 2 4 6 8
E-G52-Y625W-P599A
EG52-WT
EG52-Y625W
EG52-P599A
EG52-Y625W-P599A
ln
 k
o
b
s
 
[Urea] (M)
-3
-2
-1
0
1
2
3
4
0 2 4 6 8
E-G52-Y626W-P540A
EG52-WT
EG5
2
-Y625W
EG52-P540A
EG52-Y625W-P540A
ln
 k
o
b
s
 
[Urea] (M)
P599	P
540	
Y625	A	
B	 C	
 
Introduction 
 
 
 
18 
1.7 Intrinsically disordered proteins  
Since the first protein structure was determined 6 decades ago (Kendrew et al., 1958,1960), 
proteins were typically associated with the classical structure-function paradigm, where the 
protein biological function was defined by its specific three-dimensional structure. More 
recently, the discovery of proteins that lack a pre-defined structure has intriguided the 
scientific community. The carriers of such “structure-free“ conformations were named 
intrinsically disordered proteins (IDPs) or protein hybrids comprised by ordered domains 
and disordered regions (IDRs). Following the idea that the information required for a protein 
to fold is encoded in its amino acid sequence (Anfinsen 1973), the lack of strucutre must 
also be encoded in the IDP sequences. In comparison to folded proteins, disordered proteins 
typically comprise a higher number of prolines, glycines and charged residues (Romero et 
al. 2001; Theillet et al. 2013; Uversky, Gillespie, and Fink 2000), whereas hydrophobic 
residues are underrepresented. Together, IDPs and IDRs can often be found in nature, with 
noticeble amounts of both being present in all life kindoms and viral proteomes (Dunker et 
al., 2000; Xue, 2012; Peng et al., 2014). 
The growing interest of this intriguing class of proteins starts precisely by the challenge that 
they represent in the structure-function paradigm. Despite being very flexible and lacking a 
well defined strucutre, IDPs are biologically active and predominantly involved in 
transcription and signaling regulation (Ward, 2004). It has been suggested that the lack of a 
globular structure might represent an advantage for IDPs, as the strucuture flexibility might 
play a role in allowing them to interact with different targets in the cell (Dunker et al. 2001; 
Wright and Dyson 1999). Furthermore, the disorder-to-order transition of IDPs during 
binding processes in the cell can be a fine mechanism for cellular regulation.  
Although evolution can provide positive changes leading to better adaptation, mutations in 
proteins can be unfavourable. In folded proteins, for instance, mutations can largely affect 
protein stability (Tokuriki et al. 2007), which explains the evolutionary pressure to maintain 
the position and nature of the residues that are crutial to the protein thermodynamic stability 
(Mirny and Shakhnovich 1999). Due to the lack of structure, IDPs are more susceptible to 
mutations and evolutionary changes (Chen et al., 2006). Nevertheless, the evolution 
persistance of disorder confirms the relevance of such class of proteins and indicates that 
the functional benefits of disorder surpass the ability to tolerate mutations. The lack of 
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structure also provides more acessibility to amino acid side chains, making them more prone 
to post translation modifications (PTMs) (Bah and Forman-Kay 2016). PTMs can 
significantly affect the energy landscapes of IDPs causing structural changes and directly 
impacting on protein function. Phosphorylation and acetylation modifications, for instance, 
allow changes in the IDP conformation possibilities as well as can allow them to act as 
regulatory switches (Kouzarides 2007; Nash et al. 2001). Another feature of IDPs is their 
ability to bind weakly and promiscuously to different targets (Chen 2012; Zhou 2012). The 
kinase inhibitory domain of the cyclin-dependant  kinase (CDK), for instance, can bind to a 
diverse family of cyclin-CDK complexes (Kriwacki et al. 1996). Likewise, the GTPase-
domain of the Wiskott–Aldrich syndrome protein (WASP) can bind to its own CTA-
domain, resulting in its inhibition, whereas when in a different conformation, it can bind to 
the GTP-ase Cdc42, resulting in WASP activation (Kim et al. 2000).  
Due to their unusual strucuture and biological relevance in cellular processes, the presence 
of IDPs in the cell requires a very specific and tight regulatory mechanism (Babu et al. 
2012). Studies have shown that human transcripts that encode IDPs have higher mRNA 
decay rates as well as an increased proportion of miRNA, suggesting lower gene expression 
levels of these proteins (Chen, 2008; Edwards et al., 2009). Moreover, an increased 
proportion of ubiquitination sites are found in IDPs compared with folded proteins (Edwards 
et al. 2009; Radivojac et al. 2010), targeting those molecules to fast degradation (Tompa et 
al. 2008). Together, these are suggestions that most IDPs are predicted to have shorter half-
lifes comapared to ordered proteins (Van Der Lee et al. 2014). In some cases, once this 
cellular regulation is somehow compromised, increased expression levels and persistance 
of IDPs in the cell, can lead to multiple diseases, including cancer and different types of 
neurodegenerative disorders (Babu 2016; Uversky, Oldfield, and Dunker 2008). Together, 
all these intriguing features and functional relevance makes this class of proteins very 
interesting, which can explain the increasing number of studies involving IDPs since their 
discovery. 
 
1.7.1 Coupled folding and binding of IDPs 
In the cell, transcription and signalling regulation are typically achieved by protein 
interactions. Although lacking a pre-defined structure, a subset of IDPs can fold upon 
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binding to a partner macromolecule, known as coupled folding and binding reaction (Dyson 
and Wright 2002). In these cases, the folded partner provides the necessary free energy for 
the folding of the IDP. IDPs coupled folding and binding reactions are typically involved in 
signalling systems (Wright and Dyson 2015). A question regarding the mechanism can 
emerge: what comes first, folding or binding? The route by which the folded complex is 
formed may indeed affect function. Two extreme mechanisms are proposed: in the induced 
fit mechanism, all members of the conformational ensemble of the IDPs are binding-
competent, resulting in folding after binding to the partner macromolecule. In the 
conformational selection mechanism, only correctly folded members of the ensemble are 
binding-competent, resulting in folding before binding (Figure 1.12). 
 
 
Figure 1.12: Schematic of IDPs coupled folding and binding mechanisms. A subset of IDPs can fold 
upon binding to a folded partner. Two extreme mechanisms have been proposed. In the induced fit 
mechanism (top), any member of the structural ensemble of IDPs are binding-competent and can 
fold subsequently to binding. In the conformational selection (bottom), only the correctly folded 
structures are able to bind, hence folding precedes binding. Structures were constructed using 
PyMOL (version 1.5.0.4, Schrödinger) and the PDB code: 2VOI and 1DDB.   
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It is important to emphasise that coupled folding and binding reactions with elements of 
both mechanisms, are possible (Hammes et al. 2009; Greives and Zhou, 2014). Although 
thermodynamic arguments can often be made in order to explain coupled folding and 
binding mechanisms, only kinetic studies of these complexes can properly shed light on 
mechanisms (Gianni, Dogan, and Jemth 2016; Kiefhaber, Bachmann, and Jensen 2012; 
Shammas et al. 2016). 
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1.8 Aims of this thesis 
Throughout the decades that protein folding has been investigated, studies are typically done 
with proteins in isolation. Understanding proteins single domains and how certain properties 
(e.g. thermodynamic stability, folding and unfolding mechanisms) are conserved through 
families of proteins, is a very powerful way to understand the fundamentals of protein 
science. However, in vivo, proteins are immersed in a crowded cellular environment, where 
many other factors can alter the way they fold and function: temperature, pH, chaperones, 
interaction with other macromolecules These are just a  few examples of how context can 
affect the properties of proteins. Moreover, a vast proportion of the proteome is known to 
be intrinsically disordered, with a subset of these molecules being able to fold only upon 
binding to another protein. The aim of the work designed in this thesis was to shed light on 
how context can influence protein dynamics and protein-protein interactions.  
After a previous study of the bacterial protein SasG, where the folding mechanisms were 
extensively characterised and described (Gruszka et al. 2016), the next intriguing question 
was on the charged nature of this protein. What is the role of the numerous charged residues 
in SasG stability and ability to fold? Then, to explore protein folding in a more complex 
context, co-translational folding was also targeted: how the elongated beta-sheet structure 
of SasG can fold upon translation on the ribosome? How that compares with the folding of 
the domains in isolation? 
Intrigued by the disorder-order fine line drawn by SasG, the next step of the thesis targets 
intrinsically disordered proteins and protein-protein interactions. How coupled folding and 
binding reactions of IDPs compare to the folding of a single protein? What encodes the 
folding information: the IDP or the partner protein? Finally, as IDPs are largely studied as 
peptides, how the coupled folding and binding of an IDP peptide compares with the protein 
in the full-length context? 
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2 Thermodynamics and kinetics analysis 
2.1 Protein folding 
 
2.1.1 Equilibrium studies of proteins 
The use of denaturants, such as urea and guanidine hydrochloride, is one of the primary 
ways of measuring the conformation stability of proteins and comparing this with the 
stability of the mutated proteins. The use of denaturants is widespread (Pace 1986) even 
though their mechanism of action is not yet completely understood. It is known that the 
interactions of denaturant with protein constituent groups are more favourable in 
comparison with the interaction between these groups and water (Tanford 1970) and alter 
the equilibrium between native and denatured states of the protein. 
Different probes can be used in order to investigate to what extent a protein is folded (CD, 
fluorescence, etc.). Although many proteins denature irreversibly (Kauzmann 1959), many 
of them regain their folded conformation once the denaturant is removed. Thermal unfolding 
(another method of denaturation) of chymotrypsinogen (Brandts 1964) characterized the 
transition between folded and denatured state as being very abrupt (Figure 2.1), a 
phenomenon that was also observed for many other systems and led to the idea of a “two-
state” process representing the equilibrium between native and denatured states. In a “two-
state” process, the equilibrium reactions (D⇌N) are cooperative, occurring in a single step 
with no populated intermediates. 
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Figure 2.1: Representation of a fluorescence denaturation curve under equilibrium conditions. 
The free energy of transfer of a protein from pure water to a denaturant solution shows a 
linear dependence (Figure 2.2) in denaturant concentration (Pace 1986) and is expressed by 
the equation (Greene and Pace 1974): 
  ∆"#$% = ∆"#$%'() 	−	,#$%	[den]                 Equation 2.1 
 
Where,  ∆"#$% is the free energy of unfolding at a specific denaturant concentration. ∆"#$%'()  is the free energy of unfolding in pure water. ,#$%	is the equilibrium m-value (see details bellow). 
[den] is the concentration of denaturant. 
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The equilibrium m-value is the dependence (slope) of the free energy of unfolding on 
denaturant concentration and it is related to the change in the solvent accessible area (SASA) 
as the protein unfolds (Myers, Pace, and Scholtz 1995).  
There is a point in the denaturant concentration ([den]50%) at which 50% of proteins are 
denatured. When [den] = [den]50%, both states D and N are equally populated ([D] = [N]) 
and the energy difference between them (∆"2$3)	is zero, so: 
 
∆"#$%'() = 	,D−N	[den]50%                 Equation 2.2 
 
  
Figure 2.2: Free energy of unfolding has a linear dependence with the concentration of denaturant.   
 
The values ∆"#$%'(), mD-N and [den]50% can be extracted from an equilibrium denaturation curve 
using the following equation (Clarke and Fersht 1993): 
 ; = 	 [(=>?	@>	[ABC])?(=D?@D[ABC])BEF	{HDI>([ABC]$[ABC]JK%/MN}]P?BEF	{HDI>	([ABC]$[ABC]JK%)/MN}] 	          Equation 2.3 
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Where, 
F is the fluorescence reading at given [den]. 
αN is the fluorescence of the native protein in pure water. 
βN is the gradient of the fluorescence baseline for native protein. 
αD is the fluorescence of the denatured protein in pure water. 
βD is the gradient of the fluorescence baseline for denatured protein. 
T is the temperature at which the experiment is performed (K). 
R is the universal gas constant (1.987 cal.mol-1.K-1). 
   
The terms αN, βN, αD and βD are shown graphically in Figure 2.3: 
 
    
Figure 2.3: Diagram to explain visually the meaning of the terms from Equation 2.3.  
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To allow comparison between different equilibrium curves, the fluorescence reading (F) is 
converted to fraction folded reading, which varies between 0 and 1 to indicate the proportion 
of the protein found in the native state at given denaturant concentration:  
 
Fraction	folded = Z$(=D?@D[ABC])=>?@>[ABC])$(=D?@D[ABC])             Equation 2.4 
  
 
Thermodynamics and kinetics analysis 
 
 
 
28 
2.1.2 Kinetics studies of proteins 
Protein folding was initially considered to be a process involving a series of intermediates 
so that a random search for the correct conformation was not feasible (Levinthal paradox). 
However, the study of the chymotrypsin inhibitor 2 showed a two-state kinetic behaviour 
with no populated intermediates (Jackson and Fersht 1991). In this case, proteins would fold 
apparently directly from the denatured to the native state via a transition state (TS), which 
is the highest energy point on the reaction pathway (Figure 2.4).  
    
Figure 2.4: Free energy diagram showing the denatured, transition and native states. 
The free energies of transfer of the native, transition and denatured states from water into a 
denaturant solution are linearly proportional to [den]. As well as in the Equation 2.1, the 
following equations can be stated: ∆"#$[\ = ∆"D−TSH2O 	−	,#$[\	[den]           Equation 2.5 ∆"[\$% = ∆"TS−NH2O 	−	,[\$%	[den]											Equation 2.6 
Using the relationship k = A exp (-ΔG/RT): 
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∆"#$[\ = bc ln df 	– 	bcfg	h                     Equation 2.7 ∆"[\$% = −bc ln di 	– 	bcfg	h                  Equation 2.8 ln dj = ln diH2O	 + 	,di	[den]                       Equation 2.9 		ln dl = ln dfH2O	 + 	,df	[den]                        Equation 2.10 
 
Assuming two-state kinetics, at concentrations below [den]50% the natural log of the folding 
rate against [den] (chevron plot) will be a straight line with gradient mkf. Similarly, above 
[den]50% the natural log of the folding rate against [den] will be a straight line with gradient 
mku (Figure 2.5). Kinetic parameters can be extracted from the observed chevron plot by 
using the equation: 
 		ln dmno = ln[dl'()	 expr−,sl	[den]t + [dj'()	 exp(,sj	[den])]    Equation 2.11 
kobs is the observed rate constant at a particular [den]. 
  
Figure 2.5: Chevron plot and its kinetic parameters.  
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The kinetic free energy of unfolding in water, ∆"#$%	uvC'()  can be calculated from: 
 ∆"#$%	uvC'() = −bcfg(dw'()/dx'())          Equation 2.12 
 
And since ,#$[\	 = bc,sx and ,[\$% = bc,sw: 
 ,#$%	syz	 = 	,#$[\	 +	,[\$% = bc(,sw + ,sx)          Equation 2.13 
 
So, if kinetic and equilibrium ,#$%		are the same and if both equilibrium and kinetic ∆"#$%	'() are also the same, folding can be described as two-state, where there are no populated 
intermediates in the folding pathway. 
 
2.1.3 Φ-value analysis 
A standard experimental procedure to investigate the transition state in protein folding 
consists of mutating a single residue in the primary sequence of the polypeptide and seeing 
the effect of the mutation on the equilibrium and kinetics studies. It is known that mutations 
can affect the free energy of the native and transition states and consequently cause a 
difference in their equilibrium stabilities (ΔΔGD-N and ΔΔGD-TS). 
 ΔΔ"#$% = ∆"#$%|[ − ∆"#$%}~[                       Equation 2.14 ΔΔ"#$[\ = ∆"#$[\|[ − ∆"#$[\}~[                       Equation 2.15 
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If a particular residue is located in a region of the protein with a native conformation in the 
transition state, then ∆Δ"#$[\ will be the same as ∆Δ"#$% (Figure 2.6, A). Φ = ∆∆ÄÅIÇÉ∆∆ÄÅIÑ = 1                     Equation 2.16 
 
However, if a residue is located in a region of the protein with a denatured conformation in 
the transition state (no native contacts), then the ∆Δ"#$[\ will be 0 (Figure 2.6, B). Φ = ∆∆ÄÅIÇÉ∆∆ÄÅIÑ = 0                     Equation 2.17  
   
 
Figure 2.6: Φ-value analysis. (A) Mutation destabilizes the native and the transition states to the 
same extent, giving a Φ-value of 1. (B) Mutation destabilizes the native state but does not affect the 
transition state giving a Φ-value of 0. 
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2.2 Coupled folding and binding reactions 
 
2.2.1 Reaction rates 
As previously stated, in a reversible reaction, the rate constant k describes the flux of the 
forward and reverse reactions. For protein folding events, the rates are termed ku (rate 
constant for unfolding) and kf (rate constant for folding). Analogous to that, in a two-state 
bimolecular reaction, the rates are termed kon (association rate constant) and koff (dissociation 
rate constant).  
For a two-state protein, the change in concentration of the denatured protein is described by 
Equation 2.18:  
A[2]AÜ = dw[á]	−	dx[à]                         Equation 2.18 
 
Where [N] and [D] are the concentrations of native and denatured protein, respectively, and 
ku and kf are the rate constant of unfolding and folding, respectively. 
When equilibrium is achieved, the change in concentration of native and denatured protein 
is equal. Therefore, the equilibrium constant K for a two-state protein is described by 
Equation 2.20:  0 = 	dw[á]	−	dx[à]                         Equation 2.19 â =	 [2][3] = säsã                                             Equation 2.20  
In a reaction involving two proteins, where proteins A and B interact to form a complex C, 
like in IDP coupled folding and binding reactions, the rate by which the complex is formed, 
will depend on the concentration of both proteins. Hence, the change in concentration of 
protein A is described by Equation 2.21:  
A[å]AÜ = dmxx[ç] − dmC[h]. [è]                    Equation 2.21  
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Where [A], [B] and [C] are the concentrations of proteins A, B and complex C, respectively, 
and kon and koff are the association and dissociation rates constants, respectively. 
Analogous to the uni-molecular process, once equilibrium is achieved, the change in 
concentration of protein A is zero and the equilibrium constant Kd is described by Equation 
2.23:  0 = dmxx[ç] − dmC[h][è]                     Equation 2.22 
 
âê = 	 [å][ë][í] = 	 sìããsîï                               Equation 2.23 
 
As previously discussed, the unfolding of a protein upon rapidly mixing with denaturant can 
be followed by a change in the fluorescence. The fluorescence change can be described by 
a single exponential function, that is derived from the rate law. Starting from a two-state 
reaction (Equation 2.18), the concentration of native protein can be replaced by the change 
in concentration of denatured protein: 
A[2]AÜ = dw([à]ñ − [à])	−	dx[à]       Equation 2.24  
A[2]AÜ +	(dw+	dx)[à] = dw[à]ñ         Equation 2.25 
Equation 2.25 can be then integrated: 
[à] = 	 só[2]Ksóòsô + 	çe($sóòsô)Ü           Equation 2.26 
Which is equivalent to a single exponential function, described by equation 2.27: [à] = 	;xvCöõ + ∆;e($sìúù)Ü            Equation 2.27  
Where Ffinal is the fluorescence reading at the end of the reaction, ∆F in the fluorescence 
change along the reaction, kobs is the observed rate constant (ku + kf) and t is time.  
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For a reaction involving two proteins in near equimolar concentrations, the concentrations 
of both proteins are relevant and must be considered. The model used by Shammas et al. 
(2013) contemplates this case and the integration of the rate law is more complex than 
previously demonstrated. When one of the proteins in the reaction has a significantly higher 
concentration in comparison to the other (pseudo-first order condition), the model is again 
simplified. For instance, if the concentration of protein B is 10 times higher than the 
concentration of protein A, it can be assumed that only 10% of protein B will associate and 
go into complex. In that case, the concentration of protein B will not change upon the 
reaction and therefore can be incorporated in the association rate constant: 
A[å]AÜ = dmxx[ç] − d′mC[h]                      Equation 2.28  
where k’on is the new association rate constant and is equal to kon multiplied by the 
concentration of B (10 times in excess).  
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3 Materials and methods  
Throughout the entire course of the biophysical experiments for this thesis, all the buffers 
and reagents were prepared at room temperature, volumetrically, with deionised water 
(ddH2O) purified at 18 mΩ cm-1 of resistance by an ELGA maxima system. The pH of the 
buffers and solutions were checked using Radiometer MeterLab PHM210 instrument. 
 
In this chapter, suppliers will be referenced as a superscript: 
(a) MP Biomedicals Inc., (b) Life Technologies, (c) Sigma-Aldrich Company, (d) Fisher 
Scientific International Inc., (e) STARLAB group (f) Biotium, (g) Thermo Scientific, 
(h) Acros organics, (i) BDH laboratory supplies, (j) GE Healthcare Life Sciences, 
(k) Agarose Bead Technologies, (l) New England Biolabs, (m) Eurogentec (n) Merck. 
 
3.1 Molecular Biology 
LB 
LB media was prepared from commercially available capsulesa. 10 g tryptone, 5 g yeast 
extract and 10 g NaCl were diluted in 1 litre ddH2O and autoclaved. When stored, the 
solutions were kept 4 °C. 
 
LB agar plates 
The plates were prepared from commercially available capsulesa. 10 g tryptone, 5 g yeast 
extract, 10 g NaCl and 15 g agar were diluted in 1 litre ddH2O and autoclaved. After cooling 
down to about 50 °C, kanamycin or ampicillin was added (60 μg.ml-1 and 100 μg.ml-1 final 
concentration, respectively) and the plates were stored at 4 °C. 
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Kanamycin (KAN) 
3 g of kanamycinb was diluted in 50 ml ddH2O to prepare a [1000x] stock (60 mg.ml-1 final 
concentration). The solution was syringe filtered through a 0.2 μm cellulose acetate 
membrane and stored at 4 °C.  
 
Ampicillin (AMP) 
5 g of ampicillind was diluted in 50 ml ddH2O (100 mg.ml-1 final concentration). The 
solution was syringe filtered through a 0.2 μm cellulose acetate membrane and stored in 1 
mL aliquots at -20 °C. 
 
LB - Kanamycin and LB- Ampicillin (LB- KAN and LB- AMP) 
After the LB media was prepared using the standard procedure described before, kanamycin 
or ampicillin was added to a final concentration of 60 μg.ml-1 or 100 μg.ml-1, respectively.  
 
Tris- Acetate-EDTA buffer (TAE) 
A [1x] buffer composition consists in 40 mM Tris (pH 8.0), 20 mM acetic acid, and 1mM 
EDTA. A [50x] stock was prepared using 242 g Tris basec, 100 ml of 0.5 M EDTAg (pH 
8.0) and 57.1 ml glacial acetic acidd, diluted in 1 litre of ddH2O.  
 
Agarose gel  
0.5 g agarosee was added to 50 ml [1x] TAE buffer and heated up (> 100 °C) until it was 
dissolved. Then, 5 μl of the DNA stain GelRedf was added to produce a 1% (w/v) agarose 
gel. 
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Phusion Hot Start II DNA polymeraseg 
It is the DNA polymerase used in all site direct mutagenesis (SDM) and PCR protocols. It 
is commercially available and it is supplied with its appropriate buffer. It was stored at -20 
°C. 
 
Deoxynucleotide mix (dNTP)g 
Commercially available solution containing dATP, dCTP, dGTP and dTTP, each at final 
concentration of 10 mM. 10 μl aliquots stored at -20°C.  
 
DpnI g 
The restriction enzyme used to digest methylated DNA. It is supplied in appropriate buffer 
and stored at -20°C. 
 
Gene ruler 1kb plus g 
Commercially available ladder used for quantification and size determination of double-
stranded DNA on agarose gels. It covers a wide range (75-2000 bp) of DNA lengths and it 
is supplied with its appropriate buffer. Stored at 4 °C.  
 
3.2 Buffers and reagents 
3.2.1 Protein production and purification  
SasG  
 
Binding buffer 1: 20 mM Tris (pH 8.0), 100 mM NaCl, 20 mM imidazole.  
1.76 g Trizma acidc, 1.05 g Trizma basec, 5.84 g NaClc, 1.36 g imidazoleh were diluted in 1 
litre of ddH2O and vacuum filtered through a 0.2 μm cellulose acetate membrane. 
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Gradient buffer 1: 20 mM Tris (pH 8.0), 100 mM NaCl, 500 mM imidazole. 
1.76 g Trizma acidc, 1.05g Trizma basec, 5.84g NaClc, 34.04g imidazoleh were diluted in 1 
litre of ddH2O and vacuum filtered through a 0.2 μm cellulose acetate membrane.  
 
Phosphate buffered saline (PBS) [20x] 
A [1x] solution consists in 10 mM phosphate (pH 7.4), 136.5 mM NaCl, 2.7 mM KCl (164 
mM ionic strength). A [20x] stock solution was prepared with 28.83 g Na2HPO4 
(dihydrate)d, 5.93 g NaH2PO4 (dihydrate) d, 159.54 g NaClc, 4.03 g KCli diluted in 1 litre of 
ddH2O.  
 
Binding buffer 2: 10 mM phosphate (pH 7.4), 136.5 mM NaCl, 2.7 mM KCl, 20 mM 
imidazole. A [1x] solution was prepared from 50 ml [20x] PBS stock and 1.36 g imidazoleh 
diluted in 1 litre of ddH2O. The solution was vacuum filtered through a 0.2 μm cellulose 
acetate membrane.  
 
Gradient buffer 2: 10 mM phosphate (pH 7.4), 136.5 mM NaCl, 2.7 mM KCl, 500 mM 
imidazole.  
A [1x] solution was made with 50 ml [20x] PBS stock and 34.04 g imidazoleh diluted in 1 
litre of ddH2O. The solution was vacuum filtered through a 0.2 μm cellulose acetate 
membrane.  
 
Coomassie brilliant blue (CBB) stain: 0.2% (w/v) CBB R-250, 50% (v/v) EtOH, 10% (v/v) 
CH3COOH.  
A 500 ml stock solution was prepared dissolving 1 g of CBB R-250g in 250 ml ethanolc, 50 
ml glacial acetic acidd and 200 ml of ddH2O.  
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Coomassie brilliant blue (CBB) destain: 10% (v/v) EtOH, 10% (v/v) CH3COOH.  
A 1 litre stock solution was prepared by adding 100 ml of ethanolc, 100 ml glacial acetic 
acidd in 800 ml ddH2O. 
 
 Isopropyl β-D-1-thiogalactopyranoside (IPTG)g 
A 1 M stock was prepared diluting 2.38 g of IPTG in 10 mL dd H2O. The solution was 
filtered through a 0.22 μm sterile membrane and 400 μl aliquots stored at -20 °C. 
 
Mark 12 unstained standardb 
Commercially available ladder used for size determination of proteins on a NuPAGE gels. 
It covers a range 2.5-200 kDa and it is supplied ready to use. It was stored at 4 °C.  
 
HRV 3C proteaseg 
Commercially available protease supplied as a 10,000 units with a highly specific 
recognition sequence for Leu-Glu-Val-Leu-Phe-Gln-↓-Gly-Pro, cleaving after the 
glutamine residue. It was used to cleave histidine tags in the SasG purification process.  
 
A1 and BID full-length  
 
Tobacco etch virus (TEV) protease: 
TEV protease was expressed and purified in the lab by Tristan Kwan following Blommel 
and Fox protocol (Blommel and Fox 2007). It was stored in 20 mM TRIS (pH 7.5), 125 mM 
NaCl, 2 mM DTT, 2 mM EDTA and 50% (v/v) glycerol at -20 °C.  
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TEV cleavage buffer: 
10 mM TRIS pH 8.0, 150 mM NaCl. It was prepared with 0.866 g Trizma acidc, 0.533 g 
Trizma basec and 8.519g NaClc diluted in 1 litre of ddH2O. The solution was vacuum filtered 
through a 0.2 μm cellulose acetate membrane. 
 
Instant bluec: 
Commercially available coomassie dye-based protein stain. It is a solution formulated for 
fast and sensitive protein detection. The bands were visible in less than 15 minutes without 
the need to destain.  
 
Biophysical buffer: 
50 mM Sodium Phosphate, 0.05% Tween, pH 7. It was prepared with 5.29 g Na2HPO4  
(dihydrate)d, 3.17 g NaH2PO4 (dihydrate) d and 500 μL of Tween 20d diluted in 1 litre of 
ddH2O. The solution was vacuum filtered through a 0.2 μm cellulose acetate membrane. 
 
Ion-exchange buffer: 
20 mM Tris, 0 and 1 M NaCl, pH 7. A [10x] stock was prepared with 28.8 g Trizma acidc, 
1.94 g Trizma basec and 0 or 58.44 g NaClc diluted in 1 litre of ddH2O. The solution was 
vacuum filtered through a 0.2 μm cellulose acetate membrane. 
A [1x] solution was made by dilution of the [10x] stock. 
 
Page ruler unstained protein ladderg: 
Commercially available ladder used for protein size determination on SDS gels. It covers a 
range from 5 kDa to 250 kDa and it is supplied ready to be used. It was stored at -20 °C. 
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Glutathione Sepharose 4B GST-tagged protein purification resinj: 
Commercially available affinity chromatography resin for batch purification of GST- tagged 
proteins. 
 
Dithiothreitol (DTT)b:  
A 1 M stock was prepared with 1.54 g DTT diluted in 10 mL ddH2O or in an appropriate 
buffer. 400 μL aliquots were stored at -20 °C.  
 
Truncated BID (t-BID): 
 
Caspase 8n: 
Commercially available protein (Uniprot Q14790) employed as a protease to cleave full- 
length BID generating t-BID. Caspase was resuspended in 50 μL of biophysical buffer with 
15% glycerol. 
 
PUMA 
 
Nickel resink: 
Commercially available nickel resin that recognizes exposed histidine residues and retain a 
protein containing a His-tag. Used in PUMA purification process.  
 
Factor Xal: 
Commercially available protease with a recognition sequence of Ile-Glu/Asp-Gly-Arg, 
cleaving after the Arg residue. It was used to cleave PUMA from GB1.  
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Factor Xa cleavage buffer:  
20 mM Tris pH 8.0, 50 mM NaCl, 5 mM CaCl2. Prepared by the dilution of the [10x] 20 
mM Tris, pH 8 with the addition of 2.92 g of NaCl and 0.74 g CaCl2 in 1 litre of ddH2O. 
The solution was vacuum filtered through a 0.2 μm cellulose acetate membrane. A [10x] 
stock of 20 mM Tris was prepared with 28.8 g Trizma acidc, 1.94 g Trizma basec.  
 
PBS 25 mM imidazole buffer: 
Prepared by the dilution of the [20x] PBS and the addition of 1.70 g of Imidazole diluted in 
1 litre of ddH2O. The solution was vacuum filtered through a 0.2 μm cellulose acetate 
membrane. 
3.2.2 Ionic strength studies  
MOPS 5 mM ionic strength buffer: 
10 mM MOPS (pH 7.4), 5 mM ionic strength due to the buffer. It was prepared with 0.88 g 
of MOPS acidc, 1.32 g of MOPS basec diluted in 1 litre of ddH2O. The solution was vacuum 
filtered through a 0.2 μm cellulose acetate membrane. 
 
MOPS 1 M ionic strength buffer: 
10 mM MOPS (pH 7.4), 1 M ionic strength. It was prepared with 0.75 g of MOPS acidc, 
1.46 g of MOPS basec and 58.18 g NaClc diluted in 1 litre of ddH2O. The solution was 
vacuum filtered through a 0.2 μm cellulose acetate membrane.  
 
3.2.3 pH dependence studies  
Phosphate buffer, pH 2 
10 mM phosphate, 8 mM ionic strength, pH 2. It was prepared with 0.63 g Na2HPO4  
(dihydrate)d, 0.67 g NaH2PO4 (dihydrate)d, 0.212 g NaClc diluted in 1 litre of ddH2O. The 
solution was vacuum filtered through a 0.2 μm cellulose acetate membrane.  
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Phosphate buffer, pH 3 
10 mM phosphate, 8 mM ionic strength, pH 3. It was prepared with 0.123 g Na2HPO4  
(dihydrate)d, 1.37 g NaH2PO4 (dihydrate)d diluted in 1 litre of ddH2O. The solution was 
vacuum filtered through a 0.2 μm cellulose acetate membrane.  
 
Acetate buffer, pH 4 
10 mM acetate, 8 mM ionic strength, pH 4. It was prepared with 0.50 g acetic acid, 0.218 g 
sodium acetate, 0.374 g NaClc diluted in 1 litre of ddH2O. The solution was vacuum filtered 
through a 0.2 μm cellulose acetate membrane.  
 
Acetate buffer, pH 4.5 
10 mM acetate, 8 mM ionic strength, pH 4.5. It was prepared with 0.372 g acetic acid, 0.503 
g sodium acetate, 0.247 g NaClc diluted in 1 litre of ddH2O. The solution was vacuum 
filtered through a 0.2 μm cellulose acetate membrane.  
 
Acetate buffer, pH 5 
10 mM acetate, 8 mM ionic strength, pH 5. It was prepared with 0.204 g acetic acid, 0.880 
g sodium acetate, 0.084 g NaClc diluted in 1 litre of ddH2O. The solution was vacuum 
filtered through a 0.2 μm cellulose acetate membrane.  
 
MES buffer, pH 6 
10 mM MES, 8 mM ionic strength, pH 6. It was prepared with 1.15 g of MES acidc, 0.160 
g of MES basec and 0.231 g NaClc diluted in 1 litre of ddH2O. The solution was vacuum 
filtered through a 0.2 μm cellulose acetate membrane.  
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MOPS buffer, pH 7 
10 mM MOPS, 8 mM ionic strength, pH 7. It was prepared with 1.339 g of MOPS acidc, 
0.809 g of MOPS basec and 0.263 g NaClc diluted in 1 litre of ddH2O. The solution was 
vacuum filtered through a 0.2 μm cellulose acetate membrane.  
 
TRIS buffer, pH 8 
10 mM TRIS, 8 mM ionic strength, pH 8. It was prepared with 0.866 g Trizma acidc, 0.533 
g Trizma basec, 0.141 g NaClc diluted in 1 litre of ddH2O. The solution was vacuum filtered 
through a 0.2 μm cellulose acetate membrane.  
 
TRIS buffer, pH 9 
10 mM TRIS, 8 mM ionic strength, pH 9. It was prepared with 0.173 g Trizma acidc, 1.066 
g Trizma basec, 0.402 g NaClc diluted in 1 litre of ddH2O. The solution was vacuum filtered 
through a 0.2 μm cellulose acetate membrane.  
 
CAPS buffer, pH 10 
10 mM CAPS, 8 mM ionic strength, pH 10. It was prepared with 1.63 g acid componentc, 
0.10 g basic componentc, 0.319 g NaClc diluted in 1 litre of ddH2O. The solution was 
vacuum filtered through a 0.2 μm cellulose acetate membrane.  
CAPS buffer, pH 11 
10 mM CAPS, 8 mM ionic strength, pH 11. It was prepared with 0.487 g acid componentc, 
0.30 g basic componentc, 0.016 g NaClc diluted in 1 litre of ddH2O. The solution was 
vacuum filtered through a 0.2 μm cellulose acetate membrane.  
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3.2.4 Urea solutions  
A 9.5 M ureaj stock solution was made in the appropriate buffer (PBS or biophysical buffer). 
For equilibrium experiments, a series of dilutions were made in order to get a range of 
different concentrations. For proteins containing cysteines, DTT (10 mM final 
concentration) was also added to the urea solution in order to prevent disulphide bond 
formation. The urea concentration was measured using an Atago 1T refractometer (at 25°C 
± 0.5°C) and the equation: 
 
[Urea] =117.66x + 29.753x2 + 185.56x3    Equation 3.1 
 
Where x is the difference in reading between the urea solution and the pure buffer. 
 
 
3.3  Experimental protocols 
 
3.3.1 Preparation of chemically competent cells 
 
E. coli strains (DH5α, BL21- DE3 and C41-pLysS) were used to prepare competent cells 
following the protocol: 
In a sterile Erlenmeyer, 200 μL of bacteria cell was added to 50 mL of LB media and 
incubated in a shaker at 37 °C for approximately 5 hours (OD600 0.3-0.6). The solution was 
then pelleted by centrifugation (Heraeus Multifugue X3Rg, 3000 RPM, 10 minutes, 4 °C) 
and the supernatant was discarded. The cell pellet was resuspended in 10 ml 100 mM CaCl2, 
15% (v/v) glycerol solution and incubated on ice for 20 minutes. Once again, the solution 
was pelleted by centrifugation and the supernatant discarded. The cell pellet was 
resuspended in 2 ml 100 mM CaCl2, 15% (v/v) glycerol solution, aliquoted in 50 μl samples, 
flash-frozen in liquid nitrogen and stored at -80°C. 
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3.3.2 Heat-shock transformation 
 
1 μl of a plasmid stock of interest was added into 50 μl of chemically competent E. coli cells 
and incubated on ice for approximately 30 minutes. The cells were heated up in a water bath 
at 42 °C for 45 seconds and then transferred back into ice for 5 more minutes. Then, 850 μl 
of LB media was added and the cells were incubated in a shaker at 37 °C for 45 minutes. 
The cells were pelleted by centrifugation (2400 ×g, 3 minutes, 25 °C) and resuspended in 
approximately 50 μl of its supernatant to be spread onto either a LB-KAN or LB-AMP agar 
plate. The plate was incubated overnight at 37 °C. 
3.3.3 Plasmid production and purification  
 
On the next day following the transformation, a single colony was taken from the agar plate, 
added to 5 mL of either LB-KAN or LB-AMP media and incubated overnight at 37 °C. The 
cells were then pelleted by centrifugation (17000 ×g, 5 minutes, 25 °C) and the plasmid was 
purified using a QIAprep spin Miniprep kit (QIAGEN) following the manufacturers 
protocol and stored at - 20  °C. 
 
SasG, pH and ionic strength dependence studies: Dr. Dominika Gruszka kindly provided 
me with SasG genes (E-G52 and G52) that were inserted into a pSKB2 plasmid that 
contained a N-terminal histidine tag and a HRV 3C protease recognition cleavage site. The 
plasmid contains a T7 promoter and a kanamycin resistant gene (KanR). 
 
SasG, folding on the ribosome studies: A modified version of the commercially available 
pRSETa vector was used in all the folding on the ribosome experiments. The plasmid 
contains a T7 promoter and an ampicillin resistant gene (AmpR). This modified plasmid 
also encodes an N-terminal polyhistidine tag (6 x His) and a Thrombin cleavage site. 
 
SasG, effect of the charges on the ribosome studies: To study the effect of the charges on 
the co-translational folding of SasG, three versions of G52 and E-G52 were designed: one 
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with all the negative charges replaced, one with all the positive charges replaced and one 
with all the charges replaced. The 3 genes for E-G52 were purchased from GenScript in 
pUC57 vector. The 3 genes for G52 were cut from the purchased E-G52 ones. Then, a 
molecular biology step was done to insert all genes into the same modified pRSETa, the 
same used for all the other ribosome studies (see above).  
 
A1: Bonsu Ku (Korea Research Institute of Bioscience and Biotechnology) donated the A1 
gene inserted into a slighted modified pGEX-4T-3 plasmid, which contained a TEV 
cleavage site. As a result of TEV cleavage, an additional GS was left at the N-terminus of 
A1. 
 
PUMA: Expressed as a GB1 fusion protein. PUMA gene was inserted into a modified 
version of pRSETa plasmid, engineered by Dr Joseph Rogers, which contained an 
N-terminal histidine tag preceding the GB1 and a Factor Xa cleavage site between GB1 and 
PUMA.  
 
Full-length BID and t-BID: The protein encoding genes were designed and purchased 
from GenScript in pUC57 vector. In the lab, I designed a molecular biology strategy to insert 
both genes into the pGEX-4T-3 plasmid, the same used for A1. The proteins were expressed 
and purified using a very similar protocol to A1.     
 
3.3.4 Calculating plasmid concentration 
 
With the purified plasmid DNA, its concentration was calculated using A260  nm absorption 
readings of a 10x diluted sample, measured on a CARY 50 BIO UV-Vis spectrometer. The 
sample was prepared using 10 μL of plasmid DNA diluted into 90 μL ddH2O and measured 
against a blank sample consisted of 10 μL buffer EB (elution buffer, QIAGEN) diluted in 
90 μL ddH2O. 
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Considering that a solution containing 50 μg.ml-1 of double-stranded DNA has an 
absorbance at 260 nm of 1 and taking into account the dilution factor of the sample (DF = 
10), the plasmid concentration was calculated following the equation: 
[Plasmid] = A260 . DF . 50 ug.ml-1           Equation 3.2 
The quality of the DNA was determined by the ratio between A260 and A280 nm readings, 
with values in the range of 1.8-2.0 taken to mean good quality DNA. 
 
3.3.5 Polymerase chain reaction (PCR) 
 
The PCR protocol used in this thesis followed the Phusion Hot Start II DNA Polymerase 
specifications and the samples prepared in order to have a 50 μL total volume per reaction 
tube.  
Table 3.1: Phusion Hot Start II DNA Polymerase recommended PCR sample preparation 
protocol for optimal performance. 
Reaction Mix Final concentration 
H2O - 
HF buffer  1x 
dNTPs  200 μM each 
Primer forward  0.5 μM 
Primer reverse  0.5 μM 
Template DNA (plasmid) 10 ng. μl-1 
Phusion Hot Start II DNA Polymerase  0.02 U/μl 
 
The reaction was performed in a PTC-100 Programmable Thermal Controller (Thermo 
Fisher Scientific). 
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Table 3.2: Cycling program used for PCR  
Step Temperature (°C) Time 
Initial denaturation 95 2 min 
 35 cycles  
Denaturation 95 30 sec 
Annealing  55 30 sec 
Extension  72 4 min 
 End of cycles  
Final extension 72 20 min 
Hold 10 ∞ 
 
3.3.6 Site directed mutagenesis (SDM) 
 
In order to edit a gene by adding, removing or mutating its DNA sequence, SDM was 
performed. The desired plasmid DNA was used as a template and complementary primers 
(30-40 nucleotides in length) were designed containing the desired change in its sequence.   
The SDM protocol followed the Phusion Hot Start II DNA Polymerase specifications in 
order to get an optimal condition for the enzyme. The volumes for the sample preparation 
were calculated in order to have a 50 μL total volume per reaction tube.  
Table 3.3: Phusion Hot Start II DNA Polymerase recommended SDM sample preparation 
protocol for optimal performance. 
Reaction Mix Final concentration 
H2O - 
HF buffer  1x 
dNTPs  200 μM each 
Primer forward  0.5 μM 
Primer reverse  0.5 μM 
Template DNA (plasmid) 20-50 ng. μl-1 
Phusion Hot Start II DNA Polymerase  0.02 U/μl 
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The SDM was performed in a PTC-100 Programmable Thermal Controller (Thermo Fisher 
Scientific). 
Table 3.4: Cycling program used for SDM 
Step Temperature (°C) Time 
Initial denaturation 98 3 sec 
 25 cycles  
Denaturation 98 30 sec 
Annealing  65 30 sec 
Extension  72 3 min 
 End of cycles  
Final extension 72 10 min 
Hold 4 ∞ 
To digest the remaining methylated template DNA, 3 μL of DpnI (10 U/ μL) was then added 
to each reaction tube and incubated overnight at 37 °C. Then, 10 μL of the sample was 
transformed into 100 μL chemically competent cells (DH5α) and the purified plasmid DNA 
was stored at -20 °C. In order to confirm the SDM success, the sample was sent for 
sequencing (Genewiz Inc.). 
3.3.7 Ligation  
 
Ligation reaction was employed in order to join two nucleic acid fragments and to create 
recombinant DNA molecules, such as when a foreign DNA fragment was inserted into a 
plasmid. The ligation reaction is described in Table 3.5. 
Table 3.5: Sample preparation for ligation. 
Reaction Mix Volumes 
H2O 6 μl  
[10x] ligase buffer T4 1 μl 
T4 ligase (5 U/μL) 1 μl 
Plasmid DNA (~100 ng/μL) 1 μl 
DNA insert (~100 ng/μL) 1 μl 
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The sample was incubated at 4 °C overnight in order to guarantee an optimal efficiency of 
the reaction. In the following day, the sample was transformed into DH5α cells (10 μl of the 
ligation sample in 100 μl cells).  
The plasmid was then purified using the QIAprep spin Miniprep kit following the 
manufacturer protocol (QIAGEN) and stored at -20 °C. The purified plasmid was sent for 
sequencing to confirm the reaction’s success. 
3.3.8 Protein production 
 
1 μl of the desired plasmid DNA (~100 ng.μL-1) was transformed into 50 μL BL21-DE3 
(SasG and BID full-length) or C41-pLysS (PUMA and A1) chemically competent cells. On 
the following day, a single colony was added to 50 mL of LB-KAN or LB-AMP media and 
the solution incubated overnight at 37 °C.  
Then, 10 mL of the pre-culture was used to inoculate 1 litre of LB-KAN or LB-AMP media. 
The flask was incubated in a shaker at 37 °C until OD600 was 0.6-0.8 when the cells have 
reached the exponential growth phase. To induce protein expression, 400 μl of IPTG (1 M 
stock) was added to each flask. The temperature was reduced (25 °C for SasG, 24 °C for A1 
and 18 °C for PUMA) and the flask incubated overnight, shaking at 180 rpm. For BID full- 
length, after induction, the temperature was kept at 37 °C for 6 hours.  
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3.3.9 Protein purification 
 
SasG  
S. aureus, Uniprot Q2G2B2, residues 502-629 
 
EG52    
GPETIAPGHRDEFDPKLPTGEKEEVPGKPGIKNPETGDVVRPPVDSVTKYGPVKGDSIVE
KEEIPFEKERKFNPDLAPGTEKVTREGQKGEKTITTPTLKNPLTGEIISKGESKEEITKD
PINELTEYGPET   
G52 
YGPVKGDSIVEKEEIPFEKERKFNPDLAPGTEKVTREGQKGEKTITTPTLKNPLTGEIIS
KGESKEEITKDPINELTEYGPET  
Figure 3.1: Amino acid sequence of SasG E-G52 and G52.  
After the protein expression step, the cells were centrifuged (8000 x g, 15 minutes, 8° C) 
and the pellet was resuspended in 35 ml binding buffer 1 on ice. Cells were lysed by 
sonication (3 minutes total time, 3 seconds on, 7 seconds off) and the cell debris was pelleted 
by centrifugation (38000 ×g, 45 minutes, 8° C). The supernatant was filtered (0.22 μm) and 
purified by FPLC (AKTA, GE Healthcare). The sample was initially loaded onto a 5 ml 
HisTrap column equilibrated with Binding buffer 1. The protein was eluted from the 
HisTrap column using a linear Gradient buffer 1, (20-500 mM Imidazole gradient). The 
fractions containing the protein were collected and cleaved overnight with HRV 3C protease 
in order to remove the N-terminal His-tag. The sample was dialysed (3.5 KDa membrane) 
against 4 litres of [1x] PBS buffer overnight at 4 °C. 
The protein sample in PBS buffer was submitted to a second step of purification using a 
HisTrap column. This step was to separate the cleaved His-tag and the remaining impurities 
from the protein. The sample was loaded into the column and eluted from the HisTrap with 
the Binding buffer 2. As a final step, Gradient buffer 2 was used to wash the HisTrap 
column. The purified protein was stored at -20 °C. 
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The purity of the protein was verified by SDS-PAGE (NuPAGE Bis Tris Mini Gels, Novex 
by Life Technologies) and the correct molecular weight confirmed by mass spectroscopy.  
A1  
Mouse, Uniprot Q07440, residues 1-152 containing P104K and C113S mutations 
 
GSMAESELMHIHSLAEHYLQYVLQVPAFESAPSQACRVLQRVAFSVQKEVEKNLKSYLDD
FHVESIDTARIIFNQVMEKEFEDGIINWGRIVTIFAFGGVLLKKLKQEQIALDVSAYKQV
SSFVAEFIMNNTGEWIRQNGGWEDGFIKKFEPKS 
Figure 3.2: Amino acid sequence of A1. The plasmid containing the P104K and C113S mutations 
was kindly donated by Bonsu Ku. The additional N-terminus GS was left as a result of a TEV 
cleavage.  
 
The A1 sequence containing the mutations P104K and C113S was the same used to solve 
the structures of A1: PUMA and A1: BID (Smits et al. 2008). Cells were pelleted by 
centrifugation (8000 x g, 15 minutes, 8° C), resuspended in 35 mL of PBS and sonicated (3 
minutes total time, 15 seconds on, 45 seconds off). The cell debris was pelleted by 
centrifugation (38000 ×g, 45 minutes, 8° C) and the supernatant was incubated with 
glutathione sepharose 4B resin (approximately 10 mL) for four hours at 4° C. Then, the 
resin containing the bound protein was washed once with PBS and twice with TEV cleavage 
buffer. Each washing step consisted in topping up the falcon tube with buffer, mixing it with 
the resin by inverting the tube and spinning it down by centrifugation (500 ×g, 5 minutes, 
4° C). The supernatant was discarded after each wash. The resin was resuspended in TEV 
cleavage buffer and a final concentration of 2 mM EDTA and 10 mM DTT were added to 
the solution. In order to cleave the protein off the resin, 5 µM of TEV protease was added 
and the protein was incubated overnight at room temperature. The purification of the 
cleaved protein consisted of two FPLC steps: an ion-exchange followed by a size exclusion. 
Using an AKTA FPLC instrument, cleaved A1 was loaded onto an ion-exchange column 
(HiTrapTM SP HP, 5 mL) using the buffers 20 mM TRIS pH 7.0 with 0 and 1 M NaCl. A 
gradient of 0 – 23% NaCl over 60 mL was used to elute A1. Fractions containing the almost 
pure A1 (assessed by SDS-PAGE) were combined. As a final step of purification, the 
protein was loaded into a Superdex G75 gel filtration column used also to exchange the 
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buffer into the 50 mM sodium phosphate biophysical buffer. The purity of the protein was 
verified by SDS-PAGE and the correct molecular weight confirmed by mass spectroscopy. 
The protein was stored at 4° C. 
PUMA peptide  
Mouse, Uniprot Q99ML1, residues 127-161, containing the mutation M144A 
 
RVEEEEWAREIGAQLRRAADDLNAQYERRRQEEQH 
Figure 3.3: Amino acid sequence of PUMA peptide. The peptide was produced containing the 
M144A mutation to prevent oligomerization.  
The mutation M144A was introduced to make the peptide less prone to self-association 
(Joseph M. Rogers, Wong, and Clarke 2014). Cells were pelleted by centrifugation (8000 x 
g, 15 minutes, 8° C), resuspended in 35 mL of PBS, 25 mM imidazole buffer and cells were 
lysed by sonication (3 minutes total time, 15 seconds on, 45 seconds off). Sonicate 
supernatant was incubated with Ni+2 agarose resink (1.25 mL per litre of culture) for 1 hour 
at 4° C. The resin was washed twice with PBS, 25 mM imidazole and once with Factor Xa 
cleavage buffer. Washing steps consisted in filling up the falcon tube with buffer, mixing it 
by inversion and decanting the resin by centrifugation (500 ×g, 5 minutes, 4°C). The 
supernatant was discarded after each wash. The resin was resuspended in Factor Xa 
cleavage buffer and incubated with 20 ug of Factor Xal overnight at room temperature. The 
purification of PUMA consisted of two steps: an ion exchange followed by size exclusion. 
Using an AKTA FPLC instrument, the resin supernatant was loaded onto an ion-exchange 
column (HiTrapTM SP HP, 5 mL), using the buffers 20 mM TRIS pH 7.0 with 0 and 1 M 
NaCl. PUMA was eluted from the column with a gradient of 0 – 250 mM NaCl over 90 mL. 
Fractions containing PUMA (assessed by SDS-PAGE) were pooled and loaded onto a size 
exclusion column (HiLoadTM 26/600 Superdex 30 pg). This final step was used also to 
exchange the buffer into the 50 mM sodium phosphate biophysical buffer. The purity of the 
protein was verified by SDS-PAGE and the correct molecular weight confirmed by mass 
spectroscopy. Purified PUMA was aliquoted, flash frozen in liquid nitrogen and stored at 
- 80 °C.  
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BID-TAMRA peptides  
Mouse, Uniprot P70444, residues 76- 110 
 
Mouse BID peptides, wild-type and mutants, were purchased from Biomatik (Canada). The 
peptides were N-terminally labelled with TAMRA fluorescent dye. The peptides were 
synthetized as trifluroacetate salts and were reconstituted in biophysical buffer. The 
solutions were filtered, aliquoted, flash frozen in liquid nitrogen and stored at - 80°C.  
WT   SESQEEIIHNIARHLAQIGDEMDHNIQPTLVRQLA 
E81G    SESQEGIIHNIARHLAQIGDEMDHNIQPTLVRQLA 
E81A    SESQEAIIHNIARHLAQIGDEMDHNIQPTLVRQLA 
I82A    SESQEEAIHNIARHLAQIGDEMDHNIQPTLVRQLA 
I83A    SESQEEIAHNIARHLAQIGDEMDHNIQPTLVRQLA 
N85G   SESQEEIIHGIARHLAQIGDEMDHNIQPTLVRQLA 
N85A   SESQEEIIHAIARHLAQIGDEMDHNIQPTLVRQLA 
I86A   SESQEEIIHNAARHLAQIGDEMDHNIQPTLVRQLA 
R88G   SESQEEIIHNIAGHLAQIGDEMDHNIQPTLVRQLA 
R88A   SESQEEIIHNIAAHLAQIGDEMDHNIQPTLVRQLA 
L90A   SESQEEIIHNIARHAAQIGDEMDHNIQPTLVRQLA 
Q92G   SESQEEIIHNIARHLAGIGDEMDHNIQPTLVRQLA 
Q92A   SESQEEIIHNIARHLAAIGDEMDHNIQPTLVRQLA 
I93A   SESQEEIIHNIARHLAQAGDEMDHNIQPTLVRQLA 
E96G   SESQEEIIHNIARHLAQIGDGMDHNIQPTLVRQLA 
E96A   SESQEEIIHNIARHLAQIGDAMDHNIQPTLVRQLA 
M97A   SESQEEIIHNIARHLAQIGDEADHNIQPTLVRQLA 
H99G   SESQEEIIHNIARHLAQIGDEMDGNIQPTLVRQLA 
H99A   SESQEEIIHNIARHLAQIGDEMDANIQPTLVRQLA 
I101A   SESQEEIIHNIARHLAQIGDEMDHNAQPTLVRQLA 
I86A-M97A SESQEEIIHNAARHLAQIGDEADHNIQPTLVRQLA 
Figure 3.4: Amino acid sequences of synthetized BID wild-type and mutants. The peptides were 
synthesized with an N-terminal TAMRA fluorescent dye. 
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Figure 3.5: Chemical structure of TAMRA fluorescent dye. 5 Carboxytetramethylrhodamine 
(TAMRA) dye was attached to the N-terminus of all synthesized BID peptides. The presence of 
TAMRA did not change the net charge of the peptides. TAMRA chemical structure was constructed 
using ChemDraw Professional (version 17.0). 
 
BID full-length  
 
Mouse, Uniprot P70444, residues 1- 195 
 
GSMDSEVSNGSGLGAEHITDLLVFGFLQSSGCTRQELEVLGRELPVQAYWEADLEDELQT
DGSQASRSFNQGRIEPDSESQEEIIHNIARHLAQIGDEMDHNIQPTLVRQLAAQFMNGSL
SEEDKRNCLAKALDEVKTAFPRDMENDKAMLIMTMLLAKKVASHAPSLLRDVFHTTVNFI
NQNLFSYVRNLVRNEMD 
Figure 3.6: Amino acid sequence of BID full-length. The gene that encodes the protein was 
purchased from GenScript in the pUC57 vector. The additional GS at the N-terminus of the sequence 
was left as a result of a TEV cleavage.      
 
Cells were pelleted by centrifugation (8000 x g, 15 minutes, 8° C), resuspended in 25 mL 
of PBS and the cells were lysed by sonication (3 minutes total time, 15 seconds on, 45 
seconds off). The sonicate supernatant was incubated with glutathione sepharose 4B resin 
(approximately 10 mL) for four hours at 4° C. Resin was washed once with PBS and twice 
with TEV cleavage buffer. The beads were resuspended in TEV cleavage buffer and EDTA 
and DTT (2 and 10 mM final concentrations, respectively) were added to the solution. Then, 
5 µM final concentration of TEV protease was added and the protein was incubated at room 
(CH2)2N O NH(CH2)2
C
O
O
C
O NH
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temperature overnight. Differently than what was done for A1 purification, a HisTrap step 
was used for BID instead of an ion-exchange. BID full- length has an overall charge of -15 
(32 positively charged and 17 negatively charged residues) and adding an ion-exchange step 
would be particularly challenging, as a very high salt concentration would be required. Since 
TEV has a His-tag, a His-Trap step was employed to separate cleaved TEV from the protein. 
Firstly, 20 mM imidazole was added to the protein sample to prevent BID binding to the 
nickel resin. Then, the solution was passed through a HisTrap column (2 mL/min flow rate). 
As a final purification step, the protein was loaded onto a Superdex G75 gel filtration 
column used also to exchange the buffer into the 50 mM sodium phosphate biophysical 
buffer. The purity of the protein was verified by SDS-PAGE and the correct molecular 
weight confirmed by mass spectroscopy. The protein was stored at 4 °C. 
t-BID 
 
Mouse, Uniprot P70444, residues 61- 195 
 
SQASRSFNQGRIEPDSESQEEIIHNIARHLAQIGDEMDHNIQPTLVRQLAAQFMNGSLSE
EDKRNCLAKALDEVKTAFPRDMENDKAMLIMTMLLAKKVASHAPSLLRDVFHTTVNFINQ
NLFSYVRNLVRNEMD 
Figure 3.7: Amino acid sequence of t-BID. The gene that encodes t-BID was purchased from 
GenScript in the pUC57 vector but the truncated protein could not be produced directly. It required 
the production of BID full-length and its truncation was produced using caspase 8.  
 
Purified BID full-length was cleaved by caspase 8 in order to produce t-BID. The 25 U of 
the purchased caspase was resuspended in 50 μL of biophysical buffer with 15% glycerol. 
The protease was added to 10 mL of BID full-length (approximately 70 μM) with 5% 
glycerol, 10 mM DTT and 10 mM EDTA. The reaction was carried out at room temperature 
overnight. After the reaction, SDS-PAGE shows three components present: t-BID, BID 
fragment (60 residues cleaved from BID) and a small amount of uncleaved BID full-length. 
To unfold t-BID and BID fragment that remain folded after cleavage, the protein sample 
was incubated with 8 M urea for 2 hours at room temperature, before a size exclusion gel 
 
Materials and methods 
 
 
 
58 
filtration step. Using an AKTA FPLC instrument, the protein sample was loaded onto a G75 
gel filtration column, previously equilibrated with 8 M urea in the biophysical buffer. 
Fractions containing separated t-BID, BID fragment and BID full-length were collected and 
the proteins were stored at 4 °C. 
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3.3.10 Calculating protein concentration 
 
Protein concentration was calculated following the Beer-Lambert equation: 
 
A= ε.c.l                     Equation 3.3 
Where,   
A is the absorbance at a specific wavelength. 
ε is the extinction coefficient of the solution (M-1.cm-1). 
c is the solution concentration (M). 
l is the path length of the cuvette in which the sample is contained (cm). 
The absorbance readings were taken in a CARY 50 BIO UV-Vis spectrometer. A sample of 
the corresponding buffer was used as a blank and the total absorbance calculated by the A280 
values from the protein sample. The extinction coefficient for SasG (ε= 2980 M-1.cm-1) was 
obtained from the ProtParam tool (ExPASy). For a more accurate extinction coefficient and 
concentration calculation, multiple samples of A1, BID peptides and BID full-length were 
sent for amino acid analysis (AAA) performed at the Biochemistry department. The 
experimental concentration values from AAA were then plotted against the A280 (A555 for 
TAMRA labeled peptides) values and the gradients of the straight-line fits gave the 
extinction coefficients. (A1: ε= 24200 M-1.cm-1, BID-TAMRA peptides ε= 85000 M-1.cm-1 
and BID full-length ε= 8700 M-1.cm-1).  
 
3.3.11 Equilibrium folding stability: data acquisition and data analysis 
 
Two solutions were prepared volumetrically to perform equilibrium experiments: 9 M and 
0 M urea, both in 1x PBS. A Hamilton Microlab® was used to dispense the solutions in order 
to create a set of 68 tubes (800 μl samples) with urea concentration ranging from 0 to 9 M. 
A 100 μl sample of 45 μM protein stock solution in 1x PBS was added to each tube in order 
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to give a final protein concentration of 5 μM. The set of tubes were left to equilibrate at 
25 °C for 30 minutes. The data were collected using a LS-50 luminescence 
spectrophotometer (PerkinElmer). Fluorescence readings were obtained from each solution 
equilibrated at 25 °C. The excitation wavelength was set to 276 nm and the scan taken from 
290-390 nm (300 nm.min-1).  
The acquired data were exported to a Kaleidagraph spreadsheet (Synergy Software) plotted 
and fitted to Equation 2.3 (chapter 2), from which thermodynamic parameters (,#$%, 
[den]50% and ∆"#$%'(); see chapter 2 for details) were obtained. To allow comparison the 
fluorescence data were converted into fraction folded using the Equation 2.4 (chapter 2). 
3.3.12 Folding on the ribosome: the arrest peptide assay 
 
The arrest peptide assay with the incorporation of 35S methioninel into nascent protein 
chains was performed using the PUREfrexm in vitro translation kit. Up to 24 reactions could 
be run simultaneously. 
A master mix reaction containing the solutions with the volumes recommended on the kit 
protocol and the 35S methionine was prepared. 9 μl of the master mix was added to 1 μl of 
the template DNA within a 20 seconds interval between each sample. The final 10 μl 
reaction (Table 3.6) was incubated in a thermo mixer at 37 °C for 15 minutes and 500 rpm.  
Table 3.6: Reaction mix for the incorporation of 35S methionine into nascent protein chains.  
Reaction Volume 
Solution I 5 μl 
Solution II 0.5 μl 
Solution III 0.5 μl 
Template DNA 1.0 μl 
35S methioninel 0.5 μl 
ddH2O 2.5 μl 
To stop the reaction after 15 minutes, 10 μl of ice-cold 10 % (v/v) trichloroacetic acid (TCA) 
in water was added to each tube within a 20 seconds interval between each sample. They 
were incubated on ice for 30 minutes. 
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Precipitated samples were pelleted by centrifugation for 5 minutes at 4°C and 14000 rpm. 
The supernatants were removed and discharged via the radioactivity waste sink. 10 μl of 
[1x] protein loading buffer was added to each tube and the pellets were resupended by 
agitation (15 minutes, 37°C and 1400 rpm). Then 1.5 μl of RNase A (4 mg/ml) was added 
to each tube and samples were incubated for 15 minutes at 37° C with shaking at 700 rpm. 
The samples were loaded (11.5 μl) onto a standard NuPage gel and run for 50 minutes at 
200 V. After running, the gel was fixed in 50 ml Instant Blue solution for 45 minutes and 
then dried in a gel drier for 2 hours at 80 °C. 
The dried gel was transferred to a phosphorimaging plate and left for two days. After that, 
the phosphorimaging plate was read on the Typhoon trioj and the image saved and analysed 
using the program ImageJ (Schneider, Rasband, and Eliceiri 2012); Figure 2.1).  
 
Figure 3.8: Arrest peptide assay. (A) A generic protein imaged gel. (B) The intensity of the two 
bands is quantified to generate a profile of intensity vs. position using the ImageJ program.  
  
Full-length  
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The data can be fitted to an equation involving the two Guassians and a flat baseline. 
 
ü = h + 	ç†I(°IÅ)((¢( + 	;†I(°I£)((§(             Equation 3.4 
 
 
From equation 3.4, the area of each band can be quantified using: 
 
Area	1 = 	ç•√2ß                                   Equation 3.5 
Area	2 = 	;®√2ß                                   Equation 3.6 
 
And finally, each band can be quantified as a percentage of the total area or, in other words, 
we can find out the fraction full-length of the protein in each linker length sample and then 
get the force profile (fraction full-length vs. linker length). 
 
3.3.13 Circular Dichroism (CD) 
 
CD was employed in order to investigate the proteins and peptides secondary structures. 
The experiments were performed using an Applied Photophysics Chirascan spectrometer. 
Samples were prepared by weight to ensure an accurate concentration. In each experiment, 
the buffer in use was scanned and subtracted from each protein spectrum. The CD signal 
(millidegrees (mdeg)), obtained from far-UV CD is dependent on protein secondary 
structure as well as on the number of peptide bonds. Therefore, to allow comparison 
between different proteins, the CD signal was converted to mean residual ellipticity (MRE), 
which accounts for protein concentration, number of amino acids (aa) and cuvette path 
length (Equation 3.7): 
MRE = ¨#	ov≠Cöõ	(ÆAB≠)Pñ	E	ØmCØBC∞±ö∞vmC	(})	E		CwÆnB±	mx	öö	E	Fö∞≤	õBC≠≤∞	(ØÆ)  Equation 3.7 
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Path length needs to be taken into account as the interactions between the polarised light 
and the protein molecules will vary not only with the protein concentration and its number 
of residues, but with the length that the light will pass through as well. A longer path length 
will result in a greater mdeg signal. However, increasing the path length also increases the 
background absorbance, which can be minimised by adjusting the detector voltage. The 
manufacturer’s recommendation for the Applied Photophysics instrument was a maximum 
of 800 V. An optimization of signal to noise ratio was obtained carefully balancing the 
protein concentration and the path length for each experiment.  
 
A1 
 
Due to the presence of a single cysteine residue in A1 sequence, DTT (10 mM final 
concentration) was added to the protein sample to avoid disulphide-bond formation. DTT 
absorbs in the far-UV region, which increases the background absorbance. To optimize this 
condition, a 0.2 mm cuvette was chosen to allow enough light to pass through and reach the 
detector. Experimental settings were 1 nm bandwidth, 5 s adaptive time-per-point sampling 
at 25 °C. Different A1 concentrations were used and compared to check for oligomerization.   
 
BID TAMRA peptides  
 
To check for oligomerization propensity of TAMRA labelled BID peptides, two different 
concentrations (5 and 10 μM) were scanned and the spectra of each peptide compared. The 
experimental settings were 2 mm path length, 1 nm bandwidth, 5 s adaptive time-per-point 
sampling at 25 °C. All peptide samples were prepared and scanned on the same day. Each 
sample was sent for amino acid analysis (Department of Biochemistry) for an accurate 
concentration determination. Peptide helicity was calculated from the highest concentration 
sample.  
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Coupled folding and binding  
 
CD was used to probe coupled folding and binding between IDP and partner protein, based 
on the assumption that a change in the structures would occur. Spectra of equimolar 
concentrations of each individual component were collected and converted to MRE. Then, 
the mean of the two individual sample spectra was calculated and the MRE would represent 
the spectrum expected if no structure change would occur upon binding. Next, a mixture of 
the two samples (1:1 volume ratio) was incubated at 25 °C for two hours and then scanned. 
The difference between the expected spectrum calculated from the individual scans and the 
one from the mixture, is related to the structure change upon the formation of the complex. 
To allow this comparison, the difference spectra were multiplied by the fraction of protein 
in complex. The concentration of the complex ([AB]) was estimated by the equation 3.8. 
 
[AB] = 	 (	[µ]?[∂]?	∑∏$π(([µ]?[∂]?∑∏)$∫	[µ].[∂])	)ª 								Equation 3.8 
 
Where, [A] and [B] are the total concentration of each protein and Kd is the dissociation 
constant for the complex. To calculate the fraction bound, the concentration of the complex 
([AB]) was divided by the total amount of either protein A or B.  
 
Helical content estimation 
 
The helical content estimation in this thesis was calculated from the MRE value at 222 nm 
following Muñoz and Serrano method (Muñoz and Serrano 1995). 
The method describes that the expected MRE of a helical protein at 0 °C is given by: 
MRE≤BõvE	(ñ°¨)	 = −39500	 ø1 − ª.¿¡CwÆnB±	mx	öÆvCm	öØvAo¬    Equation 3.9  
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For a random coil at a given temperature, the MRE is calculated by: 
 MREØmvõ = 400 − 45t                              Equation 3.10 
  
Where 400 is the MRE value at 222 nm for a random coil at 0 °C and t is the temperature 
in Celsius.  
The MRE for a helix at a given temperature is calculated by: 
 MRE≤BõvE = 	MRE≤BõvE	(ñ°¨) + 100t        Equation 3.11 
 
Where MRE helix (0°C) can be calculated from the Equation 3.9 and t is the temperature in 
Celsius.  
 
Then, the helical content can be estimated by: 
 
%	Helix = Pññ(P?ƒ(≈∆«(((I≈∆«»… ÀÃ)(≈∆«ÕìÀ I≈∆«((() Œ                 Equation 3.12 
 
Where MRE222 is the measured MRE at 222 nm and MREcoil and MREhelix are calculated 
from the equations 3.10 and 3.11. 
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3.3.14 Association kinetics 
 
Association kinetics experiments were performed by rapidly mixing protein solutions in a 
stopped-flow spectrometer (Applied Photophysics) and following the TAMRA dye 
fluorescence. The excitation wavelength was 555 nm and the emission was recorded above 
570 nm, with a slit width of 1 mm. The temperature was maintained at 25 °C. A cut-off 
filter (570 nm) was utilized to reduce the detection of scattered light. A minimum of 15 
traces were collected and averaged before analysis. Data collected before the instrument’s 
mixing dead-time (1 ms) were removed. 
The experiments were performed under pseudo-first order conditions, with the 
concentration of one protein at least 10-fold higher than the other. To minimize the signal 
to noise problem, the protein with the lower fluorescence was used in excess. The averaged 
trace of each concentration of protein in excess was fit to a single exponential decay function 
(Equation 2.26, chapter 2) and the observed rate constant (kobs) was calculated by: 
 dœno = dmC	[A] +	dmxx                       Equation 3.13 
 
Where [A] is the concentration of the protein in excess, and kon and koff are the association 
and dissociation rate constants, respectively. Thus, kon was determined by the gradient from 
the fit of kobs versus [A]. 
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3.3.15 Dissociation kinetics  
 
Dissociation kinetics experiments were performed using either a stopped-flow spectrometer 
(Applied Photophysics) (for kobs > 0.03 s-1) or a fluorescence spectrophotometer (Cary 
Eclipse, Varian) (for kobs < 0.03 s-1). Samples comprised of peptide/protein and its partner 
were mixed with various concentrations of an excess of competitor peptide. The idea being 
that the higher affinity peptide competitor would form a complex with the partner protein, 
releasing the peptide of interest, reaching a new equilibrium. The fluorescence change upon 
formation of the new complex was used to extract the kobs. Traces were averaged and the 
mean was fit to a single exponential decay function (Equation 2.26, chapter 2). Excess of 
the competitor was used to guarantee that kobs represents koff, whereas at a low 
competitor/complex ratio, kobs would represent the koff plus a component of kon, from the 
peptide/partner complex being reformed. 
Experimental settings were 340 nm excitation and 360 nm emission wavelengths, when 
following intrinsic tryptophan fluorescence, or 555/575 nm for TAMRA labelled peptides. 
The temperature was maintained at 25 °C and slit widths were 2.5 and 10 nm on the 
fluorimeter or 1 nm on the stopped-flow. For TAMRA labelled BID peptides, the 
fluorescence change was small. Therefore, fluorescence anisotropy (vertical/vertical 
channel) was used to follow the dissociation kinetics.  
Pre-formed complexes of 5 μM BID-TAMRA peptides/partner protein were mixed with 
different concentrations of PUMA, in a 1:9 or 1:10 ratio for the fluorimeter and stopped-
flow, respectively. Samples were manually mixed before starting to be recorded in the 
fluorimenter, which caused the start of the reaction to be missed. This lag time was taken 
into account by recording the time between the addition of the competitor and the return of 
the cuvette to the fluorimeter. That information was then used to adjust the reaction time 
scale during the data analysis. Three data points of different concentrations of competitor 
were recorded and the observed rate constants (kobs) were averaged. As the concentrations 
of competitor were sufficiently high, kobs was equal koff. 
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3.3.16 Equilibrium binding affinities 
 
Equilibrium dissociation constants (Kd) were measured following fluorescence anisotropy, 
using a spectrophotometer (Cary Eclipse, Varian) at 25 °C. The TAMRA dye fluorophore 
was excited at 555 nm and its emission was recorded at 575 nm. The emission/excitation 
slit widths were 2.5 and 10, respectively. Vertical and horizontal channels were used to 
calculate the anisotropy.  
Thus, a correction factor (G) was calculated to take into account the instrument capacity to 
detect the fluorescence in the different channels. G factor was calculated by: 
 
G = —“”—““                              Equation 3.14 
 
Where IHH is the fluorescence intensity when using the horizontal excitation/emission 
channel and IHV, the horizontal excitation and vertical emission channels.   
The anisotropy (R) can then be calculated by: 
  
R = —””$‘—”“—””?ª‘—”“                       Equation 3.15 
 
Where IVV is the fluorescence intensity when using the vertical excitation/emission channel 
and IVH, the vertical excitation and horizontal emission channels.   
To account for the changes in fluorescence intensity upon the binding reaction, the 
anisotropy can be adjusted (Radj) using the equation from Dandliker et al (Dandliker et al. 
1981): 
b’ê÷ = ◊ÿ	×	⁄ô	⁄¤×	M¤?MôP?◊ÿ×⁄ô⁄¤                              Equation 3.16 
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Where Q is the measured fluorescence, x is the difference between the measured and the 
free peptide anisotropy, y is the difference between the anisotropy of the bound peptide and 
the measured anisotropy and R is the measured anisotropy.  
Total fluorescence intensity of the free (Qf) and bound (Qb) peptide was calculated by: 
 Q = Iﬁﬁ + 2Iﬁ'                                    Equation 3.17 
After the anisotropy calculation (Equation 3.16), it is then possible to determine the 
equilibrium binding dissociation constant (Kd): 
böAﬂ = bx + ∆b ƒ∑∏?[å]?[ë]$π((∑∏?[å]?[ë])($∫[å][ë])ª[å] Œ																			Equation 3.18 
 
where [A] and [B] are the concentrations of the IDP peptide and partner protein, 
respectively, Rf is the anisotropy of the free peptide and ΔR is the difference between the 
free and bound peptide anisotropies. 
 
3.3.17 Data Analysis  
 
Throughout the thesis, biophysics data were fit using Kaleidagraph (version 4.1, Synergy). 
Quantification of the protein gels bands for the ribosome experiments was done using 
ImageJ (version 1.52a, NIH). 
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4 Role of charged residues in the stability of SasG  
4.1 Introduction 
 
4.1.1 SasG biological background 
 
Certain bacterial species are able to produce a polymeric matrix that adheres to living or 
inert surface to form functional communities, known as bacterial biofilms (Costerton et al. 
1999). Biofilms are very difficult to eradicate as they are resistant to the host immune system 
and to antimicrobial agents (Lewis 2001; Dunne 2002; Steward & Costdrton 2001), and 
present a challenge when treating chronic infections – as usually seen with inserted medical 
devices (Harris and Richards 2006). Staphylococci are a common source of infections 
mediated by biofilms, as they populate the human skin and mucous surfaces.  
Staphylococcus aureus surface protein G (SasG) promotes cell-to-cell accumulation during 
biofilm formation (Geoghegan et al. 2010b). Non-pathogenic S. aureus normally lives in 
anterior nares, where the pH is just below neutral, around 6 to 6.5 (Washington et al. 2000). 
When infection starts and S. aureus turns into a pathogen somewhere in the body, the pH is 
likely to be more acidic. It is known that during immune responses, neutrophils and other 
immune cells release their content in acidic microenvironments (Cao et al. 2015), where the 
pH is likely to drop below 5. In fact, there are some suggestions in the literature that release 
of zinc by neutrophils (and associated drop in pH) might be the trigger for biofilm formation 
(Conrady, Wilson, and Herr 2013). In this context, it is expected that during biofilm 
formation, SasG would experience a variety of different conditions in the body, including 
changes in pH. 
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4.1.2 SasG biophysical background 
 
SasG amino acid composition is very intriguing: it is comprised mainly of charged residues, 
prolines and glycines. Thus, it has a sequence composition of an IDP, but yet it folds. Its G5 
domains are folded in isolation and in multidomain constructs whereas the E domains only 
fold when preceding a G5 domain or in multidomain constructs (Dominika T Gruszka et al. 
2012).  
The second G5 domain (G52) has 38% of its sequence composed by charged amino acids 
(Arg, Lys, Asp, Glu) and lacks a hydrophobic core as the β-sheets are exposed to solvent on 
both sides. The E domain is also highly charged, which makes the E-G52 construct 
analogous, with a total of 36% of charged residues (Figure 4.1).  
  
Figure 4.1: Charged residues in SasG G52 and E-G52 constructs. Side chains of (A) G52 and (B) E-
G52, showing exposed charged amino acids and its sequences with charged residues highlighted 
and their percentage within the domain amino acid composition.  
A	
B	
!
GPVKGDSIVEKEEIPFEKERKFNPDLAPGTEKVTREGQKGEKTITT
PTLKNPLTGEIISKGESKEEITKDPINELTEYGPET!
		
38%	charged	(31/82):	Arg	(2),	Lys	(11),	Asp	(3),	Glu	(15)	
		
	
!
GPEMIAPGHRDEFDPKLPTGEKEEVPGKPGIKNPETGDVVRPPVD
SVTKYGPVKGDSIVEKEEIPFEKERKFNPDLAPGTEKVTREGQKG
EKTITTPTLKNPLTGEIISKGESKEEITKDPINELTEYGPET!
	
36%	charged	(48/132):	Arg	(4),	Lys	(16),	Asp	(7),	Glu	(21)	
		
	
 
Role of charged residues in the stability of SasG 
 
 
 
72 
4.1.3 Kappa value 
Highly charged proteins can be extended or collapsed, depending on their patterning. The 
patterning can be measured using a kappa value (κ), a parameter that can vary from 0-1 (Das 
and Pappu 2013). κ is low for well-mixed sequences, where the intra-chain interactions are 
well balanced. Segregated opposite charges generates a high κ (Figure 4.2). 
 
Figure 4.2: Kappa value example of thirty sequence variants composed by Glu-Lys residues. 
Column 1 shows the label of each sequence variant. Column 2 shows the actual sequence, with Glu 
residues in red and Lys residues in blue. Column 3 shows the κ-values (Figure taken from Das and 
Pappu 2013). 
The pattern of charged residues in a protein sequence can be related to its ability to fold. 
Low κ-values are often encountered in random coil ensembles, whereas high κ-values are 
observed in hairpin-like conformations where long-range electrostatic interactions occur. 
The κ-value for SasG G52 domain was calculated using CIDER (Holehouse et al. 2017), a 
tool developed by the Pappu laboratory that uses various algorithms to analyse protein 
sequences. 
κ-values for G52 domain and E-G52 are 0.072 and 0.080, respectively (Figure 4.3). 
According to the charged residues pattern distribution, both constructs were likely to be 
expanded. This is in agreement with the PONDR-FIT (Xue et al. 2010) disorder predictor 
analysis (Introduction, chapter 1), but not in agreement with the structural data. One might 
infer that the charges are involved in salt bridges formation, as is the case for the highly 
patterned sequences.  
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Figure 4.3: Kappa values results for SasG G52and E-G52 constructs. Values for both G52 and E-G52 
are low, 0.072 and 0.080 respectively.  
It has been shown that proline and glycine residues are very important for SasG stability at 
physiological pH (Gruszka et al. 2016). Additionally, it is known that the cooperativity 
between SasG domains could be important for sensing mechanical stress (Gruszka et al. 
2015), allowing the protein to fold and unfold in response to environmental conditions.  
Considering that the protein also naturally experiences environments with different pH and 
given the unusually charged nature of the protein, we were interested to investigate whether 
protein stability was also sensitive to this environmental input. 
 
4.1.4 Chapter aims 
In this chapter, bioinformatics analysis and biophysical experiments were performed in 
order to investigate the role of charged amino acids in the stability of SasG. It will include 
results from the peptide charge calculator tool, kappa-value analysis, salt bridges predictor, 
ionic strength dependence (for both G52 and E-G52 constructs) and pH dependence studies 
of G52. The data provide insights on the importance of the charged residues for SasG 
stability.  
Protein Name = SasG.G52
Amino Acid Sequence = 
GPVKGDSIVEKEEIPFEKERKFNPDLAPGTEKVTREGQKGEKTITTPTLKNPLTGEIISKGESKEEITKDPINELTEYGPET
Length = 82
Molecular Weight (ProtParam) = 9069.02 da
pI (ProtParam) = 4.82
Kappa Value (Assuming all Charged) = 0.072
Amino Acid Content = 
{'A': 1, 'C': 0, 'E': 15, 'D': 3, 'G': 8, 'F': 2, 'I': 7, 'H': 0, 'K': 11, 'M': 0, 'L': 4, 
'N': 3, 'Q': 1, 'P': 8, 'S': 3, 'R': 2, 'T': 10, 'W': 0, 'V': 3, 'Y': 1}
Protein Name = SasG.E-G52
Amino Acid Sequence = 
GPEMIAPGHRDEFDPKLPTGEKEçEVPGKPGIKNPETGDVVRPPVDSVTKYGPVKGDSIVEKEEIPFEKERKFNPDLAPGTEKVTREGQKGEKT
ITTPTLKNPLTGEIISKGESKEEITKDPINELTEYGPET
Length = 132
Molecular Weight (ProtParam) = 14463.01 da
pI (ProtParam) = 4.84
Kappa Value (Assuming all Charged) = 0.080
Amino Acid Content = 
{'A': 2, 'C': 0, 'E': 21, 'D': 7, 'G': 14, 'F': 3, 'I': 9, 'H': 1, 'K': 16, 'M': 1, 'L': 5, 
'N': 4, 'Q': 1, 'P': 17, 'S': 4, 'R': 4, 'T': 13, 'W': 0, 'V': 8, 'Y': 2}
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4.2 Results 
 
4.2.1 Peptide charge calculator 
The “Peptide charge calculator” (Gale Rhodes, University of Southern Maine), is a script 
that calculates the sum of each charged species of a protein sequence using the Henderson-
Hasselbach equation at each pH. Using this tool, it was possible to generate a plot with the 
profile of the net charge against increasing pH for SasG G52 and E-G52 constructs. (Figure 
4.4).  
  
Figure 4.4: Peptide charge calculator results for G52 and E-G52constructs. The script computes net 
charge on peptide from composition of ionisable residues.   
 
The plot shows the expected net charge across the pH range for G52 and E-G52. Any residues 
involved in salt bridges may experience altered pKa values (Anderson, Becktel, and 
Dahlquist 1990), stabilising the ionised state. Protein stability is altered by changes in total 
net charge (Shaw et al. 2001). Therefore, based on this net charge calculator, we might 
expect the protein stability to remain relatively unaltered in the 6-9 region, with changes in 
stability occurring in the range 3-5 and 10-12. On the other hand, if the residues are involved 
in salt bridge formation, we might expect the protein stability to remain unchanged over a 
wider range of pH.  
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4.2.2 SasG salt bridges  
 
The ESBRI tool (Evaluating the salt bridges in proteins online tool; Costantini et al. 2008), 
was used in order to check if charged residues were involved in salt bridges along SasG 
structure. A cut off of 4 Å was used as a maximum distance between two opposite charged 
residues (Kumar and Nussinov 2002). The results show that despite having 31 charged 
amino acids, G52 has only six salt bridges (Figure 4.5, A). E-G52 has 48 charged amino 
acids but only 8 salt bridges (Figure 4.5, B). Perhaps this should not be a surprise since all 
residues are solvent exposed and able to interact with water. 
 
  
 
 
 
 
 
 
 
 
Figure 4.5: Salt bridges results of SasG contructs. Salt bridges predictions for (A) G52 and (B) 
E-G52, using ESBRI tool (Costantini et al. 2008) assuming a 4 Å cut-off. 
  
G52-WT!
Residue 1! !Residue 2! !Distance!
LYS 565 ! !GLU 621 !  !3.84!
ARG 567 ! !GLU 578 !  !3.09!
LYS 586 ! !GLU 560 ! !3.23!
LYS 589 ! !GLU 612 ! !3.46!
LYS 597 ! !ASP 553 ! !3.90!
LYS 611 ! !GLU 613 ! !3.96!
!
!
EG52-WT!
Residue 1!Residue 2! ! !Distance!
HIS 506 ! !ASP 621 !  !2.92!
HIS 506 ! !ASP 578 !  !3.27!
LYS 565 ! !GLU 560 ! !3.84!
ARG 567 ! !GLU 612 ! !3.09!
LYS 586 ! !GLU 553 ! !3.23!
LYS 589 ! !GLU 613 ! !3.46!
LYS 597 ! !ASP 613 ! !3.90!
LYS 611 ! !GLU 613 ! !3.96!
!
A	
B	
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4.2.3 Ionic strength effect on SasG contructs: G52 and E-G52 
 
Both constructs G52-WT and E-G52-WT were successfully expressed in E. coli and purified 
by nickel affinity chromatography. A yield of approximately 60 mg of protein per litre of 
cell culture was obtained. The purity of each protein was verified by SDS-PAGE and 
confirmed by mass spectrometry. 
Neither G52 or E domains have a tryptophan residue in their sequence composition, so all 
equilibrium studies were performed following tyrosine fluorescence signal. There is one 
tyrosine located in the C-terminal end of each domain; one in E and one in G5 (figure 4.6).  
 
 
Figure 4.6: Tyrosine residues in E-G52 construct. 
Previous equilibrium and kinetics studies showed that the observed fluorescence signal in 
SasG EG52 construct comes mainly from the tyrosine located in the G52 domain (Y625) 
(Gruszka et al. 2016). 
In order to do a screening of the charge-charge interactions of SasG and gain some insights 
on the protein stability, we investigated the effect of the ionic strength. Equilibrium studies 
were performed in both constructs G52-WT and E-G52-WT. Urea-induced equilibrium 
unfolding curves (pH 7.4) were recorded for each construct (one in MOPS, 5 mM ionic 
strength and the other in MOPS, 1 M ionic strength) and then compared with the curves 
recorded in PBS (164 mM ionic strength) in each case (Figure 4.7). 
Y625 
Y547 
E  G52 
N
C 
 
Role of charged residues in the stability of SasG 
 
 
 
77 
 
Figure 4.7: Effect of ionic strength on the stability of SasG. Urea-induced equilibrium denaturation 
studies at pH 7.4 and varying the ionic strength. (A) G52-WT equilibrium curves and its parameters 
in different buffers: PBS with 164 mM (black), MOPS with 5 mM IS (pink) and MOPS with 1 M IS 
(purple). (B) E-G52-WT equilibrium curves and its parameters in different buffers: PBS with 164 
mM (black), MOPS with 5 mM IS (pink) and MOPS with 1 M IS (purple). 
 
In the cases of G52-WT the stability decreased slightly whereas for E-G52-WT the stability 
remained the same with an increasing concentration of salt. The data was considered the 
first sign suggesting that charge-charge interactions may not be key for the stability of both 
G52-WT and E-G52-WT in PBS. 
 
4.2.4 pH dependence of the SasG stability 
 
When a change in a folded protein environment is made, the charged amino acids, especially 
arginine, lysine, aspartic acid and glutamic acid may have an altered pKa. The pKa is the 
pH value at which 50% of the molecules will be protonated. As SasG is highly charged, the 
initial question was to investigate the role of the charged amino acids on the stability of G52 
domain (Table 4.1). 
A	 B	
Ionic	
strength	
(IS)	
						m-value	
(kcal.mol-1.M-1)	
[den]50%	
(M)	
ΔG	
(kcal.mol-1)		
5	mM	 1.03	±	0.01	 3.33	±	0.01	 3.43	±	0.03	
164	mM	 0.99	±	0.01	 2.76	±	0.01	 2.73	±	0.03	
1	M	 0.85	±	0.01	 2.38	±	0.01	 2.02	±	0.02	
Ionic	
strength	
(IS)	
						m-value	
(kcal.mol-1.M-1)	
[den]50%	
(M)	
ΔG	
(kcal.mol-1)		
5	mM	 1.29	±	0.03	 5.00	±	0.04	 6.45	±	0.16	
164	mM	 1.31	±	0.04	 4.31	±	0.01	 5.65	±	0.17	
1	M	 1.38	±	0.02	 4.43	±	0.02	 6.11	±	0.09	
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Table 4.1: Charged amino acid composition of the G52 domain. 
Amino acid Number pKa 
Lysine (K) 11 10.4 
Glutamic acid (E) 15 4.5 
Aspartic acid (D) 3 4.0 
Arginine (R) 2 12.5 
Tyrosine (Y) 1 9.6 
 
In addition to the ionic strength studies a series of urea-induced equilibrium experiments 
were performed on the G52 construct, with a range of buffers at different pH values (Table 
4.2), in order to investigate possible chemical shifts on the pKa values of the charged amino 
acids. This study would help to provide insights into the nature of the folded G52 domain, 
despite the lack of a hydrophobic core and the high percentage of charged residues. 
To discount the effect of salts on protein stability, all buffers were prepared with the lowest 
possible ionic strength, which was kept the same for the preparation of all of them (8 mM 
ionic strength). 
Table 4.2 Buffers used for the pH dependence studies of SasG G52-WT domain. 
pH Buffer pKa 
2.0 Phosphate 2.15 
3.0 Phosphate 2.15 
4.0 Acetate 4.76 
4.5 Acetate 4.76 
5.0 Acetate 4.76 
6.0 MES 6.21 
7.0 MOPS 7.31 
8.0 Tris 8.06 
9.0 Tris 8.06 
10.0 CAPS 10.51 
11 CAPS 10.51 
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In the urea-induced equilibrium denaturation studies, the pH transpired to have an effect on 
stability in the range between pH 2 and pH 5 and then in the range between pH 10 and pH 
11. Moreover, no effect on stability was verified for pH values between 6 and 9, as 
previously suggested by peptide charge calculator (Figure 4.8, A and fluorescence data on 
Appendix 1).  
This effect is very clear when we plot the variation in stability (ΔGD-N) against pH value 
where we can see a significant change in stability from pH 2 to pH 5 and pH 10 to pH 11 
whereas in the pH range between 6 and 9, the stability is relatively constant (Figure 4.8, B). 
  
 
 
Figure 4.8: Equilibrium studies and effect of pH on the stability of the G52 domain. (A) Equilibrium 
denaturation curves of G52-WT in different pH buffers (pH ranging from 3 to 11). Due to a very 
strong destabilising effect, we were not able to calculate fraction full-length at pH 2 (see 
fluorescence data on Appendix 1). (B) Variation of stability (ΔGD-N) plotted against pH values 
(triangles). The peptide charge calculator results for G52 were also plotted for comparison (data 
previously shown in figure 4.4). 
Due to the topology and structural similarity between G52 and E-G52 and because they both 
show a similar prediction using the peptide charge calculator, we decided not to perform the 
same pH dependence experiments for E-G52. 
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4.3 Conclusion 
The pH dependence studies of the G52 domain are in agreement with results observed from 
ionic strength studies, as it does not show a dramatic effect on the domain stability over the 
range of pH values. Another interesting tool, was the salt bridges predictor (ESBRI- 
evaluating the salt bridges in proteins online tool; Costantini et al. 2008), which shows that 
G52 has six salt bridges and EG52 has 8. These do not appear to have either a significant 
pKa shift and/or are not particularly stabilising to the fold of the protein. All the remaining 
charged residues (19 in G52 and 32 in E-G52) are apart from each other with distances 
greater than 4 Å. 
The acquired data when compared with the prediction from the net charge calculator, 
suggest that no significant effect on the pKa values of the amino acids is observed. From 
the results, it is clear that the unusual charge composition of SasG does not significantly 
contribute to the protein capacity to stay folded at different pH values during biofilm 
formation in the cell.  
Kappa-values of both G52 and E-G52 are low, which would be an indicative of a random 
coil. The result is in agreement with the PONDR-FIT (Xue et al. 2010) disorder predictor 
analysis, that suggest that both constructs should be disordered. Yet, the protein is folded in 
solution. The bioinformatics analysis and biophysical results of this chapter are in 
agreement, showing that SasG stability does not come greatly from the presence or the 
pattern distribution of its charged residues. Clearly this protein goes against current 
predictive methods of protein stability. Since this protein has few hydrophobic and aromatic 
residues, the reason for the stability of SasG is unclear. However, our previous studies have 
demonstrated that the interface between the two domains can contribute to the formation of 
the E-G52 construct, even when both domains were destabilised and are unfolded in 
isolation (Gruszka et al. 2016).  
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5 Co-translational Folding of SasG 
I would like to thank Dr. Jeffrey Hollins for building the constructs containing the different 
liker lengths and Dr. Lee Kwa for the assistance with the molecular biology of the charged 
constructs. I am also very grateful to Annette Steward for doing some repeats of the force 
profile experiments.  
5.1 Introduction 
In vivo, proteins fold and function under a variety of conditions, including temperature, pH 
and mechanical stress, all of which can modulate the folding energy landscapes (Sosnick & 
Barrick 2011, Guinn et al. 2015, Baldwin 2006). The ribosome, for instance, can influence 
protein folding: since folding is often faster than the rate of translation, molecules can 
attempt to fold while being translated (Cabrita, Dobson, and Christodoulou 2010). Although 
the idea that the ribosome can affect the folding process is well accepted, the mechanism by 
which it occurs is not fully understood (Kaiser et al. 2011).  
The extent to which studies in vitro compare with the folding of proteins in vivo is also not 
entirely comprehended. In contrast with in vitro conditions, aspects such as i) the 
unidirectional vectorial orientation that the peptide chain arises from the ribosome; ii) the 
conformational possibilities allowed to the emerging sequence before the entire protein is 
translated; and iii) the possible interactions between the nascent chain and the highly 
charged surface of the ribosome are examples of new possibilities of conditions which might 
influence folding in vivo (Knight et al. 2013; Nilsson et al. 2015; Tian et al. 2018).  
Our previous studies regarding the folding of SasG showed that both G52 and E-G52 fold 
via the same, highly polarised transition state, with formation of the C-terminal region of 
G52 domain being the limiting step for the folding of the entire structure. Once the main 
pathway is destabilised, it was also possible to observe and characterise an alternative 
folding pathway that starts via the interface between the two domains (Gruszka et al. 2016). 
After this extensive study to characterise SasG folding pathway in vitro, we were interested 
in using SasG as model to investigate co-translational folding and get some insights on how 
comparable the in vitro and in vivo results are.  
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5.1.1 The ribosome  
 
The ribosome is a macromolecular machine – present in all living cells – that decodes 
genetic information and converts it into amino acid sequence. It contains three large 
ribosomal RNA (rRNA) molecules, which represent two-thirds of its mass, and over fifty 
proteins (Kurland 1960). One of the first attempts to reveal the ribosome structure dates a 
bit more than 40 years, when a model of an E. coli ribosome was obtained by negative 
electron microscopy (Lake 1976). Although rudimentary compared to the most recent data, 
the study was able to show the two ribosomal subunits, referred to as small and large. Later 
on, with the development of new techniques, much more detailed structures of the ribosome 
allowed us to gain more knowledge on its architecture and function. Cryogenic electron 
microscopy (cryo-EM) for instance, was recently able to reveal the atomic structure of a 
mammalian ribosome-Sec61 complex, determined to 3.4 Å resolution (Voorhees et al. 
2014). 
Ribosome small and large subunits are named 30S and 50S in bacteria and 40S and 60S in 
eukaryotes, respectively. The small subunit is involved in decoding the messenger RNA 
(mRNA) information whereas the large one contains the peptidyl transferase centre (PTC), 
where the formation of peptide bonds occurs. The ribosome tunnel connects the PTC to the 
site where the nascent chain emerges (Frank et al. 1995). During the translation step, the 
nascent polypeptide chain travels through the ribosome tunnel in order to emerge into the 
cell cytoplasm (Milligan and Unwin 1986).  The average distance from the PTC to the end 
of the tunnel is approximately 100 Å and the diameter of the tunnel is 15 Å. At 80 Å from 
the PTC, the tunnel widens significantly to form the vestibule (Figure 5.1) (Nissen et al. 
2000).  
Early results demonstrated that the ribosome tunnel fits approximately 30-40 amino acids 
of a typical nascent chain (Malkin and Rich 1967), suggesting that translated polypeptides 
transit the ribosome tunnel in an extended conformation of approximately 3.5 Å per residue. 
For consistency to the other studies in our lab, we are going to assume that it takes about 35 
residues of an extended nascent chain to span the approximate 100 Å from the PTC to exit 
the ribosome tunnel (Tian et al. 2018).  
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Figure 5.1: A schematic representation of the ribosome tunnel cross-section. The ribosome tunnel 
connects the peptidyl transferase centre (PTC) to the exit site, where the polypeptide chain emerges. 
The tunnel total length is approximately 100 Å and can protect approximately 30-40 of a nascent 
chain. Studies showed helices being formed in the lower tunnel and formation of tertiary structure 
was encountered in the vestibule region 
 
5.1.2 Co-translational folding 
 
The relationship between the protein folding in vitro and co-translational folding has gained 
a lot of relevance in recent years and a variety of methods have been employed for that 
purpose (Thommen et al. 2017, Komar 2018). Elements of secondary and tertiary structures 
(Kudva et al. 2018), as well as small peptides, have been found to be formed in the ribosome 
tunnel (Tu & Deutsch 2017, Su et al. 2017, Mercier & Rodnina 2018; Figure 5.1). Moreover, 
entire domains like spectrin R16 and the Ig I27 have been shown to be able to fold while 
still in the ribosome vestibule, before exiting the tunnel (Nilsson et al. 2017; Tian et al. 
2018).  
In comparison to domains folding in isolation, the presence of the ribosome has been 
reported to be able to affect the folding process. For instance, in the co-translational folding 
of the Ig-like domain FLN5, the ribosome was found to modulate the folding process, as the 
domain could only fold well beyond the tunnel whereas it can fold spontaneously when in 
isolation (Cabrita et al. 2016). For T4 lysozyme, the ribosome was shown to slow down the 
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folding to the native structure compared to in vitro results. Moreover, incomplete T4 
lysozyme polypeptides are able to fold near the ribosome surface whereas misfolding and 
aggregation is observed when they are free in solution (Kaiser et al. 2011).  
Quantitative pulse-proteolysis experiments were able to identify a destabilising effect of the 
ribosome on the nascent polypeptide chain (Samelson et al. 2016) and electrostatics was 
also shown to play a role in the nascent chain. Due to the highly charged ribosome surface, 
the net charge of the polypeptide chain can define its mobility as it arises from the ribosome 
tunnel: negatively charged chains are more dynamic whereas positively charged ones are 
more static, as the latter can interact with the ribosome surface (Knight et al. 2013).  
Although some proteins are shown to fold via the same pathway on and off the ribosome 
(Tian et al. 2018), others are reported to differ (Evans et al. 2005, Nilsson et al. 2017). 
Understanding the co-translational folding has recently demonstrated that the ribosome can 
also play a role providing a further level of protein regulation (Gloge et al. 2014, Kirchner 
et al. 2017, Chaney et al. 2017).  
 
5.1.3 The arrest peptide assay 
 
The experimental procedures used in my project are based in the set up used in Gunnar von 
Heijne’s lab (Nilsson et al. 2015). The gene encoding the DNA sequence of the protein of 
interest is cloned into a series of different constructs containing a SecM stall sequence and 
a linker with variable length. Cryo-EM results were able to unravel the SecM stalling 
mechanisms upon translation (Zhang et al. 2015). The arrest sequence of SecM can interact 
extensively with the ribosome tunnel and can alter the conformations of the ribosome A-
site (where the tRNA first binds) and P-site (where the amino acid is incorporated). The 
change in conformation can cause two major consequences for translation: the tRNA 
binding in the A-site is compromised and its passage to the P-site is slowed down. Together, 
both effects contribute to the SecM stalling ability (Zhang et al. 2015). The interaction 
between the stall sequence and the ribosome can be released when a tension is applied. 
Therefore, the effectiveness of the stall is proportional to the force applied by the folding of 
the nascent polypeptide (Goldman et al. 2015) (Figure 5.2).  
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Figure 5.2: Schematic of the arrest peptide assay based on force measurements. (A) Schematic 
representation of SasG constructs. (B) Translated sequence containing the G52 domain (red), 
followed by a variable linker (purple) and the stall sequence (green). (C) Once a tension is applied 
by the folding of the G52 domain, (D) the SecM is released and the following sequence is translated 
(Lep domain, yellow).  
 
The efficiency of the arrest at each linker length can act as an indirect measurement of the 
tension applied in the stall sequence caused by the folding of the translated nascent chain. 
If the linker is too long the polypeptide chain will fold without applying a tension and will 
not release the stall. If the linker is too short, the nascent chain will not be able to fold due 
to a spatial constraint inside the ribosome tunnel. The length of the linker and the tension 
applied by the folding of the polypeptide chain needs to be optimal in order to release the 
stall sequence.  The stall sequence used in this work is the relatively weak E. coli SecM 
arrest peptide, also used in previous co-translational force profile assays  (Nilsson et al. 
2015, Nilsson et al. 2017; Tian et al. 2018; Marsden et al. 2018). The proline residue located 
at the end of the SecM sequence is the key residue for stalling and mutating it to an alanine 
completely disrupts the SecM translational stalling capacity (Yap and Bernstein 2009). 
Stall sequence: F S T P V W I S Q A Q G I R A G P 
Linker	N	 Linker	 SecM			Protein	 Lep		
Variable	length		
C	
A	
B	 C	 D	
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5.1.4 SasG as a model to study on the ribosome  
 
As previously described in the Introduction and in the previous chapter (chapters 1 and 4), 
SasG is an unusual protein, composed of tandem repeats of two domains, E and G5. Both 
domains are predicted to be disordered as their sequences are composed mainly of prolines, 
glycines and charged residues. Although the E domain is unfolded on its own, it folds when 
preceding a G5 domain. Both G5 in isolation and E-G5 can naturally fold to an extended 
three-dimensional β-sheet structure, exposed to the solvent on both sides as it lacks a 
hydrophobic core (Dominika T Gruszka et al. 2012).  
This intriguing structure folds via a very polarised transition state, with the formation of the 
far C-terminal end of the G5 domain being the limiting-step for folding the entire structure, 
in both G5 and E-G5 cases. The addition of the disordered E domain contributes to an 
increase in stability for E-G5 (6.3 kcal.mol-1) when compared to G5 in isolation (2.8 
kcal.mol-1). Furthermore, with the presence of E, an alternative pathway for folding is 
identified for E-G5 when the C-terminus of G5 is destabilised. In this context, folding of E-
G5 starts via the interface between the two domains. The interdomain interface was also 
shown to be crucial to maintain the long-range cooperativity and the cooperative folding of 
SasG (Gruszka et al. 2016). 
After characterising SasG folding pathways in vitro and the importance of the interface 
between E and G5 domains, we decided to use SasG as a model to study folding on the 
ribosome. Its unusual sequence composition, long-range interactions, extended structure 
and alternative folding pathway makes SasG a very interesting candidate to study co-
translational folding.  
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5.2 Chapter aims 
 
After an extensive study to characterise and understand how SasG is able to fold and form 
its structure in vitro, we wanted to expand this knowledge and investigate its co-translational 
folding. With the previous information regarding the role of SasG domains interface and the 
presence of an alternative pathway for folding, we performed co-translational folding 
experiments to determine the effect that the additional E domain (and the formation of the 
inter-domain interface) has on the folding of the G52 domain on the ribosome.  
This project aimed to help us to shed some light into how in vitro and in vivo studies can be 
compared and to understand to what extent the presence of the ribosome and the vectoral 
emergence of a nascent chain can influence the co-translational folding of a protein.  
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5.3 Results 
 
5.3.1 Molecular biology strategy 
 
The project started with a series of molecular biology steps in order to insert SasG DNA 
sequence in the different constructs with all linker lengths (L = 21 to 61 residues).  SasG 
DNA construct, originally in the pSKB2 vector, was subcloned into the pRSETa vector for 
consistency with all the work done in the lab. The restriction sites before and after the gene 
of interest were mutated to BamHI and EcoRI sites, respectively, by site directed mutageneis 
(SDM). The gene was extracted by double digestion and was ligated into the pRSETa 
containing the longest linker length (L61). Following up, another step of SDM was 
performed to remove the EcoRI restriction site and the stop codon in between the protein 
gene and the linker. 
In order to create all the other twenty constructs with different linker lengths, a series of 
SDM reactions were performed using the gene containing the L61 linker as template DNA. 
A series of primers were designed by Dr. Jeff Hollins based on the idea that linkers would 
be truncated from its N-terminal end, next to the protein sequence. Previous work had shown 
that truncation from the C-terminal end of the linker can alter the strength of the stall (Ismail, 
N., et al., 2012). For consistency and to keep the immediate sequence after the protein 
constant, all linker sequences started with Ser-Gly-Ser-Gly. Following the SGSG, the 
middle of the linker sequences are composed by a fraction of the Lep domain known to be 
disordered and of a variable length, followed by the SecM stall sequence. An extra fraction 
of the Lep domain comes after the stall sequence in order to differentiate by length the 
translated protein that was stalled from the one released from the ribosome (Figure 5.3).  
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Figure 5.3: Protein sequences of all primers designed to create the different linker length constructs 
for the force profile assays. Using the gene containing the protein, the longest linker length (L61) 
and the SecM stall sequence, a series of SDM were applied to truncate the linker and generate all 
constructs with variable liker lengths. Figure shows that the linker was truncated from its N-
terminus, just after the protein sequence. The primer sequences start from SGSG (green), followed 
by a sequence extracted from the Lep domain that is known to be disordered (black), and by the 
SecM stall sequence (first six residues showed in red).  
In order to create controls, the key proline residue responsible for the stall within the SecM 
sequence was mutated to an alanine in order to generate a non-stop control. In addition, the 
proline was also mutated to a stop codon (TAA) to create a control that, once translated, 
would generate a shorter sequence as translation would stop at the end of the linker and not 
at the subsequent Lep domain (Figure 5.4). At each linker length, these two controls would 
allow us to associate the bands on the gel to its correct protein: either the stalled or the full- 
length translated polypeptide nascent chain.  
Protein	 Linker	 SecM	 Lep		
L21 SGSG                                          FSTPVW 
L23 SGSG                                       SS FSTPVW 
L25 SGSG                                     WMSS FSTPVW 
L27 SGSG                                   GDWMSS FSTPVW 
L29 SGSG                                 MMGDWMSS FSTPVW 
L31 SGSG                               YFMMGDWMSS FSTPVW 
L33 SGSG                             GQYFMMGDWMSS FSTPVW 
L35 SGSG                           PPGQYFMMGDWMSS FSTPVW 
L37 SGSG                         IVPPGQYFMMGDWMSS FSTPVW 
L39 SGSG                       TWIVPPGQYFMMGDWMSS FSTPVW 
L41 SGSG                     NATWIVPPGQYFMMGDWMSS FSTPVW 
L43 SGSG                   QQNATWIVPPGQYFMMGDWMSS FSTPVW 
L45 SGSG                 PGQQNATWIVPPGQYFMMGDWMSS FSTPVW 
L47 SGSG               LVPGQQNATWIVPPGQYFMMGDWMSS FSTPVW 
L49 SGSG             KTLVPGQQNATWIVPPGQYFMMGDWMSS FSTPVW 
L51 SGSG           YQKTLVPGQQNATWIVPPGQYFMMGDWMSS FSTPVW 
L53 SGSG         PIYQKTLVPGQQNATWIVPPGQYFMMGDWMSS FSTPVW 
L55 SGSG       KDPIYQKTLVPGQQNATWIVPPGQYFMMGDWMSS FSTPVW 
L57 SGSG     GIKDPIYQKTLVPGQQNATWIVPPGQYFMMGDWMSS FSTPVW 
L59 SGSG   AYGIKDPIYQKTLVPGQQNATWIVPPGQYFMMGDWMSS FSTPVW 
L61 SGSG KFAYGIKDPIYQKTLVPGQQNATWIVPPGQYFMMGDWMSS FSTPVW 
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Figure 5.4: Controls involved in the folding on the ribosome experiments. (A) Proline to alanine 
mutation in the stall sequence prevents the stalling on the ribosome and the subsequent Lep domain 
sequence is translated. (B) Proline to stop-codon mutation in the stall sequence prevents the stalling 
on the ribosome and stops translation after the linker. 
 
5.3.2 Folding on the ribosome of the G52 domain 
 
Once the constructs containing the different linker lengths were created, folding on the 
ribosome studies were performed in order to generate the force profile of the G52 domain. 
Pro-Ala and one Pro-stop codon controls were also generated for some linker lengths. The 
experiments were performed using the in vitro translation kit (see Materials and Methods, 
chapter 3) and the force profile results for G52 are plotted in figure 5.5. 
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Figure 5.5: Cotranslational force profile for the G52 domain. (A) Example of a SDS-PAGE gel that 
was used to quantify the amount of stalled relative to full-length translated protein at different linker 
lengths. (B) Force profile of SasG G52 domain. Fraction full-length protein is plotted against the 
number of residues in the linker (linker length). The results are the average of two experiments for 
each linker length and the error bars represent the standard error. 
From the force profile experiments for the G52 domain we can see that the highest force is 
applied at the linker length L= 35 which is the position at which the protein is emerging 
from the vestibule. Apparently SasG starts to fold at linker length L31, in other words, 
before it is fully emerged from the tunnel. Interestingly, we can also observe a high force 
for the linker lengths L23 and L25, when the polypeptide chain is still inside the ribosome 
tunnel. At longer linker lengths, no significant force was observed, as the folding does not 
generate enough tension to release the stall. These results are the average of at least three 
experiments for each linker length. Pro-to-Ala and Pro-to-stop controls were also quantified 
by the SDS-PAGE gels, and some examples are shown in Figure 5.6. 
L23  L25   L29   L31  L35 L37 L41 L43 L47 L49   L51  L53   L55    L57  L59   L61 
A
B
Full length
Stalled 
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Figure 5.6: SDS-PAGE gels used to quantify the G52 domain bands at different linker lengths and 
its controls. The gel shows some examples of G52 bands at different linker lengths (black) and some 
Pro-to-Ala (red) and Pro-to-stop (green) controls.   
The controls allowed the association of each band on the gel to its respective result: Pro-Ala 
controls correspond to full-length protein, whereas Pro-stop correspond to the stalled 
protein. We chose not to do a control for every linker length as the gels were very clear, 
with just two bands appearing for each construct.  
From biophysical studies during my MPhil, I was able to characterise one Gly-to-Ala 
mutation, G587A, in G52 that was completely disruptive to the domain structure (see 
Introduction, Chapter 1). For the folding on the ribosome studies, I used G52-G587A as a 
non-folding control. The mutation was introduced to different linker length constructs via 
SDM. Force profile results are shown in figure 5.7.  
 
Figure 5.7: Force profile results for the G52 construct and its non-folding control G52-G587A. (A) 
Force profiles of G52 (red) and its non-folding control G5-G587A (purple triangles). Although the 
non-folding control was expected to not exert any force, the nascent chain was able to release the 
stall at different linker lengths. (B) Normalised data for G52 taking into account the contribution of 
extra effects apart from folding that promote the stall release for G52-G587A. The results are the 
average of at least three experiments for each linker length. The results are the average of at least 
two experiments for each linker length and the error bars represent the standard error. 
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Although the non-folding control differs from the WT results, their fraction full-length is 
significantly higher from what we expected. At lower linker lengths (L23 and L25), as well 
as we see for G52-WT, a great proportion of the translated molecules can release the stall. 
This means that the force applied while the protein is still inside the ribosome tunnel, does 
not come from a folding event. In the peak region of the force profile of G52-WT, we see a 
much lower fraction full-length for G52-G587A. This suggests that between linkers L31-
L47 is where the folding of G52 happens during translation. This is represented by 
normalised data (Figure 5.7, B) that takes into account the contribution on fraction full- 
length that comes from the non-folding control.  
The results show that the G52 domain can fold while still in the ribosome vestibule. 
Additionally, it also suggests that the domain is able to apply force and release the stall from 
additional sources that are not folding. High fraction full-length readings at lower linker 
lengths and for the non-folding control could possibly be explained by the formation of non-
native interactions or structures being formed inside the ribosome tunnel or even that the 
translated polypeptide chain could be interacting with the ribosome.  
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5.3.3 Folding on the ribosome of E-G52  
 
In order to gain more insights, E-G52 construct was also studied for comparison. The 
additional folding pathway characterised in vitro, where folding starts with the formation of 
the interface between the two domains, could possibly add some new possibilities to fold 
co-translationally. In the main folding pathway, formation of the far end of the G52 domain 
is the limiting step that drives the folding of the entire structure. Because of the vectoral 
emergence of the nascent chain on the ribosome, the E-G52 interface would be available 
earlier than the C-terminus of the G52 domain. We would predict that E-G52 could start to 
form its structure earlier than G52.  
Results of E-G52 on the ribosome showed otherwise. As well as for G52, the stall sequence 
is released at lower linker lengths (<L30) and the main peak of the E-G52 force profile 
overlays with the one from G52 (Figure 5.8), resulting in an almost identical force profiles 
for both constructs.  
 
 
Figure 5.8: Co-translational folding force profile for E-G52. (A) Force profile of SasG E-G52 
construct. (B) Comparative results of G52 and E-G52 force profiles. Force profiles of G52 (red) and 
E-G52 (blue). Fraction full-length protein is plotted against the linker length. The results are the 
average of at least two experiments for each linker length and the error bars represent the standard 
error. 
 
A B
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In order to get a non-folding control for E-G52, we identified a mutation that disrupts the 
construct stability and prevent its formation. It consists of three Ala-Gly mutations: G587A, 
G602A and G626A. Those three mutations were previously shown to be the most 
destabilising ones for E-G52 (Gruszka et al. 2016). The mutations were introduced to the E-
G52 gene, one at the time, by SDM. The protein containing the triple mutant was expressed 
and purified and equilibrium studies confirmed its unfolded state (Figure 5.9). 
 
 
Figure 5.9: Equilibrium denaturation curve of purified E-G52 non-folding control. Fluorescence 
data at 305 nm of the triple mutant E-G52-G587A-G602A-G626A shows its unfolded nature. 
 
Force profile experiments were also performed for E-G52 non-folding control. A scattered 
profile was observed throughout the entire plot. Fraction full-length values were much lower 
for all points of the non-folding control, including the ones of shorter linker lengths (Figure 
5.10). The results for E-G52 non-folding control correspond to what would be expected for 
a polypeptide nascent chain that is unable to form a structure and release the stall, which is 
not what was observed for G52-non folding control.  
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Figure 5.10: Force profile results for E-G52 and its non-folding control E-G52-G587A-G602A-
G626A. (A) Force profiles of E-G52 (dots) and its non-folding control G5-G587A-G602A-G626A 
(triangles). The results are the average of at least two experiments for each linker length. (B) 
Comparison of the normalised data for E-G52 (blue) and G52 (red) taking into account the non-
folding controls of each construct. The results are the average of at least two experiments for each 
linker length and the error bars represent the standard error. 
We also studied on the ribosome E-G52 with a single Gly-Ala mutation, the one that disrupts 
the G52 domain structure in isolation (used as G52 non-folding control) but does not have 
the same effect on E-G52. It was previously showed that E-G52-G587A folds via the 
alternative pathway that starts by the formation of the E-G52 interface (Gruszka et al. 2016). 
Thus, the force profile of E-G52-G587A could shed some light in the role of the alternative 
folding pathway on the co-translational folding of SasG. 
To our surprise, the force profile results of E-G52-G587A are very similar to the E-G52 non-
folding control, the triple mutant G587A-G602A-G626A (Figure 5.11), suggesting that this 
single mutation in the E-G52 construct is unable to fold on the ribosome.  
 
A B
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Figure 5.11: Comparative results of E-G52, E-G52-G587A and E-G52 non-folding control. Force 
profiles of E-G52 (blue), EG52-G587A mutant (cyan) and EG52-G587A-G602A-G626A non-folding 
control (triangles). The results are the average of at least two experiments for each linker length 
and the error bars represent the standard error. 
These results suggest that the alternative pathway for folding might not be an available 
option for E-G52 to fold on the ribosome. This is in agreement with what we see for G52 
and E-G52, where no difference between the two force profiles was identified. The initial 
hypothesis that E-G52 would fold earlier, once the interface between the two domains was 
translated, did not prove to be correct. It has been shown that the ribosome can have 
destabilising effect on polypeptide nascent chains (Liu et al. 2017; Samelson et al. 2016), 
which could maybe explain the inability of E-G52 construct to fold via its alternative 
pathway for folding.  
  
 
Co-translational Folding of SasG 
 
 
 
98 
5.3.4 Role of charged residues on co-translational folding of SasG 
 
The unexpectedly high values of fraction full-length for G52 non-folding control (G587A) 
were very intriguing. The ribosome has a highly charged surface, mainly negatively charged 
and electrostatics is known to play an important role on the nascent chain dynamics. It has 
been shown that the amplitude of local motion of a highly negatively charged nascent chain 
that is in close proximity with the ribosome is higher when compared with disordered 
polypeptides under physiological conditions. Moreover, highly positively charged 
polypeptides are shown to be less dynamic, as they can interact with the ribosome surface 
(Knight et al. 2013, Figure 5.12). 
 
 
Figure 5.12: Schematics of the role of electrostatics on ribosome-nascent chain interaction. Due to 
the overall negatively charged nature of the ribosome surface, the more negatively charged the 
nascent chain, the more dynamic it will behave. Positively charged nascent chains will tent to 
interact with the ribosome surface and stay static (Figure taken from Knight et al. 2013). 
 
The unusual charged content of SasG raised the hypothesis that the folding on the ribosome 
experiments could also be reporting some electrostatics contributions. In order get some 
insights on that, we designed three SasG constructs for both G52 and E-G52: one where all 
the positively charged residues were removed (only negative left), one with all negatively 
charged residues removed (only positive left) and one with all the charges removed (no 
charges left).  
Positively charged lysine and arginine were mutated to methionine whereas negatively 
charged residues aspartic acid and glutamic acid were mutated to asparagine and glutamine, 
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respectively (all sequences are shown in Appendix 2). The mutations were chosen to 
minimise their effect as much as possible, as we wanted to test for the effect of the charges 
only. Charged residues in SasG are distributed all over the domain E and G52 domains 
(Figure 5.12).  
 
Figure 5.13: Charges content and distribution in SasG. (A) Cartoon representation of SasG E-G52 
structure showing the charged residues distributions represented as sticks (positively charged in 
blue and negatively charged in red)). (B) Number of charged amino acids in E-G52 and E-G52 
constructs. 
 
The genes were purchased from GenScript in the standard pUC57 vector. The same 
molecular biology strategy previously used was employed to insert the genes into the 
pRSETa vector containing all linker lengths for the folding on the ribosome studies. 
Furthermore, the genes were also inserted into the pSKB2 plasmid for protein expression. 
The six constructs, G52 and E-G52 only positive, only negative and no charges, were 
expressed. All proteins but E-G52 only positive and only negative charges were insoluble 
and went to the cell pellet. To check for the protein stabilities, equilibrium denaturation 
studies were performed for both E-G52 only positive and only negative charges. The results 
showed that the two proteins were unfolded (Figure 5.13). 
E	 G52	
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B	
	 Positively	charged	 Negatively	charged	
E	domain	 7	 10	
G52	domain	 13	 18	
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Figure 5.14: Equilibrium denaturation curves of purified proteins: E-G52 only negative and only 
positive charges. Fluorescence data at 305 nm of (A) E-G52 only negative and (B) E-G52 only 
positive charges show their unfolded nature. 
 
With the preliminary knowledge that all designed proteins cannot fold, force profile 
experiments were performed for all six constructs. Results of both G52 and E-G52 were 
similar, showing that in the absence of negatively charged residues (only positive 
constructs), force profiles showed the lower fraction full-length readings. In contrast, the 
presence of negatively charged residues (only negative charges constructs) showed the 
higher read through. Constructs with no charges showed intermediate fraction full-length 
values almost through the entire force profiles (Figure 5.14). 
The data suggest that the charge composition of the nascent chain can play a significant role 
in the force profile experiments, as the stall sequence can be released even by disordered 
polypeptides. The results show that force profile experiments can report not only on folding 
events but also other sources of non-native interactions intra- or/and inter-molecular, 
possibly between nascent chain and ribosome. They also reveal that the interactions largely 
occur while some parts of the chain are still sequestered in the tunnel (i.e. at linker lengths 
<35).  
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Figure 5.15: Effect of charged residues in SasG folding on the ribosome. (A) Comparative force 
profile results of G52: only positive charges (blue), only negative charges (red) and no charge (grey). 
(B) Comparative force profile results of G52: only positive charges (blue), only negative charges 
(red) and no charge (grey). The results are the average of at least two experiments for each linker 
length and the error bars represent the standard error.  
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5.4 Discussion 
 
After an extensive study of SasG in vitro, it was possible not only to understand the folding 
pathway of both G52 domain in isolation and E-G52, but we have also identified an 
alternative pathway for folding of the multidomain construct E-G52 (Gruszka et al. 2016). 
The results showed very clearly that the interface between the two domains is key for this 
intriguing protein to maintain its stability. The lack of a hydrophobic core, the highly 
charged sequence composition and with the preliminary knowledge of the ability of E-G52 
to fold via the interface between the two domains, SasG became an interesting system to 
study on the ribosome. 
Force profile experiments results showed an early folding of G52, while the domain is still 
inside the ribosome vestibule (linker length L31). Surprisingly, high fraction full-length 
values were also observed for G52-G587A, a Gly-Ala mutant that is known to disrupt the 
domain structure. The result was an indication that force profile experiments can report not 
only the folding of a nascent chain, but other factors could also contribute to the release of 
the stall sequence.  
It was interesting to notice high read through of fraction full-length for shorter linker lengths 
(<L30). It has been previously reported that at very short linker lengths (L18-L20), the 
ribosome tunnel available space (10-15 Å wide) can accommodate alpha helices formation 
(Wilson et al. 2011). It has also been shown that small β-sheet proteins (<4.2 KDa) can 
apply a force and release the stall at short linker lengths, folding while still inside the 
ribosome tunnel (Marino, Von Heijne, and Beckmann 2016). But SasG results also showed 
high fraction full-length values for G52 non-folding control (G52-G587A), which is an 
indication that the stall release does not come from the folding of the domain in this case.  
In comparison to the G52 domain, the E-G52 construct shows an almost identical force 
profile. They are both able to fold at similar positions when being translated, while still 
inside the ribosome vestibule. Our initial prediction was that E-G52 could fold earlier than 
G52 on the ribosome, as it has an alternative pathway that starts by the formation of the 
inter-domain interface. The results did not support this hypothesis. Moreover, a single 
mutant G587A, that is known to disrupt the G52 domain in isolation but does not prevent 
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the E-G52 to fold in vitro, showed a similar force profile result when compared to the non-
folding control (E-G52-G587A-G602A-G626A). In vitro, this Gly-Ala mutation on E-G52 
disrupts the main folding pathway (via the C-terminal end of G52) but the structure is formed 
via its alternative one (via the domains interface). All together, these data suggest that the 
alternative folding pathway might not be available on the co-translational folding of SasG 
E-G52, maybe due to the additional destabilising effect that the ribosome can confer to the 
nascent chain. Despite the unexpected results, co-translational studies of SasG show the first 
example of the formation of large all β-sheet structures (≈10 kDa for G52 and ≈15 kDa for 
E-G52) inside the ribosome.  
Based on the highly charged nature of SasG and to try to gain some more insights about 
other factors that could contribute to the stall release on the force profiles, electrostatic 
effects were tested. Constructs containing only positive, only negative and no charged 
residues were designed for both G52 and E-G52. The results show that nascent chains 
containing only positive charges were mostly unable to release the stall whereas the ones 
with only negatively charged residues showed the higher fraction full-length values 
throughout their force profiles. In the absence of charged residues, the constructs showed 
intermediate fraction full-length values for a great proportion of linker lengths, including 
the ribosome vestibule region, where both G52 and E-G52 were shown to fold co-
translationally (≈L30 – L40).  
It has been shown that nascent chain dynamics varies depending on its charged nature when 
in close proximity with the ribosome (Knight et al. 2013). Highly negatively charged 
polypeptides were found to be very dynamic, with higher amplitude of local motion in 
comparison to disordered polypetides. Highly positively charged nascent chains, on the 
other extreme, were shown to be static as they can interact with the negatively charged 
ribosome surface. In light of those findings, we could hypothesise that SasG only negative 
charges constructs are the most dynamic of the designed constructs, what could explain the 
release of the stall at most linker lengths. The only positive charges constructs can interact 
with the ribosome surface, thus they stay attached to the surface and are not able to release 
the stall. No charged SasG variants show an intermediate behaviour. Maybe the lack of 
charged residues causes a hydrophobic collapse of the structures that can also apply a 
tension on the stall and allow its release. 
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The results also show high fraction full-length readings at shorter linker lengths for nearly 
all constructs, suggesting that electrostatics on its own is not enough to explain that 
behaviour. Despite that, the study suggests that force profile experiments can report both on 
intramolecular folding of a protein when being translated, as well as, intermolecular 
interactions between the nascent protein chain and the ribosome.  
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6 Encoding IDP coupled folding and binding 
This chapter is the result of a project done in collaboration with other two students in my 
group, Dr. Michael Crabtree and Quenton Bubb. Each of us worked with one system 
composed by an IDP and a partner protein. The biophysical results of the three systems were 
then combined with the work done by Dr. Joseph Rogers. Together, the four systems 
allowed us to gain some knowledge on the encoding of coupled folding and binding 
reactions of IDPs. I would like to thank Tristan Kwan for the expression and purification of 
PUMA-35 used in my dissociation experiments as a competitor peptide. The results of this 
chapter were published in Crabtree et al. 2018. 
 
6.1 Introduction 
 
6.1.1 What does it mean for a protein to be disordered? 
 
Natively disordered proteins comprise an important and well represented group of proteins. 
Their biological relevance is well established in nature (e.g. cell signalling and regulatory 
processes) as we can see their persistence throughout evolution. But what are these proteins? 
To be considered intrinsically disordered, a protein should be an extended, flexible 
polypeptide with very little or no secondary structure present under physiological 
conditions, although transient secondary structures is known to occur in such disordered 
ensembles. Over the past two decades, an increasing amount of those proteins have been 
reported and characterised (Uversky 2002).  
Although disordered in isolation, a variety of those IDPs can gain structure and become 
relatively rigid upon binding to natural partners. This phenomenon is known as coupled 
folding and binding (Figure 6.1). 
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Figure 6.1: Schematic of a coupled folding and binding reaction. Adapted from Rogers et al. 2014. 
 
6.1.2 Encoding protein folding and function 
 
Since the discovery of the first protein structure reported in 1958, the protein structure-
function paradigm has been simply described as: in order for a polypeptide to function, it 
needs to fold. Adopting a three-dimensional structure was believed to be the key 
requirement for a protein to be able to function (Alberts 2008). With the discovery of IDPs, 
natively unstructured proteins that are able to play important roles in vivo, our attention was 
brought back to the fundamental definition of what encodes protein folding and function. 
Early experiments performed by Anfinsen demonstrated that the information required for a 
polypeptide chain to fold into its unique three-dimensional structure is built in the protein 
sequence composition (Anfinsen et al., 1961; Anfinsen, 1973). However, IDPs are natively 
unstructured, so we might say that they have disorder encoded in their sequence (Romero 
et al. 2001). Nonetheless, some IDPs become folded upon binding to a partner protein, 
which raises the question: what encodes a coupled and folding and binding reaction – IDPs 
or partner proteins?  
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6.1.3 The BCL-2 family network 
 
B-cell lymphoma 2 (BCL-2) family is well known and described as the cell apoptosis 
regulator. The family is composed by a number of proteins that share the evolutionary 
conserved BCL-2 homology (BH) domains (Reed, 1998; Korsmeyer, 1999). Protein 
members of this family act as pro- or anti-apoptotic in the cell by controlling the 
permeabilisation of the mitochondrial outer membrane (Kvansakul et al. 2008). Pro-survival 
and pro-apoptotic proteins share four BH domains (BH1-BH4, Figure 6.2, A) and fold to 
similar globular structures: seven amphipathic α‑helices surrounding a central hydrophobic 
helix (α5) (Muchmore et al., 1996; Figure 6.2, B). BH3-only proteins are composed only 
by the BH3 amphipathic helix (Figure 6.2, A), which mediates their interaction with the 
hydrophobic groove (formed by helices 2-5) on the surface of the globular protein members 
of the family. Unlike the other family members, BH3-only proteins are intrinsically 
disordered in isolation but become helical upon binding to the partner proteins (Hinds et al. 
2007), which makes the BCL-2 family an interesting network to study coupled folding and 
binding.  
 
Figure 6.2: The role of the BCL-2 family network in controlling cell death. (A) Schematic of the 
BCL-2 family protein members divided in three categories: initiators, pro-survival and pro-
apoptotic. Initiator proteins contain only the BH3 helix, whereas pro-survival and pro-apoptotic 
proteins have four BCL-2 homology regions (BH1-BH4) (B) Example of a BCL-2 family member 
fold, composed by seven amphipathic α‑helices and a central hydrophobic helix (α5). Figure adapted 
from Czabotar et al. 2014.  
The	BCL-2	Family			A	 B	
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6.1.4 The BCL-2 family as a model to study encoding of coupled folding 
and binding reactions using Φ-value analysis 
 
Previous work carried out by Dr. Joseph Rogers was able to characterise the transition state 
of the coupled folding and binding reaction between the disordered PUMA peptide and 
MCL-1. Φ-value analysis revealed that at the transition state, PUMA is partially folded 
towards its N-terminus whereas the rest of the peptide remains disordered (Rogers et al. 
2014; Figure 6.3). 
 
Figure 6.3: Φ-value analysis of PUMA peptide binding to MCL-1. The results show that formation 
of PUMA structure starts via the N-terminus (intermediate Φ-values) whereas the rest of the 
molecule is still disordered at the transition state (low Φ-values). Data and figure from Rogers et 
al. 2014. 
Using the previous results from PUMA:MCL-1, we decided to use the BCL-2 family as a 
model to unravel the encoding of IDPs coupled folding and binding. We chose to study two 
IDPs (PUMA and BID) and two partner proteins (MCL-1 and A1), which have low 
sequence identity (≈20%) but very high structure identity between them (Figure 6.4 and 
6.5). Comparative Φ-value analysis of the four systems (BID:A1, BID:MCL-1, PUMA:A1 
and PUMA:MCL-1) would help us to shed some light and understand the encoding of 
coupled folding and binding reactions.  
Change Partner Protein: A1
0.2<F >0.6	
0<F >0.2	
R V E E E E W A R I GE A L RQ R A …
0.2< φ >0.6 
0< φ >0.2 
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Figure 6.4: Sequence and structural alignment of A1, MCL-1, PUMA and BID constructs. (A) Left: 
sequence alignment for A1 and MCL-1 with helical regions represented by green and grey cylinders, 
respectively. Right: structural alignment of A1 (green) and MCL-1 (grey). The proteins are in 
complex with PUMA peptide, shown in blue. (B) Left: sequence alignment for PUMA and BID 
peptides. Right: structural alignment of PUMA (blue) and BID (yellow) peptides. The peptides are 
in complex with A1, shown in green. Alignments were produced using Clustal Omega (Goujon et al. 
2010, Sievers et al. 2011): conserved residues are indicated with an asterisk, residues with strongly 
similar properties with a colon, and residues with weakly similar properties with a period. Note that 
in addition to the sequences shown above, both MCL-1 and A1 contained a GS at the N-terminus, 
which was a remnant from protease cleavage during purification. Figure adapted from Crabtree et 
al. 2018. 
  
A1         MAESELMH-IHSLAEHYLQYVLQ-----VP--AFESAPSQACRVLQRVAFSVQKEVEK
MCL-1        EDDLYRQSLEIISRYLREQATGSKDSKPLGEAGAAGRRALETLRRVGDGVQRNHET
* :* :   .: .:**:          *     :*  :* ..*:**. .**:: *.
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6.2 Chapter aims 
 
The protein structure-function paradigm has been assumed for decades. With the discovery 
of IDPs and their biological relevance, we had to rethink the assumption that function is 
strictly related to folding. However, a subset of IDPs is able to fold upon binding to a partner 
protein. Since the early studies performed by Anfinsen, we know that the information 
required for a protein to fold is encoded in its own sequence, but what about IDPs? Is the 
folding of an IDP in a coupled folding and binding reaction encoded by the disordered 
polypeptide or is it templated by the folded partner? In this chapter we will use Φ-value 
analysis to investigate different systems and get some insights in what drives the folding of 
proteins that have disorder encoded in their sequences. 
To do so, we are going to use four systems composed by two BH3-only IDPs (PUMA and 
BID) and two partner proteins (A1 and MCL-1), all members of the BCL-2 family (Figure 
6.5). 
   
Figure 6.5: Structural homology and sequence identity of the complexes formed by the BH3-only 
BID and PUMA with the pro-survival MCL-1 and A1 proteins. The BH3-only IDPs PUMA (blue) 
and BID (yellow) can fold to an alpha helix structure upon binding to partner proteins like MCl-1 
(grey) and A1 (green). Root mean square deviation (RMSD) were obtained by structural aligments 
using PyMOL and sequence identities were calculated from the sequence alignments of the mouse 
protein constructs. Figure taken from Crabtree et al. 2018.  
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6.3 Results 
 
6.3.1  Molecular biology strategy 
 
Mouse A1 gene was kindly donated from Bonsu Ku’s lab in the pGEX vector as a GST 
fusion protein, containing a TEV cleavage site. Unlabeled PUMA-35 peptide used in this 
chapter as a competitor of BID in the dissociation experiments was expressed and purified 
in the lab by Tristan Quan. TAMRA labeled BID-WT and mutants peptides were purchased 
from Biomatik (Canada).  
 
6.3.2 Purification of A1  
 
A1 was expressed as a GST fusion protein, with a TEV cleavage site in between. The 
expressed protein was bound to the glutathione sepharose (GS) resin and cleaved using 
TEV. A1 was purified by ion exchange chomatography. An additional step in Superdex 75 
gel filtration (Figure 6.6, A) was employed to buffer exchange the protein. SDS-PAGE 
confirms the purity of the protein although the sample runs further than it would be expected 
by its mass (Figure 6.6, B).  
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Figure 6.6: Purification of A1. (A) Chromatogram image of A1 purification after G75 size exclusion 
run showing peaks 1 and 2. (B) SDS-PAGE of purified A1 after a G75 run showing protein fractions 
and NuPage unstained protein ladder for comparison. The gel starts from marker and show one 
fraction of peak 1 followed by peak 2. Pure A1 is present in all fractions.  
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Purified A1 was sent for mass spectroscopy analysis at the Department of Chemistry. 
Results confirmed A1 identity and purity with the confirmation of its expected mass. Figure 
6.7 shows a chromatogram as an example (sample sent by Dr. Michael Crabtree).  
 
Figure 6.7: Mass spectroscopy results of A1 after purification. The obtained mass of A1 was 17633 
± 5 Da and the expected mass was 17635 Da. Dr. Michael Crabtree submitted the sample to 
analysis. 
 
6.3.3 TAMRA labelled peptides 
 
Mouse BID peptides (WT and mutants) with an N-terminal TAMRA fluorescent dye 
attached were designed and purchased from Biomatik. The mutations were aimed to allow 
the investigation of coupled folding and binding of BID and a partner protein using Φ-value 
analysis.  
Similarly to folding, Φ-value analysis of a coupled folding and binding reaction is 
performed by comparing the difference in free energy between the transition state and the 
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bound state of the two proteins (complex formation). To do so, mutations are designed to 
disrupt interactions between the proteins allowing a change in free energy between the WT 
and mutant. This difference in free energy (ΔΔG) is required to be greater than 0.6 kcal.mol-
1 to allow us to have confidence in the calculated Φ-value. (Fersht and Sato 2004).  
Two sets of single mutations were designed: 
• Hydrophobic to alanine mutants: designed to disrupt the interactions between 
BID and its partner protein (e.g. A1, MCL-1). Hydrophobic residues of BID are 
found buried in the partner protein’s hydrophobic groove upon binding. Mutating 
them to alanine reduces the side chain of the residues resulting in a loss in affinity 
of the complex. 
• Alanine to glycine mutants: designed to probe the peptide helicity within the 
BID:partner complex transition state. In a coupled folding and binding reaction, 
the helicity of the peptide can be investigated by mutating residues that are not 
involved in intermolecular interactions. Charged residues in the peptide that are 
solvent exposed and do not make contact with the partner protein in the bound state 
are the target for this mutations. Firstly they are mutated to alanine, which will be 
our pseudo-WT. Next, they are mutated to glycine and the difference in free energy 
between the glycine and our pseudo-WT allow us to calculate the Φ-values. 
Importantly, when designing the mutations for Φ-value analysis, we want to guarantee that 
they are not too disruptive or they can affect the transition state otherwise. This could change 
the reaction pathway by involving different interactions in the transition state when 
compared to WT. To test for that hypothesis, a double mutant comprised of two mutations 
that have been previously characterised individually is employed: if we take BID-I86A-
M97A double mutant for instance, the Φ-value of M97A can be calculated from the 
difference in free energy between the double mutant and I86A mutant. If the same Φ-value 
is obtained, we can assume that the I86A mutation does not affect the interaction of M97A 
in the transition state. 
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6.3.4 Extinction coefficient  
In order to get an accurate concentration measurement, experimental extinction coefficients 
were calculated for both A1 and the TAMRA labelled BID peptides. A precise volume of 
each sample was sent for amino acid analysis (Biochemistry department) and the accurate 
concentration was plotted against the absorption at 280 nm for A1 and 555 nm for TAMRA. 
The results allowed us to calculate the experimental extinction coefficient (ε280) (Figure 
6.8). The values were 24,200 ± 200 M-1.cm- 1 and 85,000 ± 1,000 M-1.cm- 1, for A1 and BID 
peptides respectively. Throughout this chapter, A1 and BID peptides concentrations were 
calculated using the experimental extinction coefficient values.  
 
Figure 6.8: Extinction coefficient for A1 and TAMRA labelled BID. Extinction coefficient values 
were calculated from amino acid analysis (AAA). Concentration results for different A1 samples 
and TAMRA BID peptides were plotted against its absorbance readings at (A) 280 nm for A1 and 
(B) 550 nm for BID. The experimental extinction coefficients obtained were 24,200 ± 200 M-1.cm-1 
and 85,000 ± 1,000 M-1.cm-1 for A1 and BID, respectively. The experimental values were used for 
all A1 and BID concentration calculations in this chapter. 
6.3.5 Effect of mutations in TAMRA-BID peptides 
To investigate the oligomerisation propensity of BID peptides, CD data were collected for 
all designed peptides at two concentrations: 5 and 10 μM. Results are shown in figures 6.9 
and 6.10. For all peptides, no significant change was observed with the increase on 
concentration, meaning that the residual helicity was independent of the peptide 
concentration. The results gave us enough confidence that the CD spectrum represents the 
peptide monomer.  
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Figure 6.9: Concentration dependence CD spectra of hydrophobic to alanine mutants of BID. CD 
spectra of all BID peptides containing a hydrophobic to alanine mutation at two different 
concentrations (5 and 10 μM) show that the residual structure is maintained for all peptides with an 
increase in concentration.  
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Figure 6.10: Concentration dependence CD spectra of alanine to glycine mutants of BID. CD 
spectra of BID peptides containing a charged to alanine/glycine mutation at two different 
concentrations (5 and 10 μM). The data show that the residual structure is maintained for all 
peptides with an increase in concentration.   
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Residual helicity was calculated for all BID peptides using the mean residual ellipticity 
(MRE) at 222 nm and the Muñoz and Serrano method (1995) (Figure 6.11). The mutation 
N85A showed an evident increase in helicity compared to WT whereas all other peptides 
displayed a very similar or reduced result. Alanine to glycine mutations decreased the 
residual helicity of the peptides as expected (Serrano et al. 1992). 
 
  
Figure 6.11: Comparative helicity of BID mutants. BID peptides helicities at 5 μM (blue) and 10 
μM (red). Residual helicities were calculated from the MRE at 222 nm. 
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intensity change or anisotropy over time were monitored. Association experiments were 
performed by rapidly mixing BID and different concentrations of A1 under pseudo-first 
order conditions using a stopped flow instrument. A series of individual traces were 
averaged for each concentration and the data fitted to a single exponential (Figure 6.12, A, 
B and C). Dissociation kinetics were performed by competing a pre-formed complex of 
BID:A1 with an excess of unlabelled WT-PUMA peptide at different concentrations (Figure 
6.12, D, E and F). 
 
Figure 6.12: Association and dissociation kinetics raw data for WT-BID:A1. Fluorescence intensity 
change of the association kinetics were obtained by rapidly mixing BID and A1 under a pseudo-first 
order condition: 0.05 μM BID with (A) 1 μM A1, (B) 2 μM A1 and (C) 2.5 μM A1. Data represent 
the average of 20-30 traces at each concentration. The results were fit to a single exponential 
function. Fluorescence intensity change of the dissociation kinetics were obtained by mixing a pre-
formed complex of BID:A1 with PUMA in excess: 4 μM BID:A1 competing with (D) 80 μM PUMA, 
(E) 120 μM PUMA and (F) 160 μM PUMA. The data were fit to a single exponential plus drift 
function.  
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For both association and dissociation experiments, the fit of the signal change at each 
concentration gave us an observed rate constant (kobs). kobs was plotted against the 
concentration of the partner protein and the association rate constant (kon) was obtained from 
the gradient of the straight line (Figure 6.13, A). For dissociation experiments, kobs was 
plotted against the ratio between the concentrations of competitor over the complex and the 
dissociation rate constant (koff) was the means of the observed rates (Figure 6.13, B).  
 
Figure 6.13: Kinetics data for WT-BID:A1. (A) Association kinetics of BID interacting with A1. The 
experiments were performed in a pseudo-first order condition with two different A1 stocks. The 
gradient of the straight line gave an association rate constant of 8.2 ± 0.2 μM-1 s-1. (B) Dissociation 
kinetics was done using a pre-formed complex of BID:A1 mixed with unlabelled PUMA peptide. The 
mean of the observed rate constants gave a dissociation rate constant of 0.155 ± 0.005 x10-3 s-1. 
Errors in kon represent the error from the fit whereas in koff it comes from the standard error of the 
mean. 
 After characterising WT-BID, the same experiments were performed for all BID mutants. 
Figures 6.14 and 6.15 show the association and dissociation data for all hydrophobic to 
alanine mutants in comparison with WT-BID. Alanine to glycine mutants data are shown in 
figures 6.16 and 6.17. 
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Figure 6.14: Association kinetics of BID hydrophobic to alanine mutants interacting with A1. BID 
peptides were rapidly mixed (stopped flow) with an excess of A1 at different concentrations. The 
observed rate constant (kobs) was obtained by fitting the change in fluorescence at each 
concentration to a single exponential. Association rate constant (kon) was obtained from the gradient 
of the straight line fit of kobs against the concentration of A1. 
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Figure 6.15: Dissociation kinetics of BID hydrophobic to alanine mutants interacting with A1. A 
pre-formed complex composed by BID and A1 was mixed with unlabelled PUMA peptide at different 
concentrations. The observed rate constant (kobs) was obtained by fitting the change in fluorescence 
at each concentration to a single exponential. Dissociation rate constant (koff) was obtained from 
the mean of the observed rate constants. 
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Figure 6.16: Association kinetics of BID alanine to glycine mutants interacting with A1. BID 
peptides were rapidly mixed (stopped flow) with an excess of A1 at different concentrations. The 
observed rate constant (kobs) was obtained by fitting the change in fluorescence at each 
concentration to a single exponential. Association rate constant (kon) was obtained from the gradient 
of the straight line fit of kobs against the concentration of A1. 
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Figure 6.17: Dissociation kinetics of BID alanine to glycine mutants interacting with A1. A pre-
formed complex composed by BID and A1 was mixed with unlabelled PUMA peptide at different 
concentrations. The observed rate constant (kobs) was obtained by fitting the change in fluorescence 
at each concentration to a single exponential. Dissociation rate constant (koff) was obtained from 
the mean of the observed rate constants. 
 
In a two-state reaction, equilibrium and kinetics dissociation constants (Kd (eq) and Kd (kin)) 
should be the same. To check for that hypothesis, an equilibrium binding experiment was 
performed for the most destabilising mutant L90A. The reason for choosing that mutation 
is simply because complexes of higher affinity would require very low concentrations 
pushing the experimental limits and increasing the errors. An equilibrium dissociation 
constant of 360 ± 40 nM was obtained (Figure 6.18). Kd (eq) showed reasonable agreement 
with the kinetic dissociation constant of 210 ± 14 nM. For that reason, the Φ-values for all 
mutants were then calculated using the kinetic data.  
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Figure 6.18: Equilibrium binding curve for BID-L90A binding A1. BID-L90A was incubated with 
different concentrations of A1. Data were fit to equation 3.18 (chapter 3) to obtain equilibrium Kd. 
Equilibrium and kinetic comparison of Kd show a two-state coupled folding binding reaction for 
BID-A1.  
Assuming a two-state reaction, Kd can be calculated from the ratio of koff over kon (Equation 
2.22, chapter 2). Φ-values were calculated using Equation 6.1: 
 
Φ = ln‡donWTdonMut„ln‰âdMutâdWTÂ                                        Equation  6.1 
 
Table 6.1 summarises all the biophysical parameters that characterise the coupled folding 
and binding of BID peptide and A1. Φ-values were very low (0 - 0.2) throughout the entire 
BID peptide, suggesting that the peptide is still mainly disordered at the transition state. 
0.06
0.08
0.1
0.12
0.14
0.16
0.001 0.01 0.1 1 10 100
A
ni
so
tro
py
 (A
.U
.)
[A1] uM
 Encoding IDP coupled folding and binding 
 
 
 
 
126 
Table 6.1. Coupled folding and binding of BID–A1: biophysical parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Helicity of all peptides were calculated using the MRE at 222 nm and the method of Muñoz & Serrano 1995. kon and koff errors were obtained from error of  the 
curve fit and from the standard error of the mean, respectively. n is number of repeats. Kd was calculated from the ratio between koff and kon, with the respective 
errors propagated using standard methods. Φ-values were calculated using the kinetic rate constants and errors represent the propagated error. For Ala-Gly 
mutants ΔΔG and Φ are the comparison of the Gly and the pseudo-WT Ala mutants. Table adapted from Crabtree et al. 2018. 
BID Helicity (CD) 
%  
kon (μM-1s-1) koff (s-1) x10-3 n Kd (koff/kon) (nM) ΔΔG (kcal.mol-1) Φ 
WT 11.5 8.2 ± 0.2 0.155 ± 0.005  3 0.019 ± 0.001 - - 
I82A 10.7 6.8 ± 0.2 0.300 ± 0.004 4 0.004 ± 0.001 0.49 ± 0.03 0.23 ± 0.04 
I83A 12.0 7.0 ± 0.2 2.0 ± 0.5 4 0.29 ± 0.01 1.47  ± 0.02 0.06 ± 0.01 
I86A 9.0 2.9 ± 0.1 22.0 ± 0.5 4 7.6 ± 0.2 3.55 ± 0.03 0.17 ± 0.01 
L90A 7.5 3.1 ± 0.2 660 ± 3 5 210 ± 14 5.52 ± 0.04 0.10 ± 0.01 
I93A 8.9 5.6 ± 0.1 2.5 ± 0.2 4 0.44 ± 0.03 1.87 ± 0.04 0.12 ± 0.01 
M97A 11.5 8.1 ± 0.1 1.50 ± 0.04  4 0.190 ± 0.006 1.35 ± 0.03 0.004 ± 0.015 
I101A 10.1 8.6 ± 0.3 0.20 ± 0.01 3 0.022 ± 0.001 0.10 ± 0.03 -0.3 ± 0.3 
I86A- M97A 9.0 2.2 ± 0.1 110 ± 36 4 50 ± 16 4.650 ± 0.002 - 
E81A 10.0 10.7 ± 0.5  0.213 ± 0.004  4 0.020 ± 0.001 - - 
E81G 7.0 9.6 ± 0.1 0.454 ± 0.001 4 0.047 ± 0.001 0.51 ± 0.03 0.12 ± 0.05 
R88A 11.3 5.3 ± 0.2 0.88 ± 0.02 4 0.16 ± 0.08 - - 
R88G 5.8 4.9 ± 0.6  3.03 ± 0.06 4 0.6 ± 0.1 0.8 ± 0.3 0.06 ± 0.09 
E96A 13.0 10 ± 2 0.146 ± 0.005 4 0.015 ± 0.002 - - 
E96G 11.5 7.8 ± 0.3 0.77 ± 0.02 4 0.098 ± 0.005 1.1 ± 0.1 0.13 ± 0.04 
H99A 
H99G 
11.6 
13.0 
8.2 ± 0.2 
8.2 ± 0.1 
0.182 ± 0.004 
0.17 ± 0.01 
5 
4 
0.002 ± 0.001 
0.002 ± 0.001 
- 
-0.04 ± 0.04 
- 
-0.03 ± 0.01 
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6.4 Discussion 
Intrinsically disordered proteins and intrinsically disordered regions are well represented in 
nature, comprising over 30% of the proteome (Ward et al., 2004). They are commonly found 
in cell signalling mechanisms, as is the case of our family of interest, the BCL-2. IDPs 
biological function together with their lack of a predefined structure challenges the idea that 
in order to function a protein needs to fold.  
Although disordered in isolation, some IDPs can fold to a stable three-dimensional structure 
upon binding to a partner protein. Our main interest in this project was to identify what 
encodes a coupled folding and binding reaction: the IDP or is it templated by the folded 
partner? Using the BCL-2 family as a model to study coupled folding and binding, we have 
compared four systems composed by two IDPs (BID and PUMA) and two folded proteins 
(A1 and MCL-1) using Φ-value analysis. 
Φ-value analysis has been widely employed in protein folding studies to reveal the pathway 
by which a protein goes from unfolded to its folded state. A few IDP coupled folding and 
binding studies also uses Φ-value analysis in order to unravel the mechanism by which a 
disordered peptide folds and binds to a folded partner (Dahal et al. 2017; Dogan et al. 2013; 
Gianni et al. 2014; Giri et al. 2013; Hill et al. 2014; J. M. Rogers et al. 2014; Toto et al. 
2014). Most studies have shown that few interactions are usually formed at the transition 
state of the coupled folding and binding reactions, which is in agreement with the results 
we got for disordered BH3-only proteins binding to folded BCL-2–like proteins.  
My results on BID:A1 using Φ-value analysis revealed that BID peptide remains 
unstructured at the transition state upon binding to A1, with low Φ-values observed along 
the entire peptide  (0< Φ <0.2). Considering that some IDPs can fold to different structures 
upon binding to different partner proteins (Avalos et al. 2002; Lowe et al. 2002; Richard R. 
Rustandi, Baldisseri, and Weber 2000), it would be reasonable to hypothesise that coupled 
folding and binding reactions would be templated by the folded partner. If this hypothesis 
is correct, using a different partner protein should affect the transition state interactions. To 
challenge this hypothesis, we did a comparative Φ-value analysis using the same BID 
peptide binding to a different partner, MCL-1 (Figure 1.19, A). 
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Figure 6.19: Comparative Φ-values of PUMA and BID binding to MCL-1 and A1. (A) Φ-value 
analysis data of BID peptides binding to the partners MCL-1 and A1. BID:MCL-1 data was taken 
from Quenton Bubb. (B) Φ-value analysis data of PUMA peptides binding to the partners MCL-1 
and A1. Data were taken from Rogers et al. 2014 and Dr. Michael Crabtree. (C) Correlation plot 
of Φ-values obtained for PUMA and BID peptides when binding to MCL-1 and A1. Together with 
the hydrophobic mutants, Ala-Gly mutations in PUMA that destabilises both MCL-1 and A1 by >0.6 
kcal.mol-1 are included in the plot. (D) Correlation plot of Φ-values obtained for MCL-1 and A1 
when binding to PUMA and BID peptides. Only hydrophobic mutants are represented, as Ala-Gly 
mutations did not destabilise BID complexes enough to allow Φ-value calculations. Error bars 
represent the propagated errors. Figure adapted from Crabtree et al. 2018. 
Surprisingly, the results showed a very good agreement for all mutants. In both cases, BID 
remains disordered at the transition state upon binding to the partner protein, showing low 
Φ-values throughout the entire peptide sequence. These results indicated that the disordered 
peptide BID is responsible for encoding the transition state upon binding to a partner protein. 
Interestingly, the results for PUMA peptide binding to A1 (work done by Dr. Michael 
Crabtree) show a similar Φ-value pattern to PUMA binding to MCL-1 (work done by Dr. 
Joseph Rogers), with intermediate Φ-values (0.2< Φ <0.6) observed at the N-terminal of the 
PUMA peptide whereas low Φ-values (0< Φ <0.2) are observed along rest of the peptide 
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sequence (Figure 1.19, B). Most importantly, the results show that the pattern of Φ-values 
is maintained for the peptides PUMA and BID when binding to MCL-1 and A1. A strong 
correlation of Φ-values is observed for both peptides when binding to MCL-1 and A1 
(Figure 6.19, C). In contrast, a correlation is not observed when we plot Φ-values obtained 
for MCL-1 and A1 when binding to PUMA and BID peptides. (Figure 6.19, D). The results 
support the conclusion that the IDPs encode the interactions of the transition states. 
Simulations of the unbound PUMA suggest that although mainly disordered, the peptide 
displays a higher degree of helicity at its N-terminus (Harmon et al. 2016), whereas CD data 
show that BID peptide is largely disordered in the unbound state. Both results are in 
agreement with the transition states structures findings: PUMA is partially structured with 
higher Φ-values at the N-terminal region whereas BID remains disordered. That might 
indicate that the residual structure of the IDP in the unbound state can determine the 
transition state interactions upon binding to a protein partner. IDPs encode their level of 
residual structure, and our study shows that they have also the potential to encode the 
transition state structures in a coupled folding and binding reaction. The ability of 
controlling residual structure and encoding transition state interactions provides a fine way 
of how evolution can modulate the affinity of the IDP and partner protein complexes, which 
could be one good reason for the strong conservation of disorder on the proteome. 
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7 Coupled folding and binding in a full-length 
IDP context 
7.1 Introduction 
 
7.1.1 The role of IDP sequence context on its ability to bind and interact 
 
Natively unfolded or intrinsically disordered proteins (IDPs) lack a defined structure but 
nonetheless represent a significant proportion of the proteome (Ward et al., 2004). They 
play significant roles in transcription regulation, DNA binding, intracellular transportation 
etc, where they are commonly involved in networks comprised by multiple partners (Ward 
et al., 2004; Dunker et al., 2005).  
Although the discovery of IDPs is relatively new, a significant number have been reported 
over the past 20 years (Uversky 2002). A great proportion of experimental studies 
investigate IDPs as peptides or shorter versions of the whole protein sequence, usually the 
binding motif. However, these motifs are often part of larger proteins.  
Even though studying IDPs as peptides is a much simpler way to work and can offer 
significant insights on these intriguing molecules, it has already been shown that the 
sequence context of the binding motif could affect IDPs properties. For instance, mutations 
on conserved proline residues located in flanking regions of IDPs were shown to modulate 
their binding affinities for partner proteins by controlling the lifetime of the IDP/protein 
complex and its in vivo function (Borcherds et al. 2014; Crabtree et al. 2017). Furthermore, 
the coupled folding and binding of cMyb and KIX is altered when cMyb is extended by the 
addition of the transactivation domain TAD (Shammas et al. 2014, Arai et al. 2015).   
On the previous chapter, we demonstrated that IDPs encode coupled folding and binding 
reactions with its partner proteins, as their sequences contain the necessary information for 
complex formation: same IDP binds to different partner proteins following the same 
 Coupled folding and binding in a full-length IDP context 
 
 
 
 
131 
pathway (Crabtree et al. 2018). The research was performed using the binding motif (35 
residues) of the IDPs but they all exist in a longer context. The study opened new ideas on 
how to explore the same IDP-partner complex using the IDP in its full-length form. That 
would allow us to shed some light onto how the full-length context compares to what we 
know for the peptides.  
 
7.1.2 BID as a model of an IDP in its full-length context 
 
The BCL-2 family is well known to be involved in cell apoptosis comprising a complex 
network between pro-apoptotic, pro-survival and “initiator” proteins. The precise 
mechanism by which apoptosis occurs is still not fully understood (L.Omonosova and 
C.Hinnadurai 2008). That makes the BCL-2 a very intriguing and interesting family of 
proteins to be explored. Protein members of the BCL-2 family all have in common the 
presence of a BH3 (BCL-2 homology 3) motif. Pro-apoptotic (e.g BAK, BAX, BOK) and 
pro-survival (e.g MCL-1, A1, BCL-XL) are multi domain proteins, whereas the stimuli 
activators or “initiators” (e.g. PUMA, tBID, BIM, BAD) are BH3-only proteins and mostly 
disordered (Czabotar et al. 2014).  
A potential candidate to be studied in a full-length context is the previously studied BID. In 
contrast to all other “initiators” proteins of the BCL-2 family, full-length BID (BIDFL) has 
a defined globular structure with eight helices. Helix 3 contains the BH3 motif and it is 
connected to helices 1 and 2 by a long flexible loop, which contains a caspase cleavage site 
(Figure 7.1). Despite the low sequence identity, the structure of BIDFL is very similar to the 
other BCL-2 family proteins, like BAX and MCL-1 (Petros et al. 2004, Fesik 2000). 
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Figure 7.1: BIDFL structure (PDB 1DDB). BIDFL structure showing N- and C-terminus. The 
structure shows the first 60 residues that are cleaved in tBID in light pink, the 35 residues that 
comprise the BH3 motif are shown in yellow and the rest of the molecule is shown in dark pink. The 
35 amino acids long fragment was previously used as a peptide to study coupled folding and binding 
(Chapter 6). 
In the cell, BID is cleaved by caspase 8, where 60 N-terminal residues are removed 
generating the truncated BID (tBID) (Figure 7.2). tBID plays a key role in the cell death 
pathway, amplifying the apoptotic response which is required for an effective apoptosis 
(Czabotar et al. 2014). Although BIDFL is located in the cytosol, tBID translocates to the 
mitochondria where it signals apoptosis (Li et al. 1998).  
 
Figure 7.2: Sequence alignment of BIDFL and tBID. BIDFL is N-terminally truncated by caspase 8, 
where 60 residues are removed generating tBID. Alignment was produced using Clustal Omega 
(Goujon et al. 2010, Sievers et al. 2011).  
Even though tBID preserves the secondary helical structure of BIDFL, it adopts an α-helical 
but dynamically disordered conformation in solution (Gong et al. 2004, Wang & Tjandra 
N
C
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2013, Yao et al. 2009). Perhaps, that might facilitate the interaction between BID and the 
pro-apoptotic and pro-survival proteins, as its BH3 motif will be exposed after cleavage. 
Studying BIDFL and tBID would possibly give us insights on why nature chooses this 
pathway for the apoptosis network trigger and function, as well as gain insights into the 
contribution of the protein context to the interaction profile of the binding motif. 
 
7.1.3 Fluorescent residues in BIDFL and tBID 
 
BIDFL contains two tryptophan and one tyrosine residues (Figure 7.3). After truncation by 
caspase and the removal of BID1-60 fragment, one tryptophan and one tyrosine located in the 
flexible loop are deleted from BID, leaving tBID with one tyrosine only. Biophysical 
experiments of BIDFL are performed following the tryptophan fluorescence, whereas 
tyrosine was used for tBID. 
 
 
Figure 7.3: BIDFL structure (PDB 1DDB) showing aromatic residues. The structure shows the 
position of the aromatic residues represented as spheres: one tryptophan (orange) and two tyrosines 
(green). The tryptophan and one tyrosine are located in the flexible loop, that gets truncated on tBID 
(light pink), whereas the other tyrosine is positioned on helix 8.  
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7.1.4 Chapter aims 
 
The majority of the studies on IDPs are performed using peptides, which are the binding 
regions of a larger protein. This chapter aims to investigate an IDP in its full-length context 
to shed some light on how that affects its ability to form complexes with partner proteins 
and how it modulates the complex affinity. For that reason, I have chosen to study BID, 
which is active as a BH3-only protein tBID but is a member of the BCL-2 family that is 
structured in a full-length context. 
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7.2 Results 
 
7.2.1 Design and production of BID and tBID  
 
Mouse BIDFL and tBID genes were purchased from GenScript in the standard pUC57 vector. 
A molecular biology strategy was designed to insert both genes into pGEX-4T-3 plasmid. 
This plasmid was previously used for A1, which made the purification protocol very similar 
to the one I was already using. Primers were designed in order to extract BIDFL and tBID 
genes from their original pUC57 vector and to remove A1 gene from pGEX-4T-3. The 
primers for BID/tBID contained extra base pairs in both ends that were complementary with 
the desired pGEX-4T-3 plasmid. A ligation was performed as a last step in order to insert 
the protein genes into the vector. The choice to work with mouse over human BID was to 
keep the consistency with the previous work (chapter 6) and allow comparison between the 
results. 
Once the molecular biology steps were finished and we had both BID and tBID in the 
pGEX-4T-3 plasmid, we wanted to develop the protocol for the proteins expression and 
purification. In order to find the optimal condition for BIDFL and tBID expressions, different 
parameters were tested and varied: three different OD600 upon induction (0.4, 0.6 and 0.8), 
two different IPTG concentrations (0.1 and 1 mM) and two temperatures after IPTG 
induction (25° and 37° C). Results for the different conditions for the two proteins are shown 
in Figure 8.4. From the expression trials, it became quite clear that tBID expression was 
really poor. It was thought that the unstructured protein is likely to be insoluble so we 
decided to express only BIDFL and use it to obtain tBID with the caspase-8 cleavage later 
on. For BIDFL, we found as an optimal condition to induce expression with 0.1 mM IPTG 
at OD600 0.6-0.8 and incubate it at 37° C for 6 hours after induction (Figure 7.3). 
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Figure 7.4: Expression trials of BIDFL and tBID. Different parameters were tested in order to find 
the optimal expression protocol for the two protein constructs: three different OD600 (0.4, 0.6 and 
0.8), two different IPTG concentrations (0.1 and 1 mM) and two temperatures after induction (25° 
and 37° C). Each gel contain six samples of BIDFL and tBID in the different conditions: 1) OD 600 = 
0.4, IPTG = 0.1 mM, 2) OD 600 = 0.4, IPTG = 1 mM, 3) OD 600 = 0.6, IPTG = 0.1 mM, 4) OD 600 = 
0.6, IPTG = 1 mM, 5) OD 600 = 0.8, IPTG = 0.1 mM, 6) OD 600 = 0.8, IPTG = 1 mM. Gels represent 
the different incubation temperature and times after IPTG induction: (A) 25° C, 4 hours; (B) 25° C, 
6 hours; (C) 25° C, overnight; (D) 37° C for 6 hours, then 25 ° C overnight; (E) 37° C, 2 hours; (F) 
37° C, 3 hours; (G) 37° C, 4 hours; (H) 37° C, 5 hours (I) 37° C, 6 hours. PageRuler unstained 
standard ladder is shown in (A) for comparison (* in all gels). The trials show a very poor expression 
of tBID for all the conditions. The optimal condition for BIDFL expression was to induce with 0.1 
mM IPTG at OD600 0.6-0.8 and to incubate it at 37° C for 6 hours after induction (gel I).  
  
kDa 
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BIDFL was expressed as a GST fusion protein and the detailed purification protocol is 
described in Chapter 3 (Materials and Methods). In the final step of purification, using a 
Superdex 75 gel filtration column, we noticed that extra peaks of higher molecular weight 
appeared before the main BIDFL one (Figure 7.5, A). SDS gel of the fractions confirm the 
expected BIDFL mass and purity not only for fractions on the main peak, but also the ones 
of higher mass (Figure 7.5, B). These results suggest that that BIDFL is capable of 
homooligomerisation.  
  
  
Figure 7.5: Purification of BIDFL. (A) Chromatogram image after BIDFL G75 size exclusion run 
showing the peaks 1, 2 and 3. (B) SDS gel of BIDFL fractions after G75 purifications and NuPage 
unstained protein ladder for comparison. Gel starts from marker and show fractions from peak 3, 
followed by peaks 1 and 2. Pure BIDFL can be identified in all fractions, suggesting that the larger 
species (first and second peaks on the chromatogram) are also formed by BIDFL.  
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Purified BIDFL samples were sent for mass spectroscopy analysis at the Chemistry 
department to confirm its identity and purity. All three samples results confirmed the 
expected mass for BIDFL. Figure 7.6 show one chromatogram as an example.   
 
Figure 7.6: Mass spectroscopy results for BIDFL. Mass spectroscopy analysis of the final BIDFL 
sample in 50 mM sodium phosphate, pH 7.0 (0.05% Tween-20) provided a mass of 22,096±12.39 
Da, which is within error of the expected mass of 22,095 Da. 
For accurate concentration calculations, samples of purified BIDFL were sent for Amino 
Acid Analysis (AAA) at the Biochemistry department, performed by Peter Sharratt. The 
results allowed us to calculate the experimental extinction coefficient (ε280) (Figure 7.7). 
The experimental and the ProtParam theoretical values were slightly different, 8700 and 
8480 M-1.cm-1 respectively. Throughout this chapter, BIDFL concentrations were calculated 
using the experimental extinction coefficient value (ε280 = 8700  M1.cm-1). 
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Figure 7.7: Extinction coefficient for BIDFL. Extinction coefficient value calculated from amino acid 
analysis (AAA). Concentration results for three different samples of BIDFL plotted against its 
absorbance readings at 280 nm. ProtParam expected value was ε=8480 M-1.cm-1 whereas the 
experimental one was ε=8700 M-1.cm-1. The experimental value was used for all BIDFL concentration 
calculations in this chapter. 
Production of BIDFL was somehow straightforward whereas tBID was not. Therefore, the 
latter was obtained by cleaving BIDFL with caspase-8 after it was produced. Even though 
the cleavage was successful (as confirmed by SDS-PAGE), the N-terminal 60-residue 
fragment (BID1-60) was still bound to the rest of the molecule (as observed by SEC). Hence, 
an extra step was added to the purification protocol in order to separate tBID from BID1-60. 
After cleavage with caspase-8, the protein was incubated in 8 M urea and unfolding of the 
protein allowed tBID and BID1-60 to be separated by size exclusion chromatography (Figure 
7.8). Pure tBID was dialysed back into buffer to remove denaturant. That is an unexpected 
and interesting result demonstrating that even though caspase-8 is able cleave BIDFL, this 
event does not sufficiently destabilise the protein to result in the separation of tBID from 
the fragment.   
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Figure 7.8: Purification of tBID after unfolding in denaturant. (A) Chromatogram image after G75 
size exclusion run in 8 M urea showing peaks 1, 2 and 3. (B) SDS gel of tBID fractions after G75 
purification in urea and NuPage unstained protein ladder for comparison. Gel starts from marker 
and shows fractions from peak 1 (uncleaved BIDFL), 2 (tBID) and 3 (BID1-60 fragment). 
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7.2.2 Stability of BIDFL 
 
The stability of BIDFL was measured by urea-induced equilibrium denaturation. The 
experiment was performed in the fluorimeter with BIDFL in 50 mM sodium phosphate, pH 
7.0 (0.05% Tween-20) and 10 mM DTT, at 25 °C. Tryptophan fluorescence was followed 
with the excitation wavelength of 280 nm and emission recorded from 300 to 400 nm. Data 
were analysed calculating the fluorescence at 356 nm and the results were fitted to a two-
state model (Figure 7.9). Although BIDFL has a flexible unfolded loop on its structure, its 
stability (12.9 kcal.mol-1) is very similar to other BCL-2 family proteins, MCL-1 and A1 (≈ 
12 kcal.mol-1) for instance. 
 
 
Figure 7.9: Equilibrium curve of BIDFL. Urea-induced equilibrium denaturation curve of BIDFL in 
50 mM sodium phosphate, pH 7.0 (0.05% Tween-20) with 10 mM DTT.  
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7.2.3 CD data of BID and tBID 
 
CD data was collected during the purification steps of tBID as well as for pure BIDFL. After 
incubation of BIDFL with caspase-8 and the first run of size exclusion chromatography 
(SEC), CD spectra overlay with the one from BIDFL (Figure 7.10, A) suggesting that the 
protein has the same structure before and after cleavage. Together with the SEC and SDS 
PAGE results, CD result agrees that the fragment BID1-60 is still present with tBID after 
BIDFL is cleaved by caspase. 
The following stage was to unfold the cleaved BID, so it was incubated in denaturant and 
then another SEC run separated tBID and fragment. Although tBID is mostly disordered, 
CD spectra show a recovery in residual structure between tBID in urea and after dialysis, in 
buffer (Figure 7.10, B). That result demonstrates the tBID ability to recover residual 
structure upon denaturant removal. Figure 7.10, C shows a comparison between BIDFL and 
tBID CD spectra. Although BIDFL contains a long flexible loop on its structure, it has similar 
CD spectra when compared with other previously studied BCL-2 family proteins like A1 
(Chapter 6). In contrast, tBID is largely disordered, as are the other BH3-only proteins such 
as PUMA. 
 
Figure 7.10: CD results during the purifications steps of tBID. (A) CD spectra show the same 
residual structure of purified BIDFL before and after cleavage with caspase-8. (B) tBID after the 
final purification step using urea shows a recovery in residual structure after dialysis to remove the 
denaturant. (C) Comparison between purified BIDFl and tBID.  
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7.2.4 Oligomerisation of BIDFL 
 
BCL-2 family oligomerisation propensity 
 
The BCL-2 family proteins mechanism of cell apoptosis is being extensively discussed and 
studied over the past years. From the biological point of view, it is known that pro-apoptotic 
family members like BAK and BAX are the cell death executioners (Dewson & Kluck 2009, 
Peña-Blanco & García-Sáez 2018). Once the signal for apoptosis is triggered, these proteins 
are able to form pores in the mitochondrial outer-membrane and release its inter-membrane 
contents, activating caspases resulting in cell death. Thus, control of pro-apoptotic proteins 
oligomerisation is believed to be key in apoptosis regulation by the BCL-2 family (Czabotar 
et al. 2014, (Kale, Osterlund, and Andrews 2018). Although the relevance of BAK/BAX 
oligomerisation is appreciated, its structures and mechanism are not yet fully understood.  
The fact that many PhD students’ projects in the lab over the last few years involved the 
BCL-2 family, allowed us to gain significant insights and gave us an unique chance to 
compare results between different protein members of the family as they came out of the 
instruments and were analysed. Dr. Basile Wicky worked with pro-apoptotic BAK and BAX 
and found out that neither of them forms oligomers under buffer conditions: not 
spontaneously, nor in the presence of BH3-only peptides. Interestingly, using detergents to 
provide a membrane-like environment, BAK and BAX oligomerise in vitro in a spontaneous 
manner, without requiring the presence of any other BCL-2 protein (Wicky, 2018). With 
the focus on the oligomerisation properties of BCL-2 proteins, Dr. Michael Crabtree spotted 
some interesting and intriguing results: equilibrium denaturation curves of pro-survival 
BCL-XL and A1 proteins, showed two transitions. Further investigation showed that this 
biphasic behaviour under denaturing conditions could be explained by oligomers formation, 
with the first transition indicating monomer to oligomer formation and the second 
representing dissociation of the oligomer into unfolded monomer. This behaviour was not 
reproduced by MCL-1, for example, another pro-survival protein. When I first purified 
BIDFL I could not ignore the intriguing result from its purification: together with the 
protein’s main peak, other peaks of higher molecular weight could be seen in the 
chromatogram. SDS gel revealed that those fractions of higher order species were only 
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composed by BIDFL, again a strong indication of oligomers formation. Michael and Basile 
also observed a similar behaviour when purifying BCL-XL. The main oligomer peak was 
in fact a dimer, confirmed by analytical ultracentrifugation (AUC).  
BIDFL sequence contains two cysteines (Figure 7.11) that could be a sensible reason for 
multimerisation under oxidising conditions. In the absence of a reducing agent, although 
not huge, oxidation over time would be expected. During the BIDFL purification steps, as 
well as in all experiments, DTT was added (10 mM final concentration) to avoid oligomers 
formation. Thus, the higher species observed could not be explained by disulphide bond 
formation. 
 
   
Figure 7.11: BIDFL structure (PDB 1DDB) showing cysteine residues. The structure shows the 
position of the two cysteine residues as blue spheres: one located in the loop between helices 1 and 
2 and the other on helix 5.  
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Cross-linking of BIDFL 
 
Although the oligomerisation was not the focus of this project, I could not ignore this 
interesting result. As well as pro-apoptotic BAK and BAX and pro-survival BCL-XL and 
A1, BID in a full-length context was also able to form higher order species. The oligomeric 
state was investigated using chemical cross-linking.  
The experiment was carried out by using two crosslinkers: EDC (1-ethyl-3-[3-
dimethyllaminopropyl]carbodiimide hydrochloride) and BS3 (bis[sulfosuccinimidyl) 
suberate). This dual composition was chosen to allow short as well as longer length cross 
species formation. EDC is known as a “zero length” crosslinker as its reaction forms new 
bonds between carboxyls and amides without incorporation of any EDC’s atoms. It reacts 
with a carboxyl group forming an O-acylisourea and this intermediate rapidly reacts with 
an amino group. This reaction results in the formation of a new amide bond, or in other 
words, the proteins cross-linking. Although EDC allows cross-linking without adding a 
spacer group, it requires the two amino acids to be in close proximity, and that is why BS3 
came into use. BS3 is a N-hydroxysuccinimide (NHS) ester with an 8-atom spacer arm (11.4 
Å). This reagent is specific for primary amines on the side chain of lysine residues and O-
acylisoureas (formed by EDC reaction). The use of EDC and BS3 together allows cross-
linking of lysine with glutamate and aspartate residues that are located far from each other.  
Crossliking gel results showed formation of dimers, trimers and tetramers of BIDFL, 
confirming the preliminary indication from SEC peaks (Figure 7.12). It is important to 
highlight that chemical cross-linking is not an equilibrium reaction, which makes the bands 
distribution on the gel not a direct association with the oligomers present in solution. 
Therefore the gel result does not necessarily represent the distribution observed by SEC, but 
it shows the capability of BID to form up to tetrameric oligomers. 
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Figure 7.12: Crosslinking results of BIDFL. (A) Chromatogram image after G75 size exclusion run 
showing the peak of purified BIDFL as well as the extra peaks (regions 1, 2 and 3). (B) SDS gel of 
BIDFL fractions after a crosslinking reaction and NuPage ruler unstained protein ladder for 
comparison. Gel starts from marker and show fractions from regions 1, 2, and 3 from the 
chromatogram image. From the gel image, we can observe the presence of BIDFL monomer and its 
oligomers: dimers, trimers and tetramers. 
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7.2.5 Association kinetics of BIDFL and tBID with the pro-survival 
protein A1 
Association kinetics experiments of both BIDFL and tBID were performed against A1 
protein. Although any other folded BCL-2 family protein could have been used, the choice 
to work with A1 was to be consistent and comparable with my previous studies of A1 and 
BID-BH3 peptide (Chapter 6).  
Experiments for BIDFL:A1 were performed under pseudo-first order conditions with A1 10x 
in excess. Results show a very slow association rate (Figure 7.13). Fitted traces represent an 
average of 25-35 measurements.  
Although the current result is not sufficient to calculate the concentration dependent 
association rate constant (kon), the significantly low apparent rate constant observed 
(≈0.02 s-1) can give us insights into this system. Two reasonable hypotheses can emerge:  
1) The two folded proteins do not interact. The folded structure of BIDFL might prevent it 
to bind and interact with A1 as its BH3 region is found enclosed in the structure.  
2) Unfolding of BIDFL is required in order to expose its BH3 region and allow complex 
formation. In the latter case, the observed rate could represent the unfolding rate of BID and 
be the rate-limiting step for BIDFL and A1 to interact. 
A quick test where the light source was temporary blocked revealed that a photobleaching 
effect plays a role on the signal, but it is not sufficient to explain the observed fluorescence 
change.  
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Figure 7.13: Association kinetics of BIDFL and A1. BIDFL and A1 were rapidly mixed in a stopped 
flow instrument on a 1:1 volume ratio under pseudo-first order conditions. The final concentrations 
in the cell were (A) 1 and 10 μM and (B) 1.5 and 15 μM, of BIDFL and A1 respectively. A 320 nm 
cut-off filter was employed, and each trace is a result of 35 measurements averaged.  
 
Unfolding kinetics of BIDFL revealed that the protein unfolds in a rate of ≈0.01 s-1 (Figure 
7.14, A), a very similar rate to the one observed for BIDFL:A1 association. The results 
support the idea that the unfolding of BIDFL is the rate limiting step for the association of 
BIDFL and A1. Surprisingly, a very similar unfolding rate (≈0.02 s-1) is observed for the 
cleaved BIDFL, after incubation with caspase but before separation from the BID1-60 
fragment (Figure 7.14, B). The results show that the cleavage process on its own, is not 
sufficient to speed up the unfolding of the BIDFL molecule.  
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Figure 7.14: Unfolding kinetics of BIDFL before and after cleavage with caspase. (A) BIDFL and (B) 
BIDFL upon cleavage with caspase unfolding kinetics. The experiments were performed in a stopped-
flow instrument, in a 1:10 volume ratio. Each point represents an average of 20-25 traces.  
As tBID does not have a tryptophan residue, some preliminary tests were required in order 
to find the optimised settings to do association experiments with A1. That was to decide 
which excitation wavelength to use, as well as if a cut-off filter would be employed. Stopped 
flow experiments were performed in a 1:1 volume ratio, with both proteins at the same 
concentration (2 μM final). The results show that a 276 nm excitation wavelength with no 
cut-off filter is a good condition. Figure 7.15, A show an example of a trace using the chosen 
settings. 
Later on, association kinetics were done under pseudo-first order conditions using a 1:1 
volume ratio. A signal change was observed, and the data were fitted to a single exponential 
plus drift. The observed association rate for that concentration was ≈1.5 s-1 (Figure 7.15, B), 
which is two orders of magnitude faster when compared with the previous one from BIDFL 
and A1. Although preliminary, this result is more consistent with fast association as is 
observed for BID-BH3 peptide binding to A1.  
Additional kinetics experiments (association and dissociation) would have allowed us to 
compare BIDFL, tBID and BID peptide data and get insights on how the BID-BH3 motif 
sequence context can modulate the binding affinities for BID and A1. Unfortunately, these 
final experiments were challenged by time limitations.  
A B
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Figure 7.15: Association kinetics of tBID and A1. The two proteins were rapidly mixed in a stopped 
flow instrument on a 1:1 volume ratio. (A) Experiment done on a 1:1 concentration ratio: 2 μM final 
concentration of each protein. The trace is a result of 31 measurements averaged. (B) Experiment 
done under pseudo-first order conditions with A1 10x in excess: 1 and 10 μM of tBID and A1, 
respectively. The trace is a result of 15 measurements averaged. 
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7.3 Discussion 
Starting from the gene design and expression and purification protocols developed, BIDFL 
and tBID were successfully produced in the lab. Even under different conditions, expression 
of tBID transpired to be very poor, which is the reason why we chose to produce the protein 
via the cleavage of BIDFL by caspase-8. Unexpectedly, after cleavage, tBID and BID1-60 
fragment were not separated as we first expected. Thus, unfolding of the protein was 
necessary in order to get free tBID in solution. This fact showed that although caspase-8 is 
necessary for BIDFL cleavage, it is not sufficient to release it from its N-terminal 60 residues 
part. 
CD data also confirms the very similar structure of BIDFL and BID after caspase-8 cleavage. 
After the final purification step, although very disordered, tBID is able to recover some 
residual structure in buffer when compared with the its previous condition in denaturant. 
The CD spectra of both BIDFL and tBID are in agreement with expected structural 
knowledge from the literature: BIDFL is a folded alpha-helical protein whereas tBID is 
largely unstructured.  
Purification of BIDFL showed an intriguing result: extra peaks were observed on its 
chromatogram. Although the peaks would correspond to higher molecular weight species, 
SDS PAGE revealed that they are only composed by BIDFL. Considering that the cysteine 
potential of multimerisation is abrogated by the reducing agent, presence of higher order 
species comes from propensity of the protein sequence to form oligomers. That was also 
previously observed for other BCL-2 family members, both pro and anti-apoptotic proteins. 
BCL-XL also shows extra peaks upon purification. Similarly, A1 and BCL-XL can 
oligomerise once their folded structure is destabilized by a reducing agent. Moreover, pro-
apoptotic BAK and BAX oligomerise in a membrane-like environment, as when in contact 
with detergents. In the case of BIDFL, cross-linking experiments identified the size of the 
oligomers, with dimers, trimers and tetramers observed. Although only pro-apoptotic BAK 
and BAX have oligomerisation as an in vivo function (pore forming proteins), a spectrum 
of oligomerising ability is observed throughout the BCL-2 family members. That instigating 
evidence could shed some light in the functional evolution of these proteins. Evolutionary 
vestiges of the BCL-2 family ancestry could possibly explain self-assembly propensities of 
the proteins. 
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Biophysical characterisation of BIDFL showed that despite its long flexible loop, it has the 
stability similar to other BCL-2 proteins like A1 and MCL-1. To gain some insights into the 
BIDFL and tBID abilities to form complexes when compared to BID-BH3, some initial 
kinetics experiments were conducted. Association kinetics of BIDFL and A1 show a very 
slow rate (≈0.02 s-1). Interestingly, unfolding kinetics of BIDFL show a very similar rate 
(≈0.01 s-1), suggesting that the unfolding and consequent exposure of the BH3 motif is the 
rate-limiting step for the complex formation. Although one might think that the cleavage 
step with caspase would increase the unfolding rate of the BID molecule, no significant 
change was observed upon incubation with caspase (≈0.02 s-1). Thus, in order to activate 
BID to give it pro-apoptotic activity, BID has to not only be cleaved by caspase but also 
unfold.  
Preliminary association kinetics of tBID and A1 seemed promising. Further experiments 
would be required to show how the rates for association, dissociation and the modulation of 
complex formation of the protein in its physiological relevant length compares with the BH3 
peptide, or in other words, how relevant and informative is the use of peptides as a model 
for studying IDPs. 
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8 Conclusions and future perspectives 
8.1 Conclusions from this thesis 
The work designed and performed in this PhD thesis aimed to deepen our understanding of 
how context can influence protein folding dynamics and protein-protein interactions. SasG 
is a protein that challenges the predictions of folding and stability. The first step of the thesis 
aimed to explore the potential role of SasG unusual charged composition in the protein 
stability. Next, SasG was used as a system to study co-translational folding. Force profile 
experiments were used to shed light on how these elongated beta sheet structure would fold 
on the ribosome and how that compares with the in vitro results of the protein in isolation.  
Intrigued by protein disorder and seeking to gain more information of protein-protein 
interactions, the subsequent project was designed to investigate what encodes IDPs coupled 
folding and binding reactions. For that purpose, comparative ϕ-value analysis was employed 
utilising a family of proteins involved in cell-death regulation – the BCL-2 family. Finally, 
considering that IDPs are largely studied as peptides, the last chapter aimed to investigate 
an IDP as a full-length protein. The BCL-2 family member BID, a BH3-only protein that is 
structured in a full-length context, was used to shed some light on the role of this protein in 
the apoptosis mechanism in the cell. 
 
8.1.1 SasG stability cannot be explained exclusively by highly charged 
amino acids composition and distribution 
SasG is a bacterial multidomain protein, predicted to be disordered, but yet it folds. With an 
unusual sequence composition (65% of Glycines, Prolines and charged residues), it has an 
elongated beta sheet structure, exposed to the solvent in both sides. The lack of a 
hydrophobic core and the abundance of charged residues makes SasG structure very 
intriguing. Seeking to understand what is the contribution of the charged residues on SasG 
stability, we hypothesised that electrostatics could be key for the protein stability and that 
the pattern of charged residues could contribute for the structure formation. 
Conclusions and future perspectives 
 
 
 
 
154 
Surprisingly, equilibrium studies of SasG at different pH and ionic strength values did not 
support the initial hypothesis, as they show no dramatic effect in the G52 domain stability. 
Moreover, bioinformatics analysis confirms that the majority of the charged residues in 
SasG G52 and E-G52 constructs are not involved in salt bridges.  
 SasG clearly defies current prediction of protein disorder and its stability cannot be simply 
explained by the presence or the distribution of charged residues across the molecule. 
Nevertheless, our previous studies were able to demonstrate the role of the inter-domain 
interface in the protein stability. Formation of SasG interface was shown to drive the folding 
of E-G52 even when both domains were destabilised and unfolded in isolation (Gruszka et 
al. 2016).  
 
8.1.2 Force profile experiments can report both intramolecular folding 
and intermolecular interactions between the nascent protein chain and 
the ribosome  
A fundamental question of how in vitro and co-translational protein folding studies compare 
has gained more attention in recent years. As translation happens slowly, it can allow 
nascent chains to fold while still being translated, tethered to the ribosome, even before the 
entire sequence emerges from the ribosome tunnel.  
After previously characterising SasG folding mechanism in vitro, the follow up question 
comprised how this intriguing protein would fold upon translation on the ribosome. Force 
profile experiments were employed to characterise the co-translational folding of G52, 
revealing that the domain is able to fold while is still inside the ribosome vestibule (linker 
length L31). Remarkably, a control experiment involving a non-folding variant of the G52 
domain was also able to release the stall. Furthermore, a high read through was also 
observed at very short linker lengths (<L30), where the protein is still largely sequestered 
inside the ribosome tunnel. Together, these results suggest that other factors rather than 
folding can contribute to the stall release and subsequent high fraction full-length results. 
With the prior knowledge that E-G52 has an additional pathway for folding that starts with 
the formation of the inter-domain interface (Gruszka et al. 2016), we hypothesised that E-
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G52 would fold earlier than G52 when being translated, as soon as the interface is available. 
Surprisingly, force profile results showed that G52 and E-G52 have almost identical results, 
with both constructs folding at similar positions upon translation. That was the first 
indication that the alternative folding pathway for E-G52 might not be available during 
translation. Moreover, force profile results for EG52-G587A, a mutant that is shown in vitro 
to fold via the domains interface, basically overlays with the non-folding variant of E-G52. 
The results support the idea that the alternative folding pathway, well characterised in vitro, 
is not accessible until the peptide chain emerges from the ribosome.  
SasG cotranslational folding results showed that the presence of the ribosome can affect the 
folding process in comparison with the protein in isolation, including preventing alternative 
folding mechanism known to be accessible in the absence of the ribosome. In agreement 
with recent findings, our results contribute to the idea that the ribosome can play a role in 
protein regulation.  
Interestingly, the highly charged composition of SasG allowed us to explore the role of 
electrostatics in the co-translational folding. Non-folding variants of SasG with different 
charge composition were used to shed light on how the presence of charged residues can 
contribute for the stall sequence release. Overall, although disordered, highly positively 
charged constructs were shown to release the stall whereas highly negatively charged 
nascent chains remained stalled. Although force profile experiments can be a powerful 
technique to study co-translational folding, non-folding controls transpired to be essential 
in order to attribute the stall release to folding events. 
 
8.1.3 Intrinsically disordered proteins are able to encode coupled folding 
and binding reactions 
Intrinsically disordered proteins (IDPs) are gaining more attention as their biological 
relevance is increasingly revealed. Although lacking a structure in isolation, a subset of 
IDPs is able to fold upon binding to a partner protein. Coupled folding and binding reactions 
can be very promiscuous, with different IDPs being able to bind to the same partner protein. 
Moreover, as the stability of the IDP-partner complex is dependent on the folded molecule, 
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an immediate hypothesis would be that the folded partner templates the coupled folding and 
binding reaction.  
Comparative ϕ-value analysis of BCL-2 family proteins revealed that the folding pathway 
is essentially encoded by the IDP, not templated by the stabilising partner protein as the 
initial hypothesis suggested. The results open space for new insights regarding the role of 
disorder. The ability of IDPs to encode both their residual structure and transition states, 
provide them the capacity to develop specific kinetic profiles. In vivo, disordered proteins 
are conserved and typically present in cell signalling processes, where responses to stimuli 
may need to be irreversible (e.g. apoptosis stimulation) or occur significantly fast (e.g. cell 
receptor activation). Altering the residual structure or the encoded transition state provide a 
fine manner for evolution to modulate the lifetime of these complexes, which could be a 
good explanation for disorder conservation.  
 
8.1.4 Insights of an IDP in its full-length context 
IDPs are typically studied as peptides, the binding motifs of a bigger protein. Investigation 
of the BCL-2 family member BID on its full-length context (BIDFL) could shed some light 
on the biological mechanism by which this molecule plays a role in the apoptosis network. 
It is well known that BIDFL gets truncated by caspase in the cell. Association and unfolding 
kinetics revealed that BID cannot bind its partner protein A1 in a full-length context. 
Cleavage with caspase followed by unfolding is required for the BID molecule to open and 
expose its binding motif, the BH3 region. 
Interestingly, an oligomerisation propensity, previously identified for other BCL-2 family 
members (BAK, BAX, A1, BLC-XL), was also observed for BIDFL. Although only the pore 
forming pro-apoptotic BAX and BAK have oligomerisation as an in vivo function, the 
potential to form oligomers is observed across the BCL-2 family members. That per se can 
lead to a better understanding of the functional evolution of these proteins.  
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8.2 Future directions  
In terms of the work described in this thesis, it would be very interesting to compare how 
the association, dissociation and lifetime of the complexes are affected between BID 
peptide, cleaved BIDFL and tBID binding to A1. That would shed some light on how the use 
of IDP binding motifs only (peptides) can report on what actually happens in the cellular 
context. 
Another very interesting project to pursue is the oligomerisation propensity of the BCL-2 
family proteins. An evolutionary reconstruction could unravel whether the ancestor of the 
current family members was more, or less, susceptible to self-assembly.  
It would be also fascinating to study an IDP or IDR that can adopt different conformations 
upon binding to a partner molecule. The disordered C-terminal domain of p53, for instance, 
can bind as a helix (Rustandi, Baldisseri and Weber, 2000), as a coil (Lowe et al. 2002; 
Mujtaba et al. 2004) or as a strand (Avalos et al. 2002). Understanding how the transition 
state is encoded when multiple binding structures are possible would be very significant. 
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9 Apendix 
Appendix 1-  
Equilibrium curves of G52 at different pH values: fluorescence at 305 nm. 
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Appendix 2-  
SasG folding on the ribosome DNA and protein sequences 
G52 protein sequence:  
Y G P V K G D S I V E K E E I P F E K E R K F N P D L A P G T 
E K V T R E G Q K G E K T I T T P T L K N P L T G E I I S K G 
E S K E E I T K D P I N E L T E Y G P E T 
G52 DNA sequence: 
TACGGTCCGGTTAAAGGTGACTCTATCGTTGAAAAAGAAGAAATCCCGTTCGAAAAAGAA
CGTAAATTCAACCCGGACCTGGCGCCGGGTACCGAAAAAGTTACCCGTGAAGGTCAGAAA
GGTGAAAAAACCATCACCACCCCGACCCTGAAAAACCCGCTGACCGGTGAAATCATCTCT
AAAGGTGAATCTAAAGAAGAAATCACCAAAGACCCGATCAACGAACTGACCGAATACGGT
CCGGAAACC 
E-G52 protein sequence:  
G P E T I A P G H R D E F D P K L P T G E K E E V P G K P G I 
K N P E T G D V V R P P V D S V T K Y G P V K G D S I V E K E 
E I P F E K E R K F N P D L A P G T E K V T R E G Q K G E K T 
I T T P T L K N P L T G E I I S K G E S K E E I T K D P I N E 
L T E Y G P E T 
E-G52 DNA sequence: 
GGGCCCGAAACGATCGCGCCGGGTCACCGTGACGAATTTGACCCGAAACTGCCGACCGGT
GAAAAAGAAGAAGTTCCGGGTAAACCGGGTATCAAAAACCCGGAAACCGGTGACGTTGTT
CGTCCGCCGGTTGACTCTGTTACCAAATACGGTCCGGTTAAAGGTGACTCTATCGTTGAA
AAAGAAGAAATCCCGTTCGAAAAAGAACGTAAATTCAACCCGGACCTGGCGCCGGGTACC
GAAAAAGTTACCCGTGAAGGTCAGAAAGGTGAAAAAACCATCACCACCCCGACCCTGAAA
AACCCGCTGACCGGTGAAATCATCTCTAAAGGTGAATCTAAAGAAGAAATCACCAAAGAC
CCGATCAACGAACTGACCGAATACGGTCCGGAAACC 
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G52 only negative charges protein sequence:  
Y G P V M G D S I V E M E E I P F E M E M M F N P D L A P G T 
E M V T M E G Q M G E M T I T T P T L M N P L T G E I I S M G 
E S M E E I T M D P I N E L T E Y G P E T 
G52 only negative charges DNA sequence: 
TACGGTCCGGTTATGGGTGACTCTATCGTTGAAATGGAAGAAATCCCGTTCGAAATGGAA
ATGATGTTCAACCCGGACCTGGCGCCGGGTACCGAAATGGTTACCATGGAAGGTCAGATG
GGTGAAATGACCATCACCACCCCGACCCTGATGAACCCGCTGACCGGTGAAATCATCTCT
ATGGGTGAATCTATGGAAGAAATCACCATGGACCCGATCAACGAACTGACCGAATACGGT
CCGGAAACC 
E-G52 only negative charges protein sequence: 
G P E T I A P G H M D E F D P M L P T G E M E E V P G M P G I 
M N P E T G D V V M P P V D S V T M Y G P V M G D S I V E M E 
E I P F E M E M M F N P D L A P G T E M V T M E G Q M G E M T 
I T T P T L M N P L T G E I I S M G E S M E E I T M D P I N E 
L T E Y G P E T 
E-G52 only negative charges DNA sequence: 
GGGCCCGAAACGATCGCGCCGGGTCACATGGACGAATTTGACCCGATGCTGCCGACCGGT
GAAATGGAAGAAGTTCCGGGTATGCCGGGTATCATGAACCCGGAAACCGGTGACGTTGTT
ATGCCGCCGGTTGACTCTGTTACCATGTACGGTCCGGTTATGGGTGACTCTATCGTTGAA
ATGGAAGAAATCCCGTTCGAAATGGAAATGATGTTCAACCCGGACCTGGCGCCGGGTACC
GAAATGGTTACCATGGAAGGTCAGATGGGTGAAATGACCATCACCACCCCGACCCTGATG
AACCCGCTGACCGGTGAAATCATCTCTATGGGTGAATCTATGGAAGAAATCACCATGGAC
CCGATCAACGAACTGACCGAATACGGTCCGGAAACC 
 
G52 only positive charges protein sequence:  
Y G P V K G N S I V Q K Q Q I P F Q K Q R K F N P N L A P G T 
Q K V T R Q G Q K G Q K T I T T P T L K N P L T G Q I I S K G 
Q S K Q Q I T K N P I N Q L T Q Y G P Q T  
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G52 only positive charges DNA sequence: 
TACGGTCCGGTTAAAGGTAATTCTATCGTTCAAAAACAACAAATCCCGTTCCAAAAACAA
CGTAAATTCAACCCGAATCTGGCGCCGGGTACCCAAAAAGTTACCCGTCAAGGTCAGAAA
GGTCAAAAAACCATCACCACCCCGACCCTGAAAAACCCGCTGACCGGTCAAATCATCTCT
AAAGGTCAATCTAAACAACAAATCACCAAAAATCCGATCAACCAACTGACCCAATACGGT
CCGCAAACC 
E-G52 only positive charges protein sequence:  
G P Q T I A P G H R N Q F N P K L P T G Q K Q Q V P G K P G I 
K N P Q T G N V V R P P V N S V T K Y G P V K G N S I V Q K Q 
Q I P F Q K Q R K F N P N L A P G T Q K V T R Q G Q K G Q K T 
I T T P T L K N P L T G Q I I S K G Q S K Q Q I T K N P I N Q 
L T Q Y G P Q T 
E-G52 only positive charges DNA sequence: 
GGGCCCCAAACGATCGCGCCGGGTCACCGTAATCAATTTAATCCGAAACTGCCGACCGGT
CAAAAACAACAAGTTCCGGGTAAACCGGGTATCAAAAACCCGCAAACCGGTAATGTTGTT
CGTCCGCCGGTTAATTCTGTTACCAAATACGGTCCGGTTAAAGGTAATTCTATCGTTCAA
AAACAACAAATCCCGTTCCAAAAACAACGTAAATTCAACCCGAATCTGGCGCCGGGTACC
CAAAAAGTTACCCGTCAAGGTCAGAAAGGTCAAAAAACCATCACCACCCCGACCCTGAAA
AACCCGCTGACCGGTCAAATCATCTCTAAAGGTCAATCTAAACAACAAATCACCAAAAAT
CCGATCAACCAACTGACCCAATACGGTCCGCAAACC 
G52 no charges protein sequence:  
Y G P V M G N S I V Q M Q Q I P F Q M Q M M F N P N L A P G T 
Q M V T M Q G Q M G Q M T I T T P T L M N P L T G Q I I S M G 
Q S M Q Q I T M N P I N Q L T Q Y G P Q T 
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G52 no charges DNA sequence: 
TACGGTCCGGTTATGGGTAATTCTATCGTTCAAATGCAACAAATCCCGTTCCAAATGCAA
ATGATGTTCAACCCGAATCTGGCGCCGGGTACCCAAATGGTTACCATGCAAGGTCAGATG
GGTCAAATGACCATCACCACCCCGACCCTGATGAACCCGCTGACCGGTCAAATCATCTCT
ATGGGTCAATCTATGCAACAAATCACCATGAATCCGATCAACCAACTGACCCAATACGGT
CCGCAAACC 
E-G52 no charges protein sequence:  
G P Q T I A P G H M N Q F N P M L P T G Q M Q Q V P G M P G I 
M N P Q T G N V V M P P V N S V T M Y G P V M G N S I V Q M Q 
Q I P F Q M Q M M F N P N L A P G T Q M V T M Q G Q M G Q M T 
I T T P T L M N P L T G Q I I S M G Q S M Q Q I T M N P I N Q 
L T Q Y G P Q T 
E-G52 no charges DNA sequence: 
GGGCCCCAAACGATCGCGCCGGGTCACATGAATCAATTTAATCCGATGCTGCCGACCGGT
CAAATGCAACAAGTTCCGGGTATGCCGGGTATCATGAACCCGCAAACCGGTAATGTTGTT
ATGCCGCCGGTTAATTCTGTTACCATGTACGGTCCGGTTATGGGTAATTCTATCGTTCAA
ATGCAACAAATCCCGTTCCAAATGCAAATGATGTTCAACCCGAATCTGGCGCCGGGTACC
CAAATGGTTACCATGCAAGGTCAGATGGGTCAAATGACCATCACCACCCCGACCCTGATG
AACCCGCTGACCGGTCAAATCATCTCTATGGGTCAATCTATGCAACAAATCACCATGAAT
CCGATCAACCAACTGACCCAATACGGTCCGCAAACC 
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Appendix 3 - Table 1. Biophysical parameters for the coupled folding and binding of PUMA–A1. 
PUMA  Helicity %  kon (μM-1s-1) koff (s-1) x10-3 n Kd (koff/kon) (nM) ΔΔG (kcal.mol-1) Φ 
WT 20.1 5.9 ± 0.2 0.50 ± 0.02 4 0.085 ± 0.004 - - 
W133F 17.0 4.27 ± 0.04 2.03 ± 0.03 3 0.475 ± 0.008 1.02 ± 0.03 0.19 ± 0.02 
I137A 17.2 1.64 ± 0.05 6.0 ± 0.2 4 3.7 ± 0.2 2.23 ± 0.04 0.34 ± 0.01 
L141A 19.8 1.67 ± 0.01 1227 ± 8 4 735 ± 7 5.37 ± 0.03 0.139 ± 0.003 
L148A 20.1 4.90 ± 0.05 34.8 ± 0.3 3 7.10 ± 0.09 2.62 ± 0.03 0.042 ±0.008 
Y152A 28.6 5.1 ± 0.1 2.51 ± 0.03 3 0.49 ± 0.01 1.04 ± 0.03 0.08 ± 0.02 
E132A 21.0 8.8 ± 0.5 0.77 ± 0.01 4 0.088 ± 0.005 0.02 ± 0.05 - 
E132G 14.3 8.4 ± 0.2 0.86 ± 0.01 4 0.102 ± 0.003 0.09 ± 0.03 0.30 ± 0.02 
E136A 21.4 10.4 ± 0.2 0.48 ± 0.04 4 0.046 ± 0.004 -0.36 ± 0.06 - 
E136G 15.3 8.2 ± 0.2 2.38 ± 0.09 4 0.29 ± 0.01 1.09 ± 0.04 0.13 ± 0.01 
A139G 13.2 3.26 ± 0.05 1.08 ± 0.04 4 0.33 ± 0.01 0.81 ± 0.04 0.44 ± 0.02 
R143A 22.2 3.67 ± 0.04 0.88 ± 0.03 4 0.240 ± 0.008 0.62 ± 0.04 - 
R143G 15.8 3.03 ± 0.01 5.2 ± 0.2 3 1.72 ± 0.07 1.17 ± 0.04 0.097 ± 0.002 
D147A 30.2 9.4 ± 0.3 0.48 ± 0.02 4 0.051 ± 0.003 -0.92 ± 0.04 - 
D147G 15.9 6.76 ± 0.08 1.95 ± 0.05 4 0.288 ± 0.008 1.03 ± 0.04 0.2 ± 0.1 
A150G 13.3 4.84 ± 0.08 2.15 ± 0.02 4 0.444 ± 0.008 0.98 ± 0.03 0.12 ± 0.02 
R154A 20.0 4.86 ± 0.08 0.54 ± 0.02 4 0.111 ± 0.005 0.16 ± 0.04 - 
R154G 13.5 4.79 ± 0.03 0.44 ± 0.03 3 0.092 ± 0.006 -0.11 ± 0.05 -0.076 ± 0.002 
A139G (A150G) 9.7 2.78 ± 0.02 3.9 ± 0.1 4 1.40 ± 0.04 0.68 ± 0.03 0.48 ± 0.01 
A150G (A139G) 9.7 2.78 ± 0.02 3.9 ± 0.1 4 1.40 ± 0.04 0.82 ± 0.03 0.11 ± 0.01 
Percentage of helicity was calculated using the MRE at 222 nm and the method of Munoz and Serrano (1995). kon and koff were experimentally determined, and 
the associated errors represent the curve fit error and the standard error of the mean (n= number of repeats used to determine koff), respectively. Kd was 
calculated by taking the ratio between the dissociation and association rate constants, and the respective errors were propagated using standard methods. Φ 
was calculated using the kinetic rate constants and errors represent the propagated error. Table taken from Crabtree et al. 2018.  
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Table 2. Biophysical parameters for the coupled folding and binding of BID–MCL-1. 
BID  Helicity 
(CD) 
%  
kon 
(μM-1s-1) 
koff 
(s-1) 
x10-3 
n Kd 
(koff/kon) 
(nM) 
ΔΔG  
(kcal.mol-1) 
Φ 
WT 11.5 8.9 ± 0.1 3.0 ± 0.1 4 0.33 ± 0.01 - - 
I82A 10.7 9.5 ± 0.9 6.20 ± 0.07 2 0.65 ± 0.06 0.40 ± 0.06 0 ± 300 
I83A 12.0 8.6 ± 0.1 14 ± 4 4 1.7 ± 0.4 0.9 ± 0.1 0.02 ± 0.02 
I86A 9.0 4.0 ± 0.1 140 ± 14 3 35 ± 4 2.78 ± 0.08 0.172 ± 0.008 
L90A 7.5 2.1 ± 0.1 1300 ± 150 4 610 ± 80 4.50 ± 0.09 0.191 ± 0.008 
I93A 8.9 4.5 ± 0.2 430 ± 26 4 96 ± 7 3.39 ± 0.06 0.121 ± 0.008 
M97A 11.5 7.8 ± 0.3 30 ± 4 3 3.8± 0.5 1.47 ± 0.09 0.06 ± 0.02 
I101A 10.1 8.2 ± 0.1 2.5 ± 0.2 4 0.30 ± 0.03 -0.06 ± 0.07 0 ± 1 
I86A-M97A 9.0 3.5 ± 0.2 1360 ± 70 4 390 ± 30 4.23 ± 0.06 0.133 ± 0.007 
E81A 10.0 6.5 ± 0.3 3.6 ± 0.3 4 0.55 ± 0.05 - - 
E81G 7.0 4.8 ± 0.1 8 ± 2 3 1.6 ± 0.3 0.6 ± 0.1 0.27 ± 0.06 
R88A 11.3 10.0 ± 0.3 6.3 ± 0.7 3 0.6 ± 0.08 - - 
R88G 5.8 8.3 ± 0.5 15 ± 1 3 1.8 ± 0.2 0.6 ± 0.1 0.17 ± 0.06 
E96A 13.0 9.9 ± 0.8 3.8 ± 0.6 4 0.38 ± 0.07 - - 
E96G 11.5 10.9 ± 0.4 10 ± 1 4 0.9 ± 0.1 0.5 ± 0.1 -0.1 ± 0.1 
H99A 
H99G 
11.6 
13.0 
9.2 ± 0.4 
9.0 ± 0.2 
1.0 ± 0.3 
4.0 ± 0.1 
4 
4 
0.12 ± 0.03 
0.4 ± 0.1 
- 
0.8 ± 0.2 
- 
0.01 ± 0.04 
Percentage of helicity was calculated using the MRE at 222 nm and the method of Munoz and Serrano (1995). kon and koff were experimentally determined, and 
the associated errors represent the curve fit error and the standard error of the mean (n= number of repeats used to determine koff), respectively. Kd was 
calculated by taking the ratio between the dissociation and association rate constants, and the respective errors were propagated using standard methods. Φ 
was calculated using the kinetic rate constants and errors represent the propagated error. Table taken from Crabtree et al. 2018.  
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